<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Ovarian cancer - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Ovarian_cancer" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Ovarian_cancer&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Ovarian_cancer&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Ovarian_cancer" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Ovarian_cancer" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Ovarian_cancer","wgTitle":"Ovarian cancer","wgCurRevisionId":668902162,"wgRevisionId":668902162,"wgArticleId":414192,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Pages using citations with old-style implicit et al. in editors","All articles with dead external links","Articles with dead external links from March 2009","Articles with contributors link","All articles with unsourced statements","Articles with unsourced statements from December 2014","Articles with unsourced statements from November 2014","Articles that use a Medicine navs subtemplate","Ovarian cancer"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Ovarian_cancer","wgRelevantArticleId":414192,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/100px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg","wgULSAcceptLanguageList":[],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q172341"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Ovarian_cancer skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Ovarian cancer</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey">Ovarian cancer (human)</th>
</tr>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:Mucinous_lmp_ovarian_tumour_intermed_mag.jpg" class="image"><img alt="Mucinous lmp ovarian tumour intermed mag.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/230px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg" width="230" height="153" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/345px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/460px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg 2x" data-file-width="4272" data-file-height="2848" /></a>
<div><a href="/wiki/Micrograph" title="Micrograph">Micrograph</a> of a mucinous ovarian carcinoma <a href="/wiki/H%26E_stain" title="H&amp;E stain">stained by H&amp;E</a>.</div>
</td>
</tr>
<tr>
<th colspan="2" style="text-align:center">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th>
<td><a href="/wiki/Oncology" title="Oncology">Oncology</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2015/en#/C56">C56</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=183">183</a>, <a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=220">220</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O</a></th>
<td>varied</td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb9418.htm">9418</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000889.htm">000889</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic1698.htm">med/1698</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">NCI</a></th>
<td><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/types/ovarian">Ovarian cancer</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Patient_UK" title="Patient UK">Patient UK</a></th>
<td><a rel="nofollow" class="external text" href="http://patient.info/doctor/ovarian-cancer-pro">Ovarian cancer</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D010051">D010051</a></td>
</tr>
</table>
<p><b>Ovarian cancer</b> is a <a href="/wiki/Cancer" title="Cancer">cancer</a> that begins in an <a href="/wiki/Ovary" title="Ovary">ovary</a>.<sup id="cite_ref-NCI2014PrePt_1-0" class="reference"><a href="#cite_note-NCI2014PrePt-1"><span>[</span>1<span>]</span></a></sup> It results in abnormal <a href="/wiki/Cells_(biology)" title="Cells (biology)" class="mw-redirect">cells</a> that have the ability to invade or <a href="/wiki/Metastasis" title="Metastasis">spread</a> to other parts of the body.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2"><span>[</span>2<span>]</span></a></sup> When this process begins, symptoms may be vague or not apparent, but they become more noticeable as the cancer progresses. These symptoms may include bloating, <a href="/wiki/Pelvic_pain" title="Pelvic pain">pelvic pain</a>, and abdominal swelling, among others.<sup id="cite_ref-NCI2014TxPt_3-0" class="reference"><a href="#cite_note-NCI2014TxPt-3"><span>[</span>3<span>]</span></a></sup> Common areas to which the cancer may spread include the <a href="/wiki/Peritoneum" title="Peritoneum">lining of the abdomen</a>, lining of the bowel and bladder, <a href="/wiki/Lymph_node" title="Lymph node">lymph nodes</a>, <a href="/wiki/Lungs" title="Lungs" class="mw-redirect">lungs</a>, and <a href="/wiki/Liver" title="Liver">liver</a>.<sup id="cite_ref-:5_4-0" class="reference"><a href="#cite_note-:5-4"><span>[</span>4<span>]</span></a></sup><sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span>[</span>5<span>]</span></a></sup></p>
<p>The risk of ovarian cancer increases in women who have <a href="/wiki/Ovulate" title="Ovulate" class="mw-redirect">ovulated</a> more over their lifetime. This includes those who have <a href="/wiki/Nulliparity" title="Nulliparity" class="mw-redirect">never had children</a>, those who begin ovulation at a younger age or reach menopause at an older age.<sup id="cite_ref-WCR2014_6-0" class="reference"><a href="#cite_note-WCR2014-6"><span>[</span>6<span>]</span></a></sup> Other risk factors include <a href="/wiki/Hormone_therapy" title="Hormone therapy">hormone therapy</a> after <a href="/wiki/Menopause" title="Menopause">menopause</a>, <a href="/wiki/Fertility_medication" title="Fertility medication">fertility medication</a>, and <a href="/wiki/Obesity" title="Obesity">obesity</a>.<sup id="cite_ref-NCI2014PrePt_1-1" class="reference"><a href="#cite_note-NCI2014PrePt-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-NCI2014PrePro_7-0" class="reference"><a href="#cite_note-NCI2014PrePro-7"><span>[</span>7<span>]</span></a></sup> Factors that decrease risk include <a href="/wiki/Hormonal_birth_control" title="Hormonal birth control" class="mw-redirect">hormonal birth control</a>, <a href="/wiki/Tubal_ligation" title="Tubal ligation">tubal ligation</a>, and <a href="/wiki/Breast_feeding" title="Breast feeding" class="mw-redirect">breast feeding</a>.<sup id="cite_ref-NCI2014PrePro_7-1" class="reference"><a href="#cite_note-NCI2014PrePro-7"><span>[</span>7<span>]</span></a></sup> About 10% of cases are related to inherited genetic risk; women with mutations in the genes <i><a href="/wiki/BRCA1" title="BRCA1">BRCA1</a></i> or <i><a href="/wiki/BRCA2" title="BRCA2">BRCA2</a></i> have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma. There are five main subtypes of ovarian carcinoma, of which high-grade serous is most common. These tumors are believed to start in the cells covering the ovaries,<sup id="cite_ref-WCR2014_6-1" class="reference"><a href="#cite_note-WCR2014-6"><span>[</span>6<span>]</span></a></sup> though some may form at the <a href="/wiki/Fallopian_tube" title="Fallopian tube">Fallopian tubes</a>.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span>[</span>8<span>]</span></a></sup> Less common types of ovarian cancer include <a href="/wiki/Germ_cell_tumor" title="Germ cell tumor">germ cell tumors</a> and <a href="/wiki/Sex_cord_stromal_tumor" title="Sex cord stromal tumor" class="mw-redirect">sex cord stromal tumors</a>.<sup id="cite_ref-WCR2014_6-2" class="reference"><a href="#cite_note-WCR2014-6"><span>[</span>6<span>]</span></a></sup> A diagnosis of ovarian cancer is confirmed through a <a href="/wiki/Biopsy" title="Biopsy">biopsy</a> of tissue, usually removed during surgery.<sup id="cite_ref-NCI2014TxPt_3-1" class="reference"><a href="#cite_note-NCI2014TxPt-3"><span>[</span>3<span>]</span></a></sup></p>
<p>Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9"><span>[</span>9<span>]</span></a></sup> Those at very high risk may have their ovaries removed as a preventive measure.<sup id="cite_ref-NCI2014PrePt_1-2" class="reference"><a href="#cite_note-NCI2014PrePt-1"><span>[</span>1<span>]</span></a></sup> If caught and treated in an early stage, ovarian cancer may be curable. Treatment usually includes some combination of surgery, <a href="/wiki/Radiation_therapy" title="Radiation therapy">radiation therapy</a>, and <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a>.<sup id="cite_ref-NCI2014TxPt_3-2" class="reference"><a href="#cite_note-NCI2014TxPt-3"><span>[</span>3<span>]</span></a></sup> Outcomes depend on the extent of the disease and the subtype of the cancer present.<sup id="cite_ref-WCR2014_6-3" class="reference"><a href="#cite_note-WCR2014-6"><span>[</span>6<span>]</span></a></sup> The overall <a href="/wiki/Five-year_survival_rate" title="Five-year survival rate">five-year survival rate</a> in the United States is 45%.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10"><span>[</span>10<span>]</span></a></sup> Outcomes are worse in the developing world.<sup id="cite_ref-WCR2014_6-4" class="reference"><a href="#cite_note-WCR2014-6"><span>[</span>6<span>]</span></a></sup></p>
<p>In 2012, ovarian cancer occurred in 239,000 women and resulted in 152,000 deaths worldwide. This makes it, among women, the seventh-most common cancer and the eighth-most common cause of death from cancer. Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.<sup id="cite_ref-WCR2014_6-5" class="reference"><a href="#cite_note-WCR2014-6"><span>[</span>6<span>]</span></a></sup></p>
<div class="toclimit-3">
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Signs_and_symptoms"><span class="tocnumber">1</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Risk_factors"><span class="tocnumber">2</span> <span class="toctext">Risk factors</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Hormones"><span class="tocnumber">2.1</span> <span class="toctext">Hormones</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Genetics"><span class="tocnumber">2.2</span> <span class="toctext">Genetics</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Environmental_factors"><span class="tocnumber">2.3</span> <span class="toctext">Environmental factors</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Other"><span class="tocnumber">2.4</span> <span class="toctext">Other</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Protective_factors"><span class="tocnumber">2.5</span> <span class="toctext">Protective factors</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-8"><a href="#Pathophysiology"><span class="tocnumber">3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#Diagnosis"><span class="tocnumber">4</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-10"><a href="#Examination"><span class="tocnumber">4.1</span> <span class="toctext">Examination</span></a>
<ul>
<li class="toclevel-3 tocsection-11"><a href="#Risk_scoring"><span class="tocnumber">4.1.1</span> <span class="toctext">Risk scoring</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-12"><a href="#Pathology"><span class="tocnumber">4.2</span> <span class="toctext">Pathology</span></a>
<ul>
<li class="toclevel-3 tocsection-13"><a href="#Epithelial_carcinoma"><span class="tocnumber">4.2.1</span> <span class="toctext">Epithelial carcinoma</span></a>
<ul>
<li class="toclevel-4 tocsection-14"><a href="#Serous_carcinoma"><span class="tocnumber">4.2.1.1</span> <span class="toctext">Serous carcinoma</span></a>
<ul>
<li class="toclevel-5 tocsection-15"><a href="#Primary_peritoneal_carcinoma"><span class="tocnumber">4.2.1.1.1</span> <span class="toctext">Primary peritoneal carcinoma</span></a></li>
</ul>
</li>
<li class="toclevel-4 tocsection-16"><a href="#Clear-cell_carcinoma"><span class="tocnumber">4.2.1.2</span> <span class="toctext">Clear-cell carcinoma</span></a></li>
<li class="toclevel-4 tocsection-17"><a href="#Endometrioid"><span class="tocnumber">4.2.1.3</span> <span class="toctext">Endometrioid</span></a></li>
<li class="toclevel-4 tocsection-18"><a href="#Mucinous"><span class="tocnumber">4.2.1.4</span> <span class="toctext">Mucinous</span></a>
<ul>
<li class="toclevel-5 tocsection-19"><a href="#Adenocarcinoma"><span class="tocnumber">4.2.1.4.1</span> <span class="toctext">Adenocarcinoma</span></a></li>
<li class="toclevel-5 tocsection-20"><a href="#Pseudomyxoma_peritonei"><span class="tocnumber">4.2.1.4.2</span> <span class="toctext">Pseudomyxoma peritonei</span></a></li>
</ul>
</li>
<li class="toclevel-4 tocsection-21"><a href="#Undifferentiated_epithelial"><span class="tocnumber">4.2.1.5</span> <span class="toctext">Undifferentiated epithelial</span></a></li>
</ul>
</li>
<li class="toclevel-3 tocsection-22"><a href="#Sex_cord_stromal_tumor"><span class="tocnumber">4.2.2</span> <span class="toctext">Sex cord stromal tumor</span></a>
<ul>
<li class="toclevel-4 tocsection-23"><a href="#Granulosa_cell_tumor"><span class="tocnumber">4.2.2.1</span> <span class="toctext">Granulosa cell tumor</span></a></li>
<li class="toclevel-4 tocsection-24"><a href="#Sertoli-Leydig_cell_tumor"><span class="tocnumber">4.2.2.2</span> <span class="toctext">Sertoli-Leydig cell tumor</span></a></li>
</ul>
</li>
<li class="toclevel-3 tocsection-25"><a href="#Germ_cell_tumor"><span class="tocnumber">4.2.3</span> <span class="toctext">Germ cell tumor</span></a>
<ul>
<li class="toclevel-4 tocsection-26"><a href="#Dysgerminoma"><span class="tocnumber">4.2.3.1</span> <span class="toctext">Dysgerminoma</span></a></li>
<li class="toclevel-4 tocsection-27"><a href="#Choriocarcinoma"><span class="tocnumber">4.2.3.2</span> <span class="toctext">Choriocarcinoma</span></a></li>
<li class="toclevel-4 tocsection-28"><a href="#Immature_.28solid.29_teratoma"><span class="tocnumber">4.2.3.3</span> <span class="toctext">Immature (solid) teratoma</span></a></li>
<li class="toclevel-4 tocsection-29"><a href="#Yolk_sac_tumor.2Fendodermal_sinus_tumor"><span class="tocnumber">4.2.3.4</span> <span class="toctext">Yolk sac tumor/endodermal sinus tumor</span></a></li>
</ul>
</li>
<li class="toclevel-3 tocsection-30"><a href="#Mixed_tumors"><span class="tocnumber">4.2.4</span> <span class="toctext">Mixed tumors</span></a></li>
<li class="toclevel-3 tocsection-31"><a href="#Secondary_ovarian_cancer"><span class="tocnumber">4.2.5</span> <span class="toctext">Secondary ovarian cancer</span></a></li>
<li class="toclevel-3 tocsection-32"><a href="#Low_malignant_potential_tumors"><span class="tocnumber">4.2.6</span> <span class="toctext">Low malignant potential tumors</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-33"><a href="#Staging"><span class="tocnumber">4.3</span> <span class="toctext">Staging</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-34"><a href="#Screening"><span class="tocnumber">5</span> <span class="toctext">Screening</span></a></li>
<li class="toclevel-1 tocsection-35"><a href="#Prevention"><span class="tocnumber">6</span> <span class="toctext">Prevention</span></a></li>
<li class="toclevel-1 tocsection-36"><a href="#Management"><span class="tocnumber">7</span> <span class="toctext">Management</span></a>
<ul>
<li class="toclevel-2 tocsection-37"><a href="#Surgery"><span class="tocnumber">7.1</span> <span class="toctext">Surgery</span></a></li>
<li class="toclevel-2 tocsection-38"><a href="#Chemotherapy"><span class="tocnumber">7.2</span> <span class="toctext">Chemotherapy</span></a></li>
<li class="toclevel-2 tocsection-39"><a href="#Radiation_therapy"><span class="tocnumber">7.3</span> <span class="toctext">Radiation therapy</span></a></li>
<li class="toclevel-2 tocsection-40"><a href="#Hormonal_therapy"><span class="tocnumber">7.4</span> <span class="toctext">Hormonal therapy</span></a></li>
<li class="toclevel-2 tocsection-41"><a href="#Immunotherapy"><span class="tocnumber">7.5</span> <span class="toctext">Immunotherapy</span></a></li>
<li class="toclevel-2 tocsection-42"><a href="#Follow-up"><span class="tocnumber">7.6</span> <span class="toctext">Follow-up</span></a></li>
<li class="toclevel-2 tocsection-43"><a href="#Palliative_care"><span class="tocnumber">7.7</span> <span class="toctext">Palliative care</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-44"><a href="#Prognosis"><span class="tocnumber">8</span> <span class="toctext">Prognosis</span></a>
<ul>
<li class="toclevel-2 tocsection-45"><a href="#Survival_rates"><span class="tocnumber">8.1</span> <span class="toctext">Survival rates</span></a></li>
<li class="toclevel-2 tocsection-46"><a href="#Recurrence_rates"><span class="tocnumber">8.2</span> <span class="toctext">Recurrence rates</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-47"><a href="#Epidemiology"><span class="tocnumber">9</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-48"><a href="#Society_and_culture"><span class="tocnumber">10</span> <span class="toctext">Society and culture</span></a></li>
<li class="toclevel-1 tocsection-49"><a href="#Other_animals"><span class="tocnumber">11</span> <span class="toctext">Other animals</span></a></li>
<li class="toclevel-1 tocsection-50"><a href="#Research"><span class="tocnumber">12</span> <span class="toctext">Research</span></a></li>
<li class="toclevel-1 tocsection-51"><a href="#References"><span class="tocnumber">13</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-52"><a href="#Further_reading"><span class="tocnumber">14</span> <span class="toctext">Further reading</span></a></li>
<li class="toclevel-1 tocsection-53"><a href="#External_links"><span class="tocnumber">15</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
</div>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=1" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Signs and symptoms of ovarian cancer are frequently absent in early stages; even when they do exist, they may be subtle. In most cases, symptoms exist for several months before being recognized and diagnosed, or they may initially be misdiagnosed as a condition such as <a href="/wiki/Irritable_bowel_syndrome" title="Irritable bowel syndrome">irritable bowel syndrome</a>.<sup id="cite_ref-Jayson_11-0" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> The early stages of ovarian cancer tend to be painless unless the growing mass causes <a href="/wiki/Ovarian_torsion" title="Ovarian torsion">ovarian torsion</a>.<sup id="cite_ref-Harrisons_12-0" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Early symptoms can include bloating, abdominopelvic pain, and pain in the side.<sup id="cite_ref-:0_13-0" class="reference"><a href="#cite_note-:0-13"><span>[</span>13<span>]</span></a></sup> The most typical symptoms of ovarian cancer include <a href="/wiki/Bloating" title="Bloating">bloating</a>, abdominal or pelvic pain or discomfort, back pain, <a href="/wiki/Irregular_menstruation" title="Irregular menstruation">irregular menstruation</a> or postmenopausal vaginal bleeding, pain or bleeding after or during <a href="/wiki/Sexual_intercourse" title="Sexual intercourse">sexual intercourse</a>, difficulty eating, loss of appetite, fatigue, <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a>, <a href="/wiki/Indigestion" title="Indigestion">indigestion</a>, heartburn, <a href="/wiki/Constipation" title="Constipation">constipation</a>, nausea, early <a href="/wiki/Satiety" title="Satiety" class="mw-redirect">satiety</a>, and possibly urinary symptoms (including <a href="/wiki/Polyuria" title="Polyuria">frequent urination</a> and urgent urination); typically these symptoms are caused by a mass pressing on the other abdominopelvic organs or from metastases.<sup id="cite_ref-Harrisons_12-1" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-:0_13-1" class="reference"><a href="#cite_note-:0-13"><span>[</span>13<span>]</span></a></sup><sup id="cite_ref-:7_14-0" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> If these symptoms start to occur more often or more severely than usual, especially after no significant history of such symptoms, ovarian cancer should be considered.<sup id="cite_ref-Harrisons_12-2" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Goff2012_15-0" class="reference"><a href="#cite_note-Goff2012-15"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Hoffman35_16-0" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Metastases may cause a <a href="/wiki/Sister_Mary_Joseph_nodule" title="Sister Mary Joseph nodule">Sister Mary Joseph nodule</a>.<sup id="cite_ref-:7_14-1" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>In adolescents or children with ovarian tumors, the presenting symptoms can include severe abdominal pain, irritation of the <a href="/wiki/Peritoneum" title="Peritoneum">peritoneum</a>, or <a href="/wiki/Hemorrhage" title="Hemorrhage" class="mw-redirect">bleeding</a>.<sup id="cite_ref-Current_17-0" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup> As the cancer becomes more advanced, it can cause <a href="/wiki/Ascites" title="Ascites">an accumulation of fluid</a> in the abdomen. If the malignancy has not been diagnosed by the time it causes ascites, it is typically diagnosed shortly thereafter.<sup id="cite_ref-Harrisons_12-3" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Advanced cancers can also cause abdominal masses, lymph node masses, or <a href="/wiki/Pleural_effusion" title="Pleural effusion">pleural effusion</a>.<sup id="cite_ref-:7_14-2" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>Ovarian cancer symptoms can vary based on the subtype.<sup id="cite_ref-Harrisons_12-4" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Low malignant potential (LMP) tumors, also known as borderline tumors, do not cause an increase in <a href="/wiki/CA125" title="CA125" class="mw-redirect">CA125</a> levels and are not identifiable with an ultrasound. The typical symptoms of a LMP tumor can include abdominal distension or pelvic pain. Particularly large masses tend to be benign or borderline.<sup id="cite_ref-Hoffman35_16-1" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Risk_factors">Risk factors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=2" title="Edit section: Risk factors">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Most of the risk factors for ovarian cancer are <a href="/wiki/Endocrine_system" title="Endocrine system">hormonal</a> in nature. <a href="/wiki/Nulliparity" title="Nulliparity" class="mw-redirect">Not having children</a> is a risk factor for ovarian cancer, likely because ovulation is not suppressed due to pregnancy. Both obesity and hormone replacement therapy raise the risk for ovarian cancer.<sup id="cite_ref-Harrisons_12-5" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Hormones">Hormones</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=3" title="Edit section: Hormones">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Use of <a href="/wiki/Fertility_medication" title="Fertility medication">fertility medication</a> may contribute to borderline ovarian tumor formation, but the link between the two is disputed and difficult to study.<sup id="cite_ref-Jayson_11-1" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Fertility drugs may be associated with a higher risk of borderline tumors.<sup id="cite_ref-:7_14-3" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> Those who have been treated for infertility but remain nulliparous are at higher risk for epithelial ovarian cancer; however, those who are successfully treated for infertility and subsequently give birth are at no higher risk. This may be due to shedding of precancerous cells during pregnancy, but the cause remains unclear.<sup id="cite_ref-Hoffman35_16-2" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> The risk factor may instead be infertility itself, not the treatment.<sup id="cite_ref-CRUKRisks_18-0" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup></p>
<p>Hormonal conditions such as <a href="/wiki/Polycystic_ovary_syndrome" title="Polycystic ovary syndrome">polycystic ovary syndrome</a> and <a href="/wiki/Endometriosis" title="Endometriosis">endometriosis</a> are associated with ovarian cancer, but the link is not completely confirmed.<sup id="cite_ref-Jayson_11-2" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Postmenopausal hormone replacement therapy (HRT) with estrogen likely increases the risk of ovarian cancer. The association has not been confirmed in a large-scale study,<sup id="cite_ref-Hoffman35_16-3" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-19" class="reference"><a href="#cite_note-19"><span>[</span>19<span>]</span></a></sup> but notable studies including the <a href="/wiki/Million_Women_Study" title="Million Women Study">Million Women Study</a> have supported this link. Postmenopausal HRT with combined estrogen and progesterone may increase contemporaneous risk if used for over 5 years, but this risk returns to normal after cessation of therapy. Research is divided on the role of <a href="/wiki/Intrauterine_device" title="Intrauterine device">intrauterine devices</a> (IUDs) in causing ovarian cancers. Some studies show that short-term use of the IUD can decrease risk of ovarian cancer, but that long-term use of the IUD increases the risk; others show that use of the IUD slightly increases risk when used for any amount of time.<sup id="cite_ref-CRUKRisks_18-1" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> Estrogen HRT with or without progestins increases the risk of endometrioid and serous tumors but lowers the risk of mucinous tumors. Higher doses of estrogen increase this risk.<sup id="cite_ref-:7_14-4" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>Long periods of continuous ovulation are thought to be the main non-genetic cause of epithelial ovarian cancer. This is because during the cells are constantly stimulated to divide while ovulatory cycles continue. Therefore, people who have not borne children are at twice the risk of ovarian cancer than those who have. A longer period of ovulation caused by early <a href="/wiki/Menarche" title="Menarche">first menstruation</a> or late <a href="/wiki/Menopause" title="Menopause">menopause</a> is also a risk factor.<sup id="cite_ref-Hoffman35_16-4" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-CRUKRisks_18-2" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup></p>
<p><a href="/wiki/Endometriosis" title="Endometriosis">Endometriosis</a> is another risk factor for ovarian cancer,<sup id="cite_ref-CRUKRisks_18-3" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> as is pain with menstruation. Endometriosis is associated with clear-cell and endometrioid subtypes, low-grade serous tumors, stage I and II tumors, grade 1 tumors, and lower mortality.<sup id="cite_ref-:7_14-5" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>Before menopause, <a href="/wiki/Obesity" title="Obesity">obesity</a> can increase a person's risk of ovarian cancer, but this risk is not present after menopause. This risk is also relevant in those who are both obese and have never used HRT. A similar association with ovarian cancer appears in taller people.<sup id="cite_ref-CRUKRisks_18-4" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Genetics">Genetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=4" title="Edit section: Genetics">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="hatnote">Further information: <a href="/wiki/Hereditary_breast-ovarian_cancer_syndrome" title="Hereditary breast-ovarian cancer syndrome" class="mw-redirect">Hereditary breast-ovarian cancer syndrome</a></div>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:PedigreechartC.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/3/31/PedigreechartC.png/220px-PedigreechartC.png" width="220" height="163" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/en/thumb/3/31/PedigreechartC.png/330px-PedigreechartC.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/3/31/PedigreechartC.png/440px-PedigreechartC.png 2x" data-file-width="700" data-file-height="518" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:PedigreechartC.png" class="internal" title="Enlarge"></a></div>
Ovarian and breast cancer patients in a pedigree chart of a family</div>
</div>
</div>
<p>The major genetic risk factor for ovarian cancer is a mutation in <i>BRCA1</i> or <i>BRCA2</i> <a href="/wiki/DNA_mismatch_repair" title="DNA mismatch repair">DNA mismatch repair</a> genes, which is present in 10% of ovarian cancer cases. Only one <a href="/wiki/Allele" title="Allele">allele</a> need be mutated to place a person at high risk, because the risky mutations are <a href="/wiki/Autosomal_dominant" title="Autosomal dominant" class="mw-redirect">autosomal dominant</a>. The gene can be inherited through either the maternal or paternal line, but has variable <a href="/wiki/Penetrance" title="Penetrance">penetrance</a>.<sup id="cite_ref-Harrisons_12-6" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Hoffman35_16-5" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Though mutations in these genes are usually associated with increased risk of breast cancer, they also carry a 30-50% lifetime risk of ovarian cancer, a risk that peaks in a person's 40s and 50s.<sup id="cite_ref-Harrisons_12-7" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> This risk is also cited as 40-60% and 39-46%.<sup id="cite_ref-Jayson_11-3" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Hoffman35_16-6" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Mutations in <i>BRCA2</i> are less risky than those with <i>BRCA1</i>, with a lifetime risk of 20-40%.<sup id="cite_ref-Harrisons_12-8" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> This risk is also cited as 12-20%. On average, BRCA-associated cancers develop 15 years before their sporadic counterparts, because people who inherit the mutations on one copy of their gene only need one mutation to start the process of carcinogenesis, whereas people with two normal genes would need to acquire two mutations.<sup id="cite_ref-Hoffman35_16-7" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>In the United States, five of 100 women with a <a href="/wiki/First-degree_relative" title="First-degree relative" class="mw-redirect">first-degree relative</a> with ovarian cancer will eventually get ovarian cancer themselves, placing those with affected family members at triple the risk of women with unaffected family members. Seven of 100 women with two or more relatives with ovarian cancer will eventually get ovarian cancer.<sup id="cite_ref-Hoffman35_16-8" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-NCIPrevention_20-0" class="reference"><a href="#cite_note-NCIPrevention-20"><span>[</span>20<span>]</span></a></sup> In general, 5-10% of ovarian cancer cases have a genetic cause.<sup id="cite_ref-Hoffman35_16-9" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> BRCA mutations are associated with high-grade serous nonmucinous epithelial ovarian cancer.<sup id="cite_ref-:7_14-6" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>A strong family history of <a href="/wiki/Endometrial_cancer" title="Endometrial cancer">endometrial cancer</a>, <a href="/wiki/Colon_cancer" title="Colon cancer" class="mw-redirect">colon cancer</a>, or other <a href="/wiki/Gastrointestinal_cancer" title="Gastrointestinal cancer">gastrointestinal cancers</a> may indicate the presence of a syndrome known as <a href="/wiki/Hereditary_nonpolyposis_colorectal_cancer" title="Hereditary nonpolyposis colorectal cancer">hereditary nonpolyposis colorectal cancer</a> (also known as Lynch syndrome), which confers a higher risk for developing a number of cancers, including ovarian cancer. Lynch syndrome is caused by mutations in mismatch repair genes, including <i><a href="/wiki/MSH2" title="MSH2">MSH2</a>, <a href="/wiki/MLH1" title="MLH1">MLH1</a>, <a href="/w/index.php?title=MLH6&amp;action=edit&amp;redlink=1" class="new" title="MLH6 (page does not exist)">MLH6</a>, <a href="/wiki/PMS1" title="PMS1">PMS1</a></i>, and <i><a href="/wiki/PMS2" title="PMS2">PMS2</a></i>.<sup id="cite_ref-Harrisons_12-9" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> The risk of ovarian cancer for an individual with Lynch syndrome is between 10 and 12 percent.<sup id="cite_ref-Harrisons_12-10" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Hoffman35_16-10" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> People of <a href="/wiki/Icelandic_people" title="Icelandic people" class="mw-redirect">Icelandic descent</a>, <a href="/wiki/European_Jews" title="European Jews" class="mw-redirect">European Jewish descent</a>/<a href="/wiki/Ashkenazi_Jews" title="Ashkenazi Jews">Ashkenazi Jewish descent</a>, and <a href="/wiki/Hungarian_people" title="Hungarian people" class="mw-redirect">Hungarian descent</a> are at higher risk for epithelial ovarian cancer.<sup id="cite_ref-Hoffman35_16-11" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>Several rare genetic disorders are associated with specific subtypes of ovarian cancer. <a href="/wiki/Peutz%E2%80%93Jeghers_syndrome" title="Peutz–Jeghers syndrome">Peutz–Jeghers syndrome</a>, a rare genetic disorder, also predisposes people to <a href="/wiki/Sex_cord_tumour_with_annular_tubules" title="Sex cord tumour with annular tubules">sex cord tumour with annular tubules</a>.<sup id="cite_ref-Jayson_11-4" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Harrisons_12-11" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> <a href="/wiki/Ollier_disease" title="Ollier disease">Ollier disease</a> and <a href="/wiki/Maffucci_syndrome" title="Maffucci syndrome">Maffucci syndrome</a> are associated with <a href="/wiki/Granulosa_cell_tumor" title="Granulosa cell tumor" class="mw-redirect">granulosa cell tumors</a> in children and may also be associated with Sertoli-Leydig tumors. Benign fibromas are associated with <a href="/wiki/Nevoid_basal_cell_carcinoma_syndrome" title="Nevoid basal cell carcinoma syndrome" class="mw-redirect">nevoid basal cell carcinoma syndrome</a>.<sup id="cite_ref-Harrisons_12-12" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Environmental_factors">Environmental factors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=5" title="Edit section: Environmental factors">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Industrialized nations, with the exception of Japan, have high rates of epithelial ovarian cancer, which may be due to diet in those countries. <a href="/wiki/White_people" title="White people">White people</a> are at a 30-40% higher risk for ovarian cancer when compared to <a href="/wiki/Black_people" title="Black people">Black</a> and <a href="/wiki/Hispanic_people" title="Hispanic people" class="mw-redirect">Hispanic people</a>, likely due to socioeconomic factors: White women tend to have fewer children and different rates of gynecologic surgeries that affect risk for ovarian cancer.<sup id="cite_ref-Hoffman35_16-12" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p><a href="/wiki/Cohort_study" title="Cohort study">Cohort studies</a> have found a correlation between dairy consumption and ovarian cancer, but <a href="/wiki/Case-control_study" title="Case-control study">case-control studies</a> do not show this correlation. There is mixed evidence regarding the effect of red meat and processed meat in ovarian cancer.<sup id="cite_ref-:7_14-7" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Other">Other</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=6" title="Edit section: Other">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Alcohol consumption does not appear to be related to ovarian cancer.<sup id="cite_ref-:7_14-8" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span>[</span>21<span>]</span></a></sup> Other factors that have been investigated, such as <a href="/wiki/Talc" title="Talc">talc</a> use on the <a href="/wiki/Perineum" title="Perineum">perineum</a>, <a href="/wiki/Smoking" title="Smoking">smoking</a>, high levels of <a href="/wiki/Vitamin_D" title="Vitamin D">vitamin D</a> in the blood, presence of inclusion <a href="/wiki/Ovarian_cysts" title="Ovarian cysts" class="mw-redirect">ovarian cysts</a>, and infection with <a href="/wiki/Human_papilloma_virus" title="Human papilloma virus" class="mw-redirect">human papilloma virus</a> (the cause of some cases of <a href="/wiki/Cervical_cancer" title="Cervical cancer">cervical cancer</a>), have been disproven as risk factors for ovarian cancer.<sup id="cite_ref-Jayson_11-5" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-:7_14-9" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> However, the carcinogenicity of perineal talc is controversial, because it can act as an irritant if it travels through the reproductive tract to the ovaries.<sup id="cite_ref-Hoffman35_16-13" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-CRUKRisks_18-5" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> Use of <a href="/wiki/Talc" title="Talc">talc</a> elsewhere on the body is unrelated to ovarian cancer.<sup id="cite_ref-CRUKRisks_18-6" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> <a href="/wiki/Sitting" title="Sitting">Sitting</a> regularly for prolonged periods is associated with higher mortality from epithelial ovarian cancer. The risk is not negated by regular exercise, though it is lowered.<sup id="cite_ref-Biswas_22-0" class="reference"><a href="#cite_note-Biswas-22"><span>[</span>22<span>]</span></a></sup></p>
<p>Increased age (up to the 70s) is a risk factor for epithelial ovarian cancer because more mutations in cells can accumulate and eventually cause cancer. Those over 80 are at slightly lower risk.<sup id="cite_ref-Hoffman35_16-14" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p><a href="/wiki/Smoking" title="Smoking">Smoking</a> tobacco is associated with a higher risk of <a href="/wiki/Mucinous_tumor" title="Mucinous tumor">mucinous ovarian cancer</a>; after <a href="/wiki/Smoking_cessation" title="Smoking cessation">smoking cessation</a>, the risk eventually returns to normal. A diet high in animal fats may be associated with ovarian cancer, but the connection is unclear. Diet seems to play a very small role, if any, in ovarian cancer risk.<sup id="cite_ref-CRUKRisks_18-7" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup></p>
<p><a href="/wiki/Trans_men" title="Trans men" class="mw-redirect">Trans men</a> who have ovaries may be at higher risk of ovarian cancer, but the reason for this is unknown. Potential factors include <a href="/wiki/Testosterone" title="Testosterone">testosterone</a> therapy and lower rates of protective factors.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span>[</span>23<span>]</span></a></sup></p>
<p>Higher levels of <a href="/wiki/C-reactive_protein" title="C-reactive protein">C-reactive protein</a> are associated with a higher risk of developing ovarian cancer.<sup id="cite_ref-:7_14-10" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Protective_factors">Protective factors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=7" title="Edit section: Protective factors">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Suppression of ovulation, which would otherwise cause damage to the <a href="/wiki/Ovarian_epithelium" title="Ovarian epithelium" class="mw-redirect">ovarian epithelium</a> and, consequently, <a href="/wiki/Inflammation" title="Inflammation">inflammation</a>, is generally protective. This effect can be achieved by <a href="/wiki/Multiparity" title="Multiparity" class="mw-redirect">having children</a>, taking <a href="/wiki/Combined_oral_contraceptive" title="Combined oral contraceptive" class="mw-redirect">combined oral contraceptives</a>, and <a href="/wiki/Breast_feeding" title="Breast feeding" class="mw-redirect">breast feeding</a>, all of which are protective factors.<sup id="cite_ref-Harrisons_12-13" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> A longer period of breastfeeding correlates with a larger decrease in the risk of ovarian cancer.<sup id="cite_ref-CRUKRisks_18-8" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> Each birth decreases risk of ovarian cancer more, and this effect is seen with up to five births. Combined oral contraceptives reduce the risk of ovarian cancer by up to 50%, and the protective effect of combined oral contraceptives can last 25–30 years after they are discontinued.<sup id="cite_ref-Hoffman35_16-15" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-CRUKRisks_18-9" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> The protective effect of combined oral contraceptives may be due to <a href="/wiki/Progesterone" title="Progesterone">progesterone</a> or to the cessation of ovulation.<sup id="cite_ref-CRUKRisks_18-10" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> Regular use of <a href="/wiki/Aspirin" title="Aspirin">aspirin</a> is associated with a lower risk of ovarian cancer; other <a href="/wiki/NSAIDs" title="NSAIDs" class="mw-redirect">NSAIDs</a> do not have a similar protective effect.<sup id="cite_ref-:7_14-11" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p><a href="/wiki/Tubal_ligation" title="Tubal ligation">Tubal ligation</a> is protective because <a href="/wiki/Carcinogen" title="Carcinogen">carcinogens</a> are unable to reach the ovary and <a href="/wiki/Fimbria_(female_reproductive_system)" title="Fimbria (female reproductive system)" class="mw-redirect">fimbriae</a> via the vagina, uterus, and Fallopian tubes.<sup id="cite_ref-Harrisons_12-14" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Tubal ligation is also protective in women with the BRCA1 mutation, but not the BRCA2 mutation.<sup id="cite_ref-:7_14-12" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> <a href="/wiki/Hysterectomy" title="Hysterectomy">Hysterectomy</a> reduces the risk, and removal of both Fallopian tubes and ovaries (bilateral <a href="/wiki/Salpingo-oophorectomy" title="Salpingo-oophorectomy" class="mw-redirect">salpingo-oophorectomy</a>) dramatically reduces the risk of not only ovarian cancer, but breast cancer as well.<sup id="cite_ref-Jayson_11-6" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> This is still a topic of research, as the link between hysterectomy and lower ovarian cancer risk is controversial. The reasons that hysterectomy may be protective have not been elucidated as of 2015.<sup id="cite_ref-CRUKRisks_18-11" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup></p>
<p>A diet that includes large amounts of <a href="/wiki/Carotene" title="Carotene">carotene</a>, <a href="/wiki/Fiber" title="Fiber">fiber</a>, and <a href="/wiki/Vitamin" title="Vitamin">vitamins</a> with low amounts of fat—specifically, a diet with non-starchy vegetables (e.g. <a href="/wiki/Broccoli" title="Broccoli">broccoli</a> and <a href="/wiki/Onion" title="Onion">onions</a>)—may be protective,<sup id="cite_ref-Hoffman35_16-16" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> though research is still ongoing in this area.<sup id="cite_ref-CRUKRisks_18-12" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=8" title="Edit section: Pathophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="wikitable sortable" align="right" style="width: 50%">
<caption>Mutations found in ovarian cancer subtypes<sup id="cite_ref-Jayson_11-7" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-:7_14-13" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-DeVita100_24-0" class="reference"><a href="#cite_note-DeVita100-24"><span>[</span>24<span>]</span></a></sup></caption>
<tr>
<th>Gene mutated</th>
<th>Mutation type</th>
<th>Subtype</th>
<th>Prevalence</th>
</tr>
<tr>
<td><i><a href="/wiki/AKT1" title="AKT1">AKT1</a></i></td>
<td>amplification</td>
<td></td>
<td>3%</td>
</tr>
<tr>
<td><i><a href="/wiki/AKT2" title="AKT2">AKT2</a></i></td>
<td>amplification/mutation</td>
<td></td>
<td>6%,<sup id="cite_ref-Jayson_11-8" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> 20%<sup id="cite_ref-DeVita100_24-1" class="reference"><a href="#cite_note-DeVita100-24"><span>[</span>24<span>]</span></a></sup></td>
</tr>
<tr>
<td><i><a href="/wiki/ARID1A" title="ARID1A">ARID1A</a></i></td>
<td>point mutation</td>
<td>endometrioid and clear cell</td>
<td></td>
</tr>
<tr>
<td><a href="/wiki/BRAF_(gene)" title="BRAF (gene)"><i>BRAF</i></a></td>
<td>point mutation</td>
<td>low-grade serous</td>
<td>0.5%</td>
</tr>
<tr>
<td><i><a href="/wiki/BRCA1" title="BRCA1">BRCA1</a></i></td>
<td>nonsense mutation</td>
<td>high-grade serous</td>
<td>5%</td>
</tr>
<tr>
<td><i><a href="/wiki/BRCA2" title="BRCA2">BRCA2</a></i></td>
<td>frameshift mutation</td>
<td>high-grade serous</td>
<td>3%</td>
</tr>
<tr>
<td><i><a href="/wiki/CCND1" title="CCND1" class="mw-redirect">CCND1</a></i></td>
<td>amplification</td>
<td></td>
<td>4%</td>
</tr>
<tr>
<td><i><a href="/wiki/CCND2" title="CCND2" class="mw-redirect">CCND2</a></i></td>
<td>upregulation</td>
<td></td>
<td>15%</td>
</tr>
<tr>
<td><i><a href="/wiki/CCNE1" title="CCNE1" class="mw-redirect">CCNE1</a></i></td>
<td>amplification</td>
<td></td>
<td>20%</td>
</tr>
<tr>
<td><i><a href="/w/index.php?title=CDK12&amp;action=edit&amp;redlink=1" class="new" title="CDK12 (page does not exist)">CDK12</a></i></td>
<td></td>
<td>high-grade serous</td>
<td></td>
</tr>
<tr>
<td><a href="/wiki/P16_(gene)" title="P16 (gene)" class="mw-redirect"><i>CDKN2A</i></a></td>
<td>downregulation (30%) and deletion (2%)</td>
<td></td>
<td>32%</td>
</tr>
<tr>
<td><i><a href="/wiki/CTNNB1" title="CTNNB1" class="mw-redirect">CTNNB1</a></i></td>
<td></td>
<td>clear cell</td>
<td></td>
</tr>
<tr>
<td><a href="/wiki/DICER1" title="DICER1" class="mw-redirect">DICER1</a></td>
<td>missense mutation</td>
<td>nonepithelial</td>
<td>29%</td>
</tr>
<tr>
<td><a href="/wiki/DYNLRB1" title="DYNLRB1">DYNLRB1</a> (km23)</td>
<td>mutation</td>
<td></td>
<td>42%</td>
</tr>
<tr>
<td><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">EGFR</a></td>
<td>amplification/overexpression</td>
<td></td>
<td>20%</td>
</tr>
<tr>
<td><i><a href="/wiki/ERBB2" title="ERBB2" class="mw-redirect">ERBB2</a></i> (Her2/neu)</td>
<td>amplification/overexpression</td>
<td>mucinous and low-grade serous</td>
<td>30%</td>
</tr>
<tr>
<td><a href="/w/index.php?title=FMS_(gene)&amp;action=edit&amp;redlink=1" class="new" title="FMS (gene) (page does not exist)">FMS</a></td>
<td>coexpression with <a href="/w/index.php?title=CSF-1&amp;action=edit&amp;redlink=1" class="new" title="CSF-1 (page does not exist)">CSF-1</a></td>
<td></td>
<td>50%</td>
</tr>
<tr>
<td><i><a href="/wiki/JAG1" title="JAG1">JAG1</a></i></td>
<td>amplification</td>
<td></td>
<td>2%</td>
</tr>
<tr>
<td><i><a href="/wiki/JAG2" title="JAG2">JAG2</a></i></td>
<td>amplification</td>
<td></td>
<td>3%</td>
</tr>
<tr>
<td><i><a href="/wiki/KRAS" title="KRAS">KRAS</a></i></td>
<td>amplification</td>
<td>mucinous and low-grade serous</td>
<td>11%</td>
</tr>
<tr>
<td><i><a href="/wiki/MAML1" title="MAML1">MAML1</a></i></td>
<td>amplification and point mutation</td>
<td></td>
<td>2%</td>
</tr>
<tr>
<td><i><a href="/wiki/MAML2" title="MAML2">MAML2</a></i></td>
<td>amplification and point mutation</td>
<td></td>
<td>4%</td>
</tr>
<tr>
<td><i><a href="/w/index.php?title=MAML3&amp;action=edit&amp;redlink=1" class="new" title="MAML3 (page does not exist)">MAML3</a></i></td>
<td>amplification</td>
<td></td>
<td>2%</td>
</tr>
<tr>
<td><a href="/wiki/MLH1" title="MLH1">MLH1</a></td>
<td></td>
<td></td>
<td>1%</td>
</tr>
<tr>
<td><a href="/wiki/Nuclear_factor_1" title="Nuclear factor 1" class="mw-redirect"><i>NF1</i></a></td>
<td>deletion (8%) and point mutation (4%)</td>
<td>high-grade serous</td>
<td>12%</td>
</tr>
<tr>
<td><i><a href="/wiki/NOTCH3" title="NOTCH3" class="mw-redirect">NOTCH3</a></i></td>
<td>amplification and point mutation</td>
<td></td>
<td>11%</td>
</tr>
<tr>
<td><a href="/wiki/Neuroblastoma_RAS_viral_oncogene_homolog" title="Neuroblastoma RAS viral oncogene homolog"><i>NRAS</i></a></td>
<td></td>
<td>low-grade serous</td>
<td></td>
</tr>
<tr>
<td><a href="/wiki/PIK3C3" title="PIK3C3">PIK3C3</a> (PI3K3)</td>
<td>amplification/mutation</td>
<td></td>
<td>12-20%</td>
</tr>
<tr>
<td><i><a href="/wiki/PIK3CA" title="PIK3CA" class="mw-redirect">PIK3CA</a></i></td>
<td>amplification</td>
<td>endometrioid and clear cell</td>
<td>18%</td>
</tr>
<tr>
<td><i><a href="/wiki/PPP2R1A" title="PPP2R1A">PPP2R1A</a></i></td>
<td></td>
<td>endometrioid and clear cell</td>
<td></td>
</tr>
<tr>
<td><a href="/wiki/PTEN_(gene)" title="PTEN (gene)"><i>PTEN</i></a></td>
<td>deletion</td>
<td>endometrioid and clear cell</td>
<td>7%</td>
</tr>
<tr>
<td><i><a href="/wiki/RB1" title="RB1" class="mw-redirect">RB1</a></i></td>
<td>deletion (8%) and point mutation (2%)</td>
<td></td>
<td>10%</td>
</tr>
<tr>
<td><a href="/wiki/TGF-%CE%B2" title="TGF-β" class="mw-redirect">TGF-β</a></td>
<td>mutation/overexpression</td>
<td></td>
<td>12%</td>
</tr>
<tr>
<td><i><a href="/wiki/TP53" title="TP53" class="mw-redirect">TP53</a></i></td>
<td>mutation/overexpression</td>
<td>high-grade serous</td>
<td>20-50%</td>
</tr>
<tr>
<td><a href="/w/index.php?title=T%CE%B2RI&amp;action=edit&amp;redlink=1" class="new" title="TβRI (page does not exist)">TβRI</a></td>
<td>mutation</td>
<td></td>
<td>33%</td>
</tr>
<tr>
<td><a href="/w/index.php?title=T%CE%B2RII&amp;action=edit&amp;redlink=1" class="new" title="TβRII (page does not exist)">TβRII</a></td>
<td>mutation</td>
<td></td>
<td>25%</td>
</tr>
<tr>
<td><a href="/wiki/USP36" title="USP36">USP36</a></td>
<td>overexpression</td>
<td></td>
<td></td>
</tr>
</table>
<p>Ovarian cancer forms when errors in normal ovarian <a href="/wiki/Cell_cycle" title="Cell cycle">cell growth</a> occur. Usually, when cells grow old or get damaged, they <a href="/wiki/Apoptosis" title="Apoptosis">die</a>, and new cells take their place. Cancer starts when new cells form unneeded, and old or damaged cells do not die as they should. The buildup of extra cells often forms a mass of tissue called a growth or tumor. These abnormal cancer cells have many <a href="/wiki/Genetic_mutation" title="Genetic mutation" class="mw-redirect">genetic abnormalities</a> that cause them to grow excessively.<sup id="cite_ref-NCIGenetics_25-0" class="reference"><a href="#cite_note-NCIGenetics-25"><span>[</span>25<span>]</span></a></sup> When an ovary <a href="/wiki/Ovulation" title="Ovulation">releases an egg</a>, the <a href="/w/index.php?title=Egg_follicle&amp;action=edit&amp;redlink=1" class="new" title="Egg follicle (page does not exist)">egg follicle</a> bursts open and becomes the <a href="/wiki/Corpus_luteum" title="Corpus luteum">corpus luteum</a>. This structure needs to be repaired by dividing cells in the ovary.<sup id="cite_ref-CRUKRisks_18-13" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> Continuous ovulation for a long time means more repair of the ovary by dividing cells, which can acquire mutations in each division.<sup id="cite_ref-Hoffman35_16-17" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>Overall, the most common gene mutations in ovarian cancer occur in <i><a href="/wiki/Nuclear_factor_1" title="Nuclear factor 1" class="mw-redirect">NF1</a>, BRCA1, BRCA2,</i> and <i><a href="/w/index.php?title=CDK12&amp;action=edit&amp;redlink=1" class="new" title="CDK12 (page does not exist)">CDK12</a></i>. Type-I ovarian cancers, which tend to be less aggressive, tend to have <a href="/wiki/Microsatellite_instability" title="Microsatellite instability">microsatellite instability</a> in several genes, including <i><a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a>, <a href="/wiki/KRAS" title="KRAS">KRAS</a></i>, and <i><a href="/wiki/PTEN_(gene)" title="PTEN (gene)">PTEN</a></i>, which are <a href="/wiki/Tumor_suppressor" title="Tumor suppressor" class="mw-redirect">tumor suppressor</a> genes. Type-II cancers, the more aggressive type, have different genes mutated, including <i><a href="/wiki/P53" title="P53">p53</a>, BRCA1</i>, and <i>BRCA2</i>.<sup id="cite_ref-Jayson_11-9" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Low-grade cancers tend to have mutations in KRAS, whereas cancers of any grade that develop from low malignant potential tumors tend to have mutations in p53.<sup id="cite_ref-Hoffman35_16-18" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Type I cancers tend to develop from precursor lesions.<sup id="cite_ref-:7_14-14" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> Serous cancers that have BRCA mutations also inevitably have p53 mutations, indicating that the removal of both functional genes is important for cancer to develop.<sup id="cite_ref-Hoffman35_16-19" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>In 50% of high-grade serous cancers, homologous recombination DNA repair is dysfunctional, as are the <a href="/wiki/Notch_signaling_pathway" title="Notch signaling pathway">notch</a> and <a href="/wiki/FOXM1" title="FOXM1">FOXM1</a> signaling pathways. They also almost always have p53 mutations. Other than this, mutations in high-grade serous carcinoma are hard to characterize beyond their high degree of <a href="/wiki/Genomic_instability" title="Genomic instability" class="mw-redirect">genomic instability</a>. <i>BRCA1</i> and <i>BRCA2</i> are essential for homologous recombination DNA repair, and <a href="/wiki/Germline_mutation" title="Germline mutation">germline mutations</a> in these genes are found in about 15% of people with ovarian cancer.<sup id="cite_ref-Jayson_11-10" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> The most common mutations in BRCA1 and BRCA2 are the <a href="/wiki/Frameshift_mutations" title="Frameshift mutations" class="mw-redirect">frameshift mutations</a> that originated in a small <a href="/wiki/Founder_effect" title="Founder effect">founding population</a> of Ashkenazi Jews.<sup id="cite_ref-Hoffman35_16-20" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>Almost 100% of rare mucinous carcinomas have mutations in <i>KRAS</i> and amplifications of <i>ERBB2</i> (also known as <i>Her2/neu</i>).<sup id="cite_ref-Jayson_11-11" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Overall, 20% of ovarian cancers have mutations in <i>Her2/neu</i>.<sup id="cite_ref-Harrisons_12-15" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Serous carcinomas may develop from serous tubal intraepithelial carcinoma, rather than developing spontaneously from ovarian tissue. Other carcinomas develop from <a href="/w/index.php?title=Cortical_inclusion_cysts&amp;action=edit&amp;redlink=1" class="new" title="Cortical inclusion cysts (page does not exist)">cortical inclusion cysts</a>, which are groups of epithelial ovarian cells inside the <a href="/wiki/Stroma" title="Stroma" class="mw-disambig">stroma</a>.<sup id="cite_ref-Hoffman35_16-21" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=9" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Examination">Examination</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=10" title="Edit section: Examination">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:POvarianCA.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/c/c4/POvarianCA.png/220px-POvarianCA.png" width="220" height="165" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/c/c4/POvarianCA.png/330px-POvarianCA.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c4/POvarianCA.png/440px-POvarianCA.png 2x" data-file-width="1152" data-file-height="863" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:POvarianCA.png" class="internal" title="Enlarge"></a></div>
A very large ovarian cancer as seen on CT</div>
</div>
</div>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Serous_carcinoma_cytology.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/02/Serous_carcinoma_cytology.jpg/220px-Serous_carcinoma_cytology.jpg" width="220" height="147" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/02/Serous_carcinoma_cytology.jpg/330px-Serous_carcinoma_cytology.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/02/Serous_carcinoma_cytology.jpg/440px-Serous_carcinoma_cytology.jpg 2x" data-file-width="4272" data-file-height="2848" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Serous_carcinoma_cytology.jpg" class="internal" title="Enlarge"></a></div>
<a href="/wiki/Micrograph" title="Micrograph">Micrograph</a> of <a href="/wiki/Serous_carcinoma" title="Serous carcinoma">serous carcinoma</a>, a type of ovarian cancer, diagnosed in <a href="/wiki/Peritoneal_fluid" title="Peritoneal fluid">peritoneal fluid</a></div>
</div>
</div>
<p>Diagnosis of ovarian cancer starts with a physical examination (including a <a href="/wiki/Pelvic_examination" title="Pelvic examination">pelvic examination</a>), a blood test (for <a href="/wiki/CA-125" title="CA-125">CA-125</a> and sometimes other markers), and <a href="/wiki/Transvaginal_ultrasound" title="Transvaginal ultrasound" class="mw-redirect">transvaginal ultrasound</a>.<sup id="cite_ref-Harrisons_12-16" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Sometimes a <a href="/wiki/Rectovaginal_examination" title="Rectovaginal examination">rectovaginal examination</a> is used to help plan a surgery.<sup id="cite_ref-Hoffman35_16-22" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> The diagnosis must be confirmed with surgery to inspect the <a href="/wiki/Abdominal_cavity" title="Abdominal cavity">abdominal cavity</a>, take <a href="/wiki/Biopsies" title="Biopsies" class="mw-redirect">biopsies</a> (tissue samples for <a href="/wiki/Histopathology" title="Histopathology">microscopic analysis</a>), and look for cancer cells in the abdominal fluid. This helps to determine if an ovarian mass is <a href="/wiki/Benign" title="Benign" class="mw-redirect">benign</a> or malignant.<sup id="cite_ref-Harrisons_12-17" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Ovarian cancer's early stages (I/II) are difficult to diagnose because most symptoms are nonspecific and thus of little use in diagnosis; as a result, it is rarely diagnosed until it spreads and advances to later stages (III/IV).<sup id="cite_ref-26" class="reference"><a href="#cite_note-26"><span>[</span>26<span>]</span></a></sup> In patients in whom pregnancy is a possibility, <a href="/wiki/BHCG" title="BHCG" class="mw-redirect">BHCG</a> level should be measured during the diagnosis process. Serum <a href="/wiki/Alpha-fetoprotein" title="Alpha-fetoprotein">alpha-fetoprotein</a>, <a href="/wiki/Neuron-specific_enolase" title="Neuron-specific enolase" class="mw-redirect">neuron-specific enolase</a>, and <a href="/wiki/Lactate_dehydrogenase" title="Lactate dehydrogenase">lactate dehydrogenase</a> should be measured in young girls and adolescents with suspected ovarian tumors as younger patients are more likely to have malignant germ cell tumors.<sup id="cite_ref-Harrisons_12-18" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-:7_14-15" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>When an ovarian malignancy is included in a list of diagnostic possibilities, a limited number of laboratory tests are indicated. A complete blood count and serum electrolyte test should be obtained in all patients;<sup id="cite_ref-Miller_27-0" class="reference"><a href="#cite_note-Miller-27"><span>[</span>27<span>]</span></a></sup> when an ovarian cancer is present, these tests often show <a href="/wiki/Thrombocytosis" title="Thrombocytosis">a high number of platelets</a> (20-25% of people) and <a href="/wiki/Hyponatremia" title="Hyponatremia">low blood sodium levels</a> due to chemical signals secreted by the tumor.<sup id="cite_ref-Hoffman35_16-23" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> A positive test for <a href="/wiki/Inhibin_A" title="Inhibin A" class="mw-redirect">inhibin A</a> and <a href="/wiki/Inhibin_B" title="Inhibin B" class="mw-redirect">inhibin B</a> can indicate a granulosa cell tumor.<sup id="cite_ref-:7_14-16" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>A blood test for a marker molecule called CA-125 is useful in differential diagnosis and in follow up of the disease, but it by itself has not been shown to be an effective method to screen for early-stage ovarian cancer due to its unacceptable low sensitivity and specificity.<sup id="cite_ref-Miller_27-1" class="reference"><a href="#cite_note-Miller-27"><span>[</span>27<span>]</span></a></sup> CA-125 levels in premenopausal people over 200 U/mL may indicate ovarian cancer, as may any elevation in CA-125 above 35 U/mL in post-menopausal people. CA-125 levels are not accurate in early stage ovarian cancer, as fully half of stage I ovarian cancer patients have a normal CA-125 level.<sup id="cite_ref-:7_14-17" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Hoffman35_16-24" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> CA-125 may also be elevated in benign (non-cancerous) conditions, including <a href="/wiki/Endometriosis" title="Endometriosis">endometriosis</a>, <a href="/wiki/Pregnancy" title="Pregnancy">pregnancy</a>, <a href="/wiki/Uterine_fibroids" title="Uterine fibroids" class="mw-redirect">uterine fibroids</a>, <a href="/wiki/Menstruation" title="Menstruation">menstruation</a>, <a href="/wiki/Ovarian_cysts" title="Ovarian cysts" class="mw-redirect">ovarian cysts</a>, <a href="/wiki/Systemic_lupus_erythematosus" title="Systemic lupus erythematosus">Systemic lupus erythematosus</a>, <a href="/wiki/Liver_disease" title="Liver disease">liver disease</a>, <a href="/wiki/Inflammatory_bowel_disease" title="Inflammatory bowel disease">inflammatory bowel disease</a>, and <a href="/wiki/Pelvic_inflammatory_disease" title="Pelvic inflammatory disease">pelvic inflammatory disease</a>.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28"><span>[</span>28<span>]</span></a></sup> <a href="/wiki/HE4" title="HE4" class="mw-redirect">HE4</a> is another candidate for ovarian cancer testing, though it has not been extensively tested. Other tumor markers for ovarian cancer include <a href="/wiki/CA19-9" title="CA19-9">CA19-9</a>, <a href="/w/index.php?title=CA72-4&amp;action=edit&amp;redlink=1" class="new" title="CA72-4 (page does not exist)">CA72-4</a>, <a href="/wiki/CA15-3" title="CA15-3">CA15-3</a>, <a href="/w/index.php?title=Immunosuppressive_acidic_protein&amp;action=edit&amp;redlink=1" class="new" title="Immunosuppressive acidic protein (page does not exist)">immunosuppressive acidic protein</a>, <a href="/w/index.php?title=Haptoglobin-alpha&amp;action=edit&amp;redlink=1" class="new" title="Haptoglobin-alpha (page does not exist)">haptoglobin-alpha</a>, <a href="/w/index.php?title=OVX1&amp;action=edit&amp;redlink=1" class="new" title="OVX1 (page does not exist)">OVX1</a>, <a href="/wiki/Mesothelin" title="Mesothelin">mesothelin</a>, <a href="/wiki/Lysophosphatidic_acid" title="Lysophosphatidic acid">lysophosphatidic acid</a>, <a href="/wiki/Osteopontin" title="Osteopontin">osteopontin</a>, and <a href="/wiki/Fibroblast_growth_factor_23" title="Fibroblast growth factor 23">fibroblast growth factor 23</a>.<sup id="cite_ref-:7_14-18" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>Use of blood test panels may help in diagnosis.<sup id="cite_ref-:7_14-19" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Miller_27-2" class="reference"><a href="#cite_note-Miller-27"><span>[</span>27<span>]</span></a></sup> The OVA1 panel includes CA-125, <a href="/wiki/Beta-2_microglobulin" title="Beta-2 microglobulin">beta-2 microglobulin</a>, <a href="/wiki/Transferrin" title="Transferrin">transferrin</a>, <a href="/wiki/Apolipoprotein_A1" title="Apolipoprotein A1">apolipoprotein A1</a>, and <a href="/wiki/Transthyretin" title="Transthyretin">transthyretin</a>. OVA1 above 5.0 in premenopausal people and 4.4 in postmenopausal people indicates a high risk for cancer.<sup id="cite_ref-Hoffman35_16-25" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>Current research is looking at ways to consider tumor marker <a href="/wiki/Proteomics" title="Proteomics">proteomics</a> in combination with other indicators of disease (i.e. radiology and/or symptoms) to improve diagnostic accuracy. The challenge in such an approach is that the disparate prevalence of ovarian cancer means that even testing with very high sensitivity and specificity will still lead to a number of false positive results, which in turn may lead to issues such as performing surgical procedures in which cancer is not found intraoperatively.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup> <a href="/wiki/Genomics" title="Genomics">Genomics</a> approaches have not yet been developed for ovarian cancer.<sup id="cite_ref-:7_14-20" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>A physical examination, including a pelvic examination, and a pelvic ultrasound (transvaginal or otherwise) are both essential for diagnosis: physical examination may reveal increased abdominal girth and/or <a href="/wiki/Ascites" title="Ascites">ascites</a> (fluid within the abdominal cavity), while pelvic examination may reveal an ovarian or abdominal mass.<sup id="cite_ref-Jayson_11-12" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> An adnexal mass is a significant finding that often indicates ovarian cancer, especially if it is fixed, nodular, irregular, solid, and/or bilateral. Ovaries that can be felt are also a sign of ovarian cancer in postmenopausal women. Other parts of a physical examination for suspected ovarian cancer can include a <a href="/wiki/Breast_examination" title="Breast examination" class="mw-redirect">breast examination</a> and a <a href="/wiki/Digital_rectal_exam" title="Digital rectal exam" class="mw-redirect">digital rectal exam</a>.<sup id="cite_ref-:7_14-21" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p><a href="/wiki/CT_scanning" title="CT scanning" class="mw-redirect">CT scanning</a> is preferred to assess the extent of the tumor in the abdominopelvic cavity, though <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a> can also be used.<sup id="cite_ref-Jayson_11-13" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> CT scanning can also be useful for finding <a href="/w/index.php?title=Omental_caking&amp;action=edit&amp;redlink=1" class="new" title="Omental caking (page does not exist)">omental caking</a> or differentiating fluid from solid tumor in the abdomen, especially in low malignant potential tumors. However, it may not detect smaller tumors. Sometimes, a <a href="/wiki/Chest_radiograph" title="Chest radiograph">chest x-ray</a> is used to detect metastases in the chest or <a href="/wiki/Pleural_effusion" title="Pleural effusion">pleural effusion</a>. Another test for metastatic disease, though it is infrequently used, is a <a href="/wiki/Barium_enema" title="Barium enema" class="mw-redirect">barium enema</a>, which can show if the rectosigmoid colon is involved in the disease. <a href="/wiki/Positron_emission_tomography" title="Positron emission tomography">Positron emission tomography</a>, <a href="/wiki/Bone_scan" title="Bone scan" class="mw-redirect">bone scans</a>, and <a href="/wiki/Paracentesis" title="Paracentesis">paracentesis</a> are of limited use; in fact, paracentesis can cause metastases to form at the needle insertion site and may not provide useful results.<sup id="cite_ref-Hoffman35_16-26" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> However, paracentesis can be used in cases where there is no pelvic mass and ascites is still present.<sup id="cite_ref-Hoffman35_16-27" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> A physician suspecting ovarian cancer may also perform <a href="/wiki/Mammography" title="Mammography">mammography</a> or an <a href="/wiki/Endometrial_biopsy" title="Endometrial biopsy">endometrial biopsy</a> (in the case of abnormal bleeding) to assess the possibility of breast malignancies and endometrial malignancy, respectively. <a href="/wiki/Vaginal_ultrasonography" title="Vaginal ultrasonography">Vaginal ultrasonography</a> is often the first-line imaging study performed when an adnexal mass is found. Several characteristics of an adnexal mass indicate ovarian malignancy; they usually are solid, irregular, multilocular, and/or large; and they typically have papillary features, central vessels, and/or irregular internal septations.<sup id="cite_ref-:7_14-22" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>To definitively diagnose ovarian cancer, a surgical procedure to inspect the abdomen is required. This can be an open procedure (<a href="/wiki/Laparotomy" title="Laparotomy">laparotomy</a>, incision through the <a href="/wiki/Abdominal_wall" title="Abdominal wall">abdominal wall</a>) or <a href="/wiki/Keyhole_surgery" title="Keyhole surgery" class="mw-redirect">keyhole surgery</a> (<a href="/wiki/Laparoscopy" title="Laparoscopy">laparoscopy</a>). During this procedure, suspicious tissue is removed and sent for <a href="/wiki/Histopathology" title="Histopathology">microscopic analysis</a>. Usually, this includes a unilateral <a href="/wiki/Salpingo-oophorectomy" title="Salpingo-oophorectomy" class="mw-redirect">salpingo-oophorectomy</a>, removal of a single affected ovary and Fallopian tube. Fluid from the abdominal cavity can also be analyzed for cancerous <a href="/wiki/Cell_(biology)" title="Cell (biology)">cells</a>. If cancer is found, this procedure can also be used to determine the extent of its spread (which is a form of <a href="/wiki/Tumor_staging" title="Tumor staging" class="mw-redirect">tumor staging</a>).<sup id="cite_ref-Harrisons_12-19" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Risk_scoring">Risk scoring</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=11" title="Edit section: Risk scoring">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><span id="RMI"></span>A widely recognized method of estimating the risk of malignant ovarian cancer is the risk of malignancy index (RMI), calculated based on an initial workup.<sup id="cite_ref-Jayson_11-14" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-NICE2011_30-0" class="reference"><a href="#cite_note-NICE2011-30"><span>[</span>30<span>]</span></a></sup> An RMI score of over 200 or 250 is generally felt to indicate high risk for ovarian cancer.<sup id="cite_ref-Jayson_11-15" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-:7_14-23" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>The RMI is calculated as:</p>
<dl>
<dd>RMI = ultrasound score x menopausal score x CA-125 level in U/ml.<sup id="cite_ref-Jayson_11-16" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></dd>
</dl>
<p>Two methods can be used to determine the ultrasound score and menopausal score, with the resultant scores being referred to as RMI 1 and RMI 2, respectively, depending on what method is used.</p>
<table class="wikitable">
<tr>
<th style="width:32%;">Feature</th>
<th style="width:34%;">RMI 1<sup id="cite_ref-Jayson_11-17" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></th>
<th style="width:34%;">RMI 2<sup id="cite_ref-:7_14-24" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup></th>
</tr>
<tr>
<td>
<p>Ultrasound abnormalities:</p>
<ul>
<li>multilocular cyst</li>
<li>solid areas</li>
<li>ascites</li>
<li>intra-abdominal metastases</li>
</ul>
</td>
<td>
<div class="plainlist">
<ul>
<li>0 = no abnormality</li>
<li>1 = one abnormality</li>
<li>3 = two or more abnormalities</li>
</ul>
</div>
</td>
<td>
<div class="plainlist">
<ul>
<li>0 = none</li>
<li>1 = one abnormality</li>
<li>4 = two or more abnormalities</li>
</ul>
</div>
</td>
</tr>
<tr>
<td>Menopausal score</td>
<td>
<div class="plainlist">
<ul>
<li>1 = premenopausal</li>
<li>3 = postmenopausal</li>
</ul>
</div>
</td>
<td>
<div class="plainlist">
<ul>
<li>1 = premenopausal</li>
<li>4 = postmenopausal</li>
</ul>
</div>
</td>
</tr>
<tr>
<td>CA-125</td>
<td>Quantity in U/ml</td>
<td>Quantity in U/ml</td>
</tr>
</table>
<p>Another method for quantifying risk of ovarian cancer is the Risk of Ovarian Cancer Algorithm (ROCA), observes levels over time and determines if they are increasing rapidly enough to warrant transvaginal ultrasound.<sup id="cite_ref-Hoffman35_16-28" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> The Risk of Ovarian Malignancy algorithm uses CA-125 levels and <a href="/wiki/HE4" title="HE4" class="mw-redirect">HE4</a> levels to calculate the risk of ovarian cancer; it may be more effective than RMI. The Assessment of Different Neoplasias in the Adnexa (ADNEX) model can be used to assess risk of malignancy in an adnexal mass, based on its characteristics and risk factors. The QCancer (Ovary) algorithm is used to predict likelihood of ovarian cancer from risk factors.<sup id="cite_ref-:7_14-25" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Pathology">Pathology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=12" title="Edit section: Pathology">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:302px;"><a href="/wiki/File:Incidence_of_ovarian_cancers_by_histopathology.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Incidence_of_ovarian_cancers_by_histopathology.png/300px-Incidence_of_ovarian_cancers_by_histopathology.png" width="300" height="354" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Incidence_of_ovarian_cancers_by_histopathology.png/450px-Incidence_of_ovarian_cancers_by_histopathology.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Incidence_of_ovarian_cancers_by_histopathology.png/600px-Incidence_of_ovarian_cancers_by_histopathology.png 2x" data-file-width="2674" data-file-height="3155" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Incidence_of_ovarian_cancers_by_histopathology.png" class="internal" title="Enlarge"></a></div>
Ovarian cancers in women aged 20+, with area representing relative incidence and color representing five-year relative survival rate<sup id="cite_ref-SEER6215ch16_32-0" class="reference"><a href="#cite_note-SEER6215ch16-32"><span>[</span>32<span>]</span></a></sup></div>
</div>
</div>
<p>Ovarian cancers are classified according to the microscopic appearance of their structures (<a href="/wiki/Histology" title="Histology">histology</a> or <a href="/wiki/Histopathology" title="Histopathology">histopathology</a>). Histology dictates many aspects of clinical treatment, management, and <a href="/wiki/Prognosis" title="Prognosis">prognosis</a>. The gross pathology of ovarian cancers is very similar regardless of histologic type: tumors have solid and cystic masses.<sup id="cite_ref-Hoffman35_16-29" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> According to <a href="/wiki/Surveillance_Epidemiology_and_End_Results" title="Surveillance Epidemiology and End Results" class="mw-redirect">SEER</a>, the types of ovarian cancers in women age 20 and over are:<sup id="cite_ref-SEER6215ch16_32-1" class="reference"><a href="#cite_note-SEER6215ch16-32"><span>[</span>32<span>]</span></a></sup></p>
<table class="wikitable">
<tr>
<th>Percent of<br />
ovarian cancers<br />
in women<br />
age 20+</th>
<th><a href="/wiki/Histology" title="Histology">Histology</a></th>
<th>Five-year<br />
<a href="/wiki/Relative_survival_rate" title="Relative survival rate" class="mw-redirect">RSR</a></th>
</tr>
<tr>
<td>89.7</td>
<td><a href="/wiki/Surface_epithelial-stromal_tumor" title="Surface epithelial-stromal tumor">Surface epithelial-stromal tumor</a> (<a href="/wiki/Adenocarcinoma" title="Adenocarcinoma">adenocarcinoma</a>)</td>
<td>54.4</td>
</tr>
<tr>
<td> 26.4</td>
<td><a href="/wiki/Papillary_serous_cystadenocarcinoma" title="Papillary serous cystadenocarcinoma">Papillary serous cystadenocarcinoma</a></td>
<td>21.0</td>
</tr>
<tr>
<td> 15.9</td>
<td>"Borderline" adenocarcinoma<br />
(underestimated - short data collection interval)</td>
<td>98.2</td>
</tr>
<tr>
<td> 12.6</td>
<td>Adenocarcinoma, not otherwise specified</td>
<td>18.3</td>
</tr>
<tr>
<td> 9.8</td>
<td><a href="/wiki/Endometrioid_tumor" title="Endometrioid tumor">Endometrioid tumor</a></td>
<td>70.9</td>
</tr>
<tr>
<td> 5.8</td>
<td><a href="/wiki/Serous_cystadenocarcinoma" title="Serous cystadenocarcinoma">Serous cystadenocarcinoma</a></td>
<td>44.2</td>
</tr>
<tr>
<td> 5.5</td>
<td><a href="/wiki/Papilloma" title="Papilloma">Papillary</a></td>
<td>21.0</td>
</tr>
<tr>
<td> 4.2</td>
<td><a href="/wiki/Mucinous_cystadenocarcinoma" title="Mucinous cystadenocarcinoma">Mucinous cystadenocarcinoma</a></td>
<td>77.7</td>
</tr>
<tr>
<td> 4.0</td>
<td><a href="/wiki/Clear-cell_ovarian_tumor" title="Clear-cell ovarian tumor" class="mw-redirect">Clear-cell ovarian tumor</a></td>
<td>61.5</td>
</tr>
<tr>
<td> 3.4</td>
<td><a href="/wiki/Mucinous_adenocarcinoma" title="Mucinous adenocarcinoma" class="mw-redirect">Mucinous adenocarcinoma</a></td>
<td>49.1</td>
</tr>
<tr>
<td> 1.3</td>
<td><a href="/wiki/Cystadenocarcinoma" title="Cystadenocarcinoma">Cystadenocarcinoma</a></td>
<td>50.7</td>
</tr>
<tr>
<td>5.5</td>
<td><a href="/wiki/Carcinoma" title="Carcinoma">Carcinoma</a></td>
<td></td>
</tr>
<tr>
<td> 4.1</td>
<td>Carcinoma not otherwise specified</td>
<td>26.8</td>
</tr>
<tr>
<td> 1.1</td>
<td><a href="/wiki/Sex_cord-stromal_tumour" title="Sex cord-stromal tumour" class="mw-redirect">Sex cord-stromal tumour</a></td>
<td>87.8</td>
</tr>
<tr>
<td> 0.3</td>
<td>Other carcinomas, specified</td>
<td>37.3</td>
</tr>
<tr>
<td>1.7</td>
<td><a href="/wiki/Mullerian_tumor" title="Mullerian tumor" class="mw-redirect">Mullerian tumor</a></td>
<td>29.8</td>
</tr>
<tr>
<td>1.5</td>
<td><a href="/wiki/Germ_cell_tumor" title="Germ cell tumor">Germ cell tumor</a></td>
<td>91.0</td>
</tr>
<tr>
<td> 0.8</td>
<td><a href="/wiki/Teratoma" title="Teratoma">Teratoma</a></td>
<td>89.1</td>
</tr>
<tr>
<td> 0.5</td>
<td><a href="/wiki/Dysgerminoma" title="Dysgerminoma">Dysgerminoma</a></td>
<td>96.8</td>
</tr>
<tr>
<td> 0.3</td>
<td>Other, specified</td>
<td>85.1</td>
</tr>
<tr>
<td>0.6</td>
<td>Not otherwise specified</td>
<td>23.0</td>
</tr>
<tr>
<td>0.5</td>
<td>Epidermoid (<a href="/wiki/Squamous_cell_carcinoma" title="Squamous cell carcinoma" class="mw-redirect">squamous cell carcinoma</a>)</td>
<td>51.3</td>
</tr>
<tr>
<td>0.2</td>
<td><a href="/wiki/Brenner_tumor" title="Brenner tumor" class="mw-redirect">Brenner tumor</a></td>
<td>67.9</td>
</tr>
<tr>
<td>0.2</td>
<td>Other, specified</td>
<td>71.7</td>
</tr>
</table>
<p>Ovarian cancers are histologically and genetically divided into type I or type II. Type I cancers are of low histological grade, and include endometrioid, mucinous, and clear-cell carcinomas. Type II cancers are of higher histological grade and include serous carcinoma and carcinosarcoma.<sup id="cite_ref-Jayson_11-18" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Epithelial_carcinoma">Epithelial carcinoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=13" title="Edit section: Epithelial carcinoma">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Ovarian_carcinoma.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Ovarian_carcinoma.JPG/220px-Ovarian_carcinoma.JPG" width="220" height="131" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Ovarian_carcinoma.JPG/330px-Ovarian_carcinoma.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Ovarian_carcinoma.JPG/440px-Ovarian_carcinoma.JPG 2x" data-file-width="2995" data-file-height="1781" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Ovarian_carcinoma.JPG" class="internal" title="Enlarge"></a></div>
A pathological specimen of ovarian carcinoma</div>
</div>
</div>
<p><a href="/wiki/Surface_epithelial-stromal_tumour" title="Surface epithelial-stromal tumour" class="mw-redirect">Surface epithelial-stromal tumour</a>, also known as ovarian epithelial carcinoma, is the most common type of ovarian cancer, representing approximately 90% of ovarian cancers. It includes <a href="/wiki/Serous_tumour" title="Serous tumour">serous tumour</a>, <a href="/wiki/Endometrioid_tumor" title="Endometrioid tumor">endometrioid tumor</a>, and <a href="/wiki/Mucinous" title="Mucinous" class="mw-redirect">mucinous</a> <a href="/wiki/Cystadenocarcinoma" title="Cystadenocarcinoma">cystadenocarcinoma</a>. Less common tumors are malignant <a href="/wiki/Brenner_tumor" title="Brenner tumor" class="mw-redirect">Brenner tumor</a> and <a href="/wiki/Transitional_cell_carcinoma_of_the_ovary" title="Transitional cell carcinoma of the ovary">transitional cell carcinoma of the ovary</a>. Epithelial ovarian cancers develop from the <a href="/wiki/Epithelium" title="Epithelium">epithelium</a>, a layer of cells that covers the ovary.<sup id="cite_ref-:1_33-0" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Serous_carcinoma">Serous carcinoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=14" title="Edit section: Serous carcinoma">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<p>Most people with epithelial ovarian carcinoma, about two-thirds, have a serous carcinoma,<sup id="cite_ref-Jayson_11-19" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> though this proportion is estimated as high as 80%.<sup id="cite_ref-:7_14-26" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Levy_34-0" class="reference"><a href="#cite_note-Levy-34"><span>[</span>34<span>]</span></a></sup> Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to chemotherapy or hormonal treatments.<sup id="cite_ref-Jayson_11-20" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Serous carcinomas are thought to begin in the <a href="/wiki/Fallopian_tube" title="Fallopian tube">Fallopian tube</a>.<sup id="cite_ref-:1_33-1" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup> Histologically, serous adenocarcinomas have <a href="/wiki/Psammoma_body" title="Psammoma body">psammoma bodies</a>. Low-grade serous adenocarcinomas resemble Fallopian tube epithelium, whereas high-grade serous adenocarcinomas show <a href="/wiki/Anaplasia" title="Anaplasia">anaplasia</a> and <a href="/wiki/Nuclear_atypia" title="Nuclear atypia">nuclear atypia</a>.<sup id="cite_ref-Hoffman35_16-30" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>50% of the time, serous carcinomas are bilateral, and in 85% of cases, they have spread beyond the ovary at the time of diagnosis. Most have a diameter over 15&#160;cm.<sup id="cite_ref-Levy_34-1" class="reference"><a href="#cite_note-Levy-34"><span>[</span>34<span>]</span></a></sup></p>
<h6><span class="mw-headline" id="Primary_peritoneal_carcinoma">Primary peritoneal carcinoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=15" title="Edit section: Primary peritoneal carcinoma">edit</a><span class="mw-editsection-bracket">]</span></span></h6>
<div class="hatnote relarticle mainarticle">Main article: <a href="/wiki/Primary_peritoneal_carcinoma" title="Primary peritoneal carcinoma">Primary peritoneal carcinoma</a></div>
<p>Primary peritoneal carcinomas develop from the <a href="/wiki/Peritoneum" title="Peritoneum">peritoneum</a>, a membrane that covers the <a href="/wiki/Abdominal_cavity" title="Abdominal cavity">abdominal cavity</a> that has the same embryonic origin as the ovary. They are often discussed and classified with ovarian cancers when they affect the ovary.<sup id="cite_ref-:1_33-2" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup><sup id="cite_ref-35" class="reference"><a href="#cite_note-35"><span>[</span>35<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Clear-cell_carcinoma">Clear-cell carcinoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=16" title="Edit section: Clear-cell carcinoma">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<p>Clear-cell ovarian carcinomas do not typically respond well to chemotherapy and may be related to endometriosis.<sup id="cite_ref-Jayson_11-21" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> They represent approximately 5% of all endometrial cancers. Japanese women develop clear-cell ovarian cancer more frequently than other groups of women.<sup id="cite_ref-:7_14-27" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Endometrioid">Endometrioid</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=17" title="Edit section: Endometrioid">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<p>Endometrioid adenocarcinomas make up approximately 15-20% of epithelial ovarian cancers. Because they are typically low-grade, endometrioid adenocarcinomas have a good prognosis. These tumors frequently co-occur with <a href="/wiki/Endometriosis" title="Endometriosis">endometriosis</a> or endometrial cancer.<sup id="cite_ref-Hoffman35_16-31" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Mucinous">Mucinous</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=18" title="Edit section: Mucinous">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<h6><span class="mw-headline" id="Adenocarcinoma">Adenocarcinoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=19" title="Edit section: Adenocarcinoma">edit</a><span class="mw-editsection-bracket">]</span></span></h6>
<h6><span class="mw-headline" id="Pseudomyxoma_peritonei">Pseudomyxoma peritonei</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=20" title="Edit section: Pseudomyxoma peritonei">edit</a><span class="mw-editsection-bracket">]</span></span></h6>
<h5><span class="mw-headline" id="Undifferentiated_epithelial">Undifferentiated epithelial</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=21" title="Edit section: Undifferentiated epithelial">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<p>Undifferentiated cancers - those where the cell type cannot be determined - make up about 10% of epithelial ovarian cancers.<sup id="cite_ref-:1_33-3" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Sex_cord_stromal_tumor">Sex cord stromal tumor</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=22" title="Edit section: Sex cord stromal tumor">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Sex_cord-stromal_tumour" title="Sex cord-stromal tumour" class="mw-redirect">Sex cord-stromal tumor</a>, including <a href="/wiki/Estrogen" title="Estrogen">estrogen</a>-producing <a href="/wiki/Granulosa_cell_tumor" title="Granulosa cell tumor" class="mw-redirect">granulosa cell tumor</a>, the benign <a href="/wiki/Thecoma" title="Thecoma">thecoma</a>, and virilizing <a href="/wiki/Sertoli-Leydig_cell_tumor" title="Sertoli-Leydig cell tumor" class="mw-redirect">Sertoli-Leydig cell tumor</a> or <a href="/wiki/Arrhenoblastoma" title="Arrhenoblastoma" class="mw-redirect">arrhenoblastoma</a>, accounts for 7% of ovarian cancers. They occur most frequently in women between 50 and 69 years of age, but can occur in women of any age, including young girls. They are not typically aggressive and are usually unilateral.<sup id="cite_ref-Harrisons_12-20" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Several different cells from the <a href="/wiki/Mesenchyme" title="Mesenchyme">mesenchyme</a> can give rise to sex-cord or stromal tumors. These include <a href="/wiki/Fibroblast" title="Fibroblast">fibroblasts</a> and endocrine cells. The symptoms of a sex-cord or stromal ovarian tumor can differ from other types of ovarian cancer. Common signs and symptoms include <a href="/wiki/Ovarian_torsion" title="Ovarian torsion">ovarian torsion</a>, <a href="/wiki/Hemorrhage" title="Hemorrhage" class="mw-redirect">hemorrhage</a> from or rupture of the tumor, an abdominal mass, and hormonal disruption. In children, <a href="/wiki/Precocious_puberty#Isosexual_and_heterosexual" title="Precocious puberty">isosexual precocious pseudopuberty</a> may occur with granulosa cell tumors since they produce estrogen. These tumors cause abnormalities in menstruation (<a href="/wiki/Menometrorrhagia" title="Menometrorrhagia">excessive bleeding</a>, <a href="/wiki/Oligomenorrhea" title="Oligomenorrhea">infrequent menstruation</a>, or <a href="/wiki/Amenorrhea" title="Amenorrhea" class="mw-redirect">no menstruation</a>) or postmenopausal bleeding. Because these tumors produce estrogen, they can cause or occur at the same time as <a href="/wiki/Endometrial_cancer" title="Endometrial cancer">endometrial cancer</a> or <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a>. Other sex-cord/stromal tumors present with distinct symptoms. Sertoli-Leydig cell tumors cause <a href="/wiki/Virilization" title="Virilization">virilization</a> and <a href="/wiki/Hirsutism" title="Hirsutism">excessive hair growth</a> due to the production of <a href="/wiki/Testosterone" title="Testosterone">testosterone</a> and <a href="/wiki/Androstenedione" title="Androstenedione">androstenedione</a>, which can also cause <a href="/wiki/Cushing%27s_syndrome" title="Cushing's syndrome">Cushing's syndrome</a> in rare cases. Also, sex-cord stromal tumors occur that do not cause a hormonal imbalance, including benign fibromas, which cause ascites and <a href="/wiki/Hydrothorax" title="Hydrothorax">hydrothorax</a>.<sup id="cite_ref-Harrisons_12-21" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Granulosa_cell_tumor">Granulosa cell tumor</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=23" title="Edit section: Granulosa cell tumor">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<h5><span class="mw-headline" id="Sertoli-Leydig_cell_tumor">Sertoli-Leydig cell tumor</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=24" title="Edit section: Sertoli-Leydig cell tumor">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<h4><span class="mw-headline" id="Germ_cell_tumor">Germ cell tumor</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=25" title="Edit section: Germ cell tumor">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Germ cell tumors of the ovary develop from the ovarian <a href="/wiki/Germ_cells" title="Germ cells" class="mw-redirect">germ cells</a>.<sup id="cite_ref-:1_33-4" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup> <a href="/wiki/Germ_cell_tumor" title="Germ cell tumor">Germ cell tumor</a> accounts for about 30% of ovarian tumors, but only 5% of ovarian cancers, because most germ-cell tumors are <a href="/wiki/Teratoma" title="Teratoma">teratomas</a> and most teratomas are benign. Malignant teratomas tend to occur in older women, when one of the germ layers in the tumor develops into a <a href="/wiki/Squamous_cell_carcinoma" title="Squamous cell carcinoma" class="mw-redirect">squamous cell carcinoma</a>.<sup id="cite_ref-Harrisons_12-22" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Germ-cell tumors tend to occur in young women (20s-30s) and girls, making up 70% of the ovarian cancer seen in that age group.<sup id="cite_ref-Current_17-1" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup> Germ-cell tumors can include dysgerminomas, teratomas, yolk sac tumors/endodermal sinus tumors, and choriocarcinomas, when they arise in the ovary. Some germ-cell tumors have an <a href="/wiki/Isochromosome" title="Isochromosome">isochromosome</a> 12, where one arm of chromosome 12 is deleted and replaced with a duplicate of the other.<sup id="cite_ref-Harrisons_12-23" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> While the overall prognosis of germ-cell tumors is favorable, it can vary substantially with specific histology; for instance, the prognosis of the most common germ cell tumor (<a href="/wiki/Dysgerminomas" title="Dysgerminomas" class="mw-redirect">dysgerminomas</a>) tends to be good, whilst the second-most common (<a href="/wiki/Endodermal_sinus_tumor" title="Endodermal sinus tumor">endodermal sinus tumor</a>) tends to have a poor prognosis.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (December 2014)">citation needed</span></a></i>]</sup> Overall, they metastasize more frequently than epithelial ovarian cancers. In addition, the cancer markers used vary with tumor type: <a href="/wiki/Choriocarcinomas" title="Choriocarcinomas" class="mw-redirect">choriocarcinomas</a> are monitored with <a href="/wiki/Beta-HCG" title="Beta-HCG" class="mw-redirect">beta-HCG</a> and endodermal sinus tumors with <a href="/wiki/Alpha-fetoprotein" title="Alpha-fetoprotein">alpha-fetoprotein</a>.<sup id="cite_ref-Harrisons_12-24" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Germ-cell tumors are typically discovered when they become large, palpable masses. However, like sex cord tumors, they can cause ovarian torsion or hemorrhage and, in children, isosexual precocious puberty. They frequently metastasize to nearby lymph nodes, especially para-aortic and pelvic lymph nodes.<sup id="cite_ref-Harrisons_12-25" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Dysgerminoma">Dysgerminoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=26" title="Edit section: Dysgerminoma">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<p>Dysgerminoma accounts for 35% of ovarian cancer in young women.<sup id="cite_ref-Current_17-2" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup> These tumors may have mutations in <a href="/wiki/CD117" title="CD117">the <i>KIT</i> gene</a>, a mutation known for its role in <a href="/wiki/Gastrointestinal_stromal_tumor" title="Gastrointestinal stromal tumor">gastrointestinal stromal tumor</a>. <a href="/wiki/Intersexuality" title="Intersexuality" class="mw-redirect">People with an XY karyotype and ovaries</a> (<a href="/wiki/Gonadal_dysgenesis" title="Gonadal dysgenesis">gonadal dysgenesis</a>) who develop a unilateral dysgerminoma are at risk for a <a href="/wiki/Gonadoblastoma" title="Gonadoblastoma">gonadoblastoma</a> in the other ovary, and in this case, both ovaries are usually removed when a unilateral dysgerminoma is discovered. However, in general, dysgerminomas are bilateral 10-15% of the time.<sup id="cite_ref-Harrisons_12-26" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<h5><span class="mw-headline" id="Choriocarcinoma">Choriocarcinoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=27" title="Edit section: Choriocarcinoma">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<h5><span class="mw-headline" id="Immature_.28solid.29_teratoma">Immature (solid) teratoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=28" title="Edit section: Immature (solid) teratoma">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<h5><span class="mw-headline" id="Yolk_sac_tumor.2Fendodermal_sinus_tumor">Yolk sac tumor/endodermal sinus tumor</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=29" title="Edit section: Yolk sac tumor/endodermal sinus tumor">edit</a><span class="mw-editsection-bracket">]</span></span></h5>
<h4><span class="mw-headline" id="Mixed_tumors">Mixed tumors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=30" title="Edit section: Mixed tumors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Mixed tumors contain elements of more than one of the above classes of tumor histology. To be classed as a mixed tumor, the minor type must make up more than 10% of the tumor.<sup id="cite_ref-:7_14-28" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Secondary_ovarian_cancer">Secondary ovarian cancer</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=31" title="Edit section: Secondary ovarian cancer">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Ovarian cancer can also be a secondary cancer, the result of <a href="/wiki/Metastasis" title="Metastasis">metastasis</a> from a primary cancer elsewhere in the body.<sup id="cite_ref-Harrisons_12-27" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> About 7% of ovarian cancers are due to metastases, while the rest are primary cancers.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (November 2014)">citation needed</span></a></i>]</sup> Common primary cancers are <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a>, <a href="/wiki/Colon_cancer" title="Colon cancer" class="mw-redirect">colon cancer</a>, <a href="/wiki/Appendiceal_cancer" title="Appendiceal cancer" class="mw-redirect">appendiceal cancer</a>, and <a href="/wiki/Stomach_cancer" title="Stomach cancer">stomach cancer</a> (primary gastric cancers that metastasize to the ovary are called <a href="/wiki/Krukenberg_tumor" title="Krukenberg tumor">Krukenberg tumors</a>).<sup id="cite_ref-Harrisons_12-28" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Endometrial cancer and lymphomas can also metastasize to the ovary.<sup id="cite_ref-Levy_34-2" class="reference"><a href="#cite_note-Levy-34"><span>[</span>34<span>]</span></a></sup> Surface epithelial-stromal tumor can originate in the <a href="/wiki/Peritoneum" title="Peritoneum">peritoneum</a> (the lining of the abdominal cavity), in which case the ovarian cancer is secondary to <a href="/wiki/Primary_peritoneal_cancer" title="Primary peritoneal cancer" class="mw-redirect">primary peritoneal cancer</a>, but treatment is basically the same as for primary surface epithelial-stromal tumor involving the peritoneum.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (November 2014)">citation needed</span></a></i>]</sup></p>
<h4><span class="mw-headline" id="Low_malignant_potential_tumors">Low malignant potential tumors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=32" title="Edit section: Low malignant potential tumors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Low malignant potential ovarian tumors, also called borderline tumors, have some benign and some malignant features.<sup id="cite_ref-Hoffman35_16-32" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> LMP tumors make up approximately 10%-15% of all ovarian tumors.<sup id="cite_ref-:7_14-29" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-:1_33-5" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup> They develop earlier than epithelial ovarian cancer, around the age of 40-49. They typically do not have extensive invasion; 10% of LMP tumors have areas of stromal microinvasion (&lt;3mm, &lt;5% of tumor). LMP tumors have other abnormal features, including increased mitosis, <a href="/wiki/Pleomorphism_(cytology)" title="Pleomorphism (cytology)">changes in cell size or nucleus size</a>, <a href="/wiki/Nuclear_atypia" title="Nuclear atypia">abnormal nuclei</a>, cell stratification, and <a href="/w/index.php?title=Papillary_projections&amp;action=edit&amp;redlink=1" class="new" title="Papillary projections (page does not exist)">small projections on cells</a> (papillary projections). Serous and/or mucinous characteristics can be seen on histological examination, and serous histology makes up the overwhelming majority of advanced LMP tumors. More than 80% of LMP tumors are Stage I; 15% are stage II and III and less than 5% are stage IV.<sup id="cite_ref-Hoffman35_16-33" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Implants of LMP tumors are often non-invasive.<sup id="cite_ref-:1_33-6" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Staging">Staging</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=33" title="Edit section: Staging">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Ovarian cancer is staged using the <a href="/wiki/International_Federation_of_Gynecology_and_Obstetrics" title="International Federation of Gynecology and Obstetrics" class="mw-redirect">FIGO</a> staging system and uses information obtained after surgery, which can include a total abdominal <a href="/wiki/Hysterectomy" title="Hysterectomy">hysterectomy</a>, removal of (usually) both ovaries and Fallopian tubes, (usually) the omentum, <a href="/wiki/Pelvic_washing" title="Pelvic washing" class="mw-redirect">pelvic (peritoneal) washings</a>, and pelvic biopsies for cytopathology.<sup id="cite_ref-Jayson_11-22" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-Harrisons_12-29" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-SGO_36-0" class="reference"><a href="#cite_note-SGO-36"><span>[</span>36<span>]</span></a></sup> Around 30% of ovarian cancers that appear confined to the ovary have metastasized microscopically, which is why even stage-I cancers must be staged completely.<sup id="cite_ref-Harrisons_12-30" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> The AJCC stage is the same as the FIGO stage. The AJCC staging system describes the extent of the primary tumor (T), the absence or presence of <a href="/wiki/Metastasis" title="Metastasis">metastasis</a> to nearby <a href="/wiki/Lymph_nodes" title="Lymph nodes" class="mw-redirect">lymph nodes</a> (N), and the absence or presence of distant metastasis (M).<sup id="cite_ref-A_37-0" class="reference"><a href="#cite_note-A-37"><span>[</span>37<span>]</span></a></sup> The most common stage at diagnosis is stage IIIc, with over 70% of diagnoses.<sup id="cite_ref-Harrisons_12-31" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Tumor_deposet.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Tumor_deposet.JPG/220px-Tumor_deposet.JPG" width="220" height="164" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Tumor_deposet.JPG/330px-Tumor_deposet.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/21/Tumor_deposet.JPG/440px-Tumor_deposet.JPG 2x" data-file-width="2592" data-file-height="1936" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Tumor_deposet.JPG" class="internal" title="Enlarge"></a></div>
Ovarian adenocarcinoma deposit in the <a href="/wiki/Mesentery" title="Mesentery">mesentery</a> of the small bowel</div>
</div>
</div>
<p>The FIGO stages are as follows:<sup id="cite_ref-Jayson_11-23" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-SGO_36-1" class="reference"><a href="#cite_note-SGO-36"><span>[</span>36<span>]</span></a></sup></p>
<table class="wikitable">
<tr>
<th>Stage</th>
<th></th>
<th></th>
<th></th>
<th>Description</th>
</tr>
<tr>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td>Cancer is completely limited to the ovary</td>
</tr>
<tr>
<td></td>
<td>IA</td>
<td></td>
<td></td>
<td>involves one ovary, capsule intact, no tumor on ovarian surface, negative washings</td>
</tr>
<tr>
<td></td>
<td>IB</td>
<td></td>
<td></td>
<td>involves both ovaries; capsule intact; no tumor on ovarian surface; negative washings</td>
</tr>
<tr>
<td></td>
<td>IC</td>
<td></td>
<td></td>
<td>tumor involves one or both ovaries</td>
</tr>
<tr>
<td></td>
<td>IC1</td>
<td></td>
<td></td>
<td>surgical spill</td>
</tr>
<tr>
<td></td>
<td>IC2</td>
<td></td>
<td></td>
<td>capsule has ruptured or tumor on ovarian surface</td>
</tr>
<tr>
<td></td>
<td>IC3</td>
<td></td>
<td></td>
<td>positive ascites or washings</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>pelvic extension of the tumor (must be confined to the pelvis) or primary peritoneal tumor, involves one or both ovaries</td>
</tr>
<tr>
<td></td>
<td>IIA</td>
<td></td>
<td></td>
<td>tumor found on uterus or fallopian tubes</td>
</tr>
<tr>
<td></td>
<td>IIB</td>
<td></td>
<td></td>
<td>tumor elsewhere in the pelvis</td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td>cancer found outside the pelvis or in the retroperitoneal lymph nodes, involves one or both ovaries</td>
</tr>
<tr>
<td></td>
<td>IIIA</td>
<td></td>
<td></td>
<td>metastasis in retroperitoneal lymph nodes or microscopic extrapelvic metastasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IIIA1</td>
<td></td>
<td>metastasis in retroperitoneal lymph nodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IIIA1(i)</td>
<td>the metastasis is less than 10&#160;mm in diameter</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IIIA1(ii)</td>
<td>the metastasis is greater than 10&#160;mm in diameter</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IIIA2</td>
<td></td>
<td>microscopic metastasis in the peritoneum, regardless of retroperitoneal lymph node status</td>
</tr>
<tr>
<td></td>
<td>IIIB</td>
<td></td>
<td></td>
<td>metastasis in the peritoneum less than or equal to 2&#160;cm in diameter, regardless of retroperitoneal lymph node status; or metastasis to liver or spleen capsule</td>
</tr>
<tr>
<td></td>
<td>IIIC</td>
<td></td>
<td></td>
<td>metastasis in the peritoneum greater than 2&#160;cm in diameter, regardless of retroperitoneal lymph node status; or metastasis to liver or spleen capsule</td>
</tr>
<tr>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td>distant metastasis (i.e. outside of the peritoneum)</td>
</tr>
<tr>
<td></td>
<td>IVA</td>
<td></td>
<td></td>
<td>pleural effusion containing cancer cells</td>
</tr>
<tr>
<td></td>
<td>IVB</td>
<td></td>
<td></td>
<td>metastasis to distant organs (including the parenchyma of the spleen or liver), or metastasis to the inguinal and extra-abdominal lymph nodes</td>
</tr>
</table>
<ul class="gallery mw-gallery-traditional">
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:15px auto;"><a href="/wiki/File:Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/5/56/Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg/112px-Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg.png" width="112" height="120" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/56/Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg/168px-Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/56/Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg/225px-Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg.png 2x" data-file-width="335" data-file-height="358" /></a></div>
</div>
<div class="gallerytext">
<p>Stage 1 ovarian cancer</p>
</div>
</div>
</li>
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:28px auto;"><a href="/wiki/File:Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/19/Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg/120px-Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg.png" width="120" height="94" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/19/Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg/180px-Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/19/Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg/240px-Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg.png 2x" data-file-width="347" data-file-height="272" /></a></div>
</div>
<div class="gallerytext">
<p>Stage 2 ovarian cancer</p>
</div>
</div>
</li>
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:15px auto;"><a href="/wiki/File:Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg/101px-Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg.png" width="101" height="120" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg/152px-Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg/203px-Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg.png 2x" data-file-width="346" data-file-height="409" /></a></div>
</div>
<div class="gallerytext">
<p>Stage 3 ovarian cancer</p>
</div>
</div>
</li>
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:15px auto;"><a href="/wiki/File:Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/68/Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg/91px-Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg.png" width="91" height="120" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/68/Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg/136px-Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/68/Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg/182px-Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg.png 2x" data-file-width="340" data-file-height="448" /></a></div>
</div>
<div class="gallerytext">
<p>Stage 4 ovarian cancer</p>
</div>
</div>
</li>
</ul>
<p>Para-aortic lymph node metastases are considered regional lymph nodes (Stage IIIC). As there is only one para-aortic lymph node intervening before the thoracic duct on the right side of the body, the ovarian cancer can rapidly spread to distant sites such as the lung.</p>
<p>The AJCC/TNM staging system includes three categories for ovarian cancer, T, N, and M. The T category contains three other subcategories, T1, T2, and T3, each of them being classified according to the place where the tumor has developed (in one or both ovaries, inside or outside the ovary). The T1 category of ovarian cancer describes ovarian tumors that are confined to the ovaries, and which may affect one or both of them. The subsubcategory T1a is used to stage cancer found in only one ovary, which has left the capsule intact and which cannot be found in the fluid taken from the pelvis. Cancer that has not affected the capsule is confined to the inside of the ovaries and cannot be found in the fluid taken from the pelvis, but has affected both ovaries, is staged as T1b. T1c category describes a type of tumor that can affect one or both ovaries, and which has grown through the capsule of an ovary or it is present in the fluid taken from the pelvis. T2 is a more advanced stage of cancer. In this case, the tumor has grown in one or both ovaries and is spread to the uterus, Fallopian tubes, or other pelvic tissues. Stage T2a is used to describe a cancerous tumor that has spread to the uterus or the Fallopian tubes (or both) but which is not present in the fluid taken from the pelvis. Stages T2b and T2c indicate cancer that metastasized to other pelvic tissues than the uterus and Fallopian tubes and which cannot be seen in the fluid taken from the pelvis, respectively tumors that spread to any of the pelvic tissues (including uterus and Fallopian tubes), but which can also be found in the fluid taken from the pelvis. T3 is the stage used to describe cancer that has spread to the <a href="/wiki/Peritoneum" title="Peritoneum">peritoneum</a>. This stage provides information on the size of the metastatic tumors (tumors that are located in other areas of the body, but are caused by ovarian cancer). These tumors can be very small, visible only under the <a href="/wiki/Microscope" title="Microscope">microscope</a> (T3a), visible but not larger than 2&#160;cm (T3b) and bigger than 2&#160;cm (T3c).</p>
<p>This staging system also uses N categories to describe cancers that have or not spread to nearby lymph nodes. The two N categories are N0, which indicates the cancerous tumors have not affected the lymph nodes, and N1, which indicates the involvement of lymph nodes close to the tumor.</p>
<p>The M categories in the AJCC/TNM staging system provide information on whether the ovarian cancer has metastasized to distant organs such as liver or lungs. M0 indicates the cancer did not spread to distant organs and M1 category is used for cancer that has spread to other organs of the body.</p>
<p>The AJCC/TNM staging system also contains a Tx and a Nx subcategory which indicates the extent of the tumor cannot be described because of insufficient data, respectively the involvement of the lymph nodes cannot be described because of the same reason.</p>
<p>The ovarian cancer stages are made up by combining the TNM categories in the following manner:</p>
<ul>
<li>Stage I: T1+N0+M0
<ul>
<li>IA: T1a+N0+M0</li>
<li>IB: T1b+N0+M0</li>
<li>IC: T1c+N0+M0</li>
</ul>
</li>
<li>Stage II: T2+N0+M0
<ul>
<li>IIa: T2a+N0+M0</li>
<li>IIB: T2b+N0+M0</li>
<li>IIC: T2c+N0+M0</li>
</ul>
</li>
<li>Stage III: T3+ N0+M0
<ul>
<li>IIIA: T3a+ N0+M0</li>
<li>IIIB: T3b+ N0+M0</li>
<li>IIIC: T3c+ N0+M0 or Any T+N1+M0</li>
</ul>
</li>
<li>Stage IV: Any T+ Any N+M1</li>
</ul>
<p>In addition to being staged, like all cancers, ovarian cancer is also graded. The histologic grade of a tumor measures how abnormal or malignant its cells look under the microscope. The four grades indicate the likelihood of the cancer to spread and the higher the grade, the more likely for this to occur. Grade 0 is used to describe noninvasive tumors. Grade 0 cancers are also referred to as borderline tumors.<sup id="cite_ref-B_38-0" class="reference"><a href="#cite_note-B-38"><span>[</span>38<span>]</span></a></sup> Grade 1 tumors have well differentiated cells (look very similar to the normal tissue) and are the ones with the best prognosis. Grade 2 tumors are also called moderately well-differentiated and they are made up of cells that resemble the normal tissue. Grade 3 tumors have the worst prognosis and their cells are abnormal, referred to as poorly differentiated.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span>[</span>39<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Screening">Screening</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=34" title="Edit section: Screening">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The only screening recommended for all women is an annual pelvic examination. This is not very effective in detecting early ovarian cancer because it is usually only palpable in advanced stages.<sup id="cite_ref-Hoffman35_16-34" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Ovarian cancer screening is of high clinical interest because the disease is not typically detectable at its early stages, when it is the most curable. Screening is not recommended using <a href="/wiki/CA-125" title="CA-125">CA-125</a> measurements, <a href="/wiki/HE4" title="HE4" class="mw-redirect">HE4</a> levels, ultrasound, or adnexal palpation in women who are at average risk. Screening for any type of cancer must be accurate and reliable—it needs to accurately detect the disease and it must not give false positive results in people who do not have cancer.<sup id="cite_ref-Harrisons_12-32" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Harrisons82_40-0" class="reference"><a href="#cite_note-Harrisons82-40"><span>[</span>40<span>]</span></a></sup></p>
<p>Ovarian cancer has low prevalence, even in the high-risk group of women from the ages of 50 to 60 (about one in 2000), and screening of women with average risk is more likely to give ambiguous results than detect a problem which requires treatment. Because ambiguous results are more likely than detection of a treatable problem, and because the usual response to ambiguous results is invasive interventions, in women of average risk, the potential harms of having screening without an indication outweigh the potential benefits. The purpose of screening is to diagnose ovarian cancer at an early stage, when it is more likely to be treated successfully.<sup id="cite_ref-Harrisons_12-33" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Harrisons82_40-1" class="reference"><a href="#cite_note-Harrisons82-40"><span>[</span>40<span>]</span></a></sup> Screening with <a href="/wiki/Transvaginal_ultrasound" title="Transvaginal ultrasound" class="mw-redirect">transvaginal ultrasound</a>, pelvic examination, and CA-125 levels can be used instead of prophylactic surgery in women who have BRCA1 or BRCA2 mutations. This strategy has shown some success.<sup id="cite_ref-Hoffman35_16-35" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prevention">Prevention</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=35" title="Edit section: Prevention">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>People with strong genetic risk for ovarian cancer may consider the surgical removal of their ovaries as a preventative measure. This is often done after completion of childbearing years. This reduces the chances of developing both breast cancer (by around 50%) and ovarian cancer (by about 96%) in people at high risk. Women with <i>BRCA</i> gene mutations usually also have their Fallopian tubes removed at the same time (salpingo-oophorectomy), since they also have an increased risk of <a href="/wiki/Fallopian_tube_cancer" title="Fallopian tube cancer">Fallopian tube cancer</a>. However, these statistics may overestimate the risk reduction because of how they have been studied.<sup id="cite_ref-Harrisons_12-34" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Harrisons82_40-2" class="reference"><a href="#cite_note-Harrisons82-40"><span>[</span>40<span>]</span></a></sup></p>
<p>People with a significant family history for ovarian cancer are often referred to a <a href="/wiki/Genetic_counselor" title="Genetic counselor" class="mw-redirect">genetic counselor</a> to see if they should be tested for BRCA mutations.<sup id="cite_ref-Hoffman35_16-36" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Management">Management</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=36" title="Edit section: Management">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Treatment usually involves <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a> and surgery, and sometimes <a href="/wiki/Radiotherapy" title="Radiotherapy" class="mw-redirect">radiotherapy</a>, regardless of the subtype of ovarian cancer.<sup id="cite_ref-:1_33-7" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup> Surgical treatment may be sufficient for well-differentiated malignant tumors and confined to the ovary. Addition of chemotherapy may be required for more aggressive tumors confined to the ovary. For patients with advanced disease, a combination of surgical reduction with a combination chemotherapy regimen is standard. Borderline tumors, even following spread outside of the ovary, are managed well with surgery, and chemotherapy is not seen as useful.<sup id="cite_ref-:2_41-0" class="reference"><a href="#cite_note-:2-41"><span>[</span>41<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Surgery">Surgery</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=37" title="Edit section: Surgery">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Surgery" title="Surgery">Surgery</a> is the preferred treatment and is frequently necessary to obtain a tissue specimen for differential <a href="/wiki/Medical_diagnosis" title="Medical diagnosis">diagnosis</a> via its histology. The type of surgery depends upon how widespread the cancer is when diagnosed (the cancer stage), as well as the presumed type and grade of cancer. The surgeon, who is usually a specialized gynecologic oncology surgeon, may remove one (unilateral oophorectomy) or both ovaries (bilateral oophorectomy), the Fallopian tubes (salpingectomy), the uterus (hysterectomy), and the <a href="/wiki/Greater_omentum" title="Greater omentum">omentum</a> (omentectomy). Typically, all of these are removed. For low-grade, unilateral stage-IA cancers, only the involved ovary (which must be unruptured) and Fallopian tube will be removed. This can be done especially in young people who wish to preserve their fertility. However, a risk of microscopic metastases exists and staging must be completed.<sup id="cite_ref-Jayson_11-24" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> If any metastases are found, a second surgery to remove the remaining ovary and uterus is needed.<sup id="cite_ref-:2_41-1" class="reference"><a href="#cite_note-:2-41"><span>[</span>41<span>]</span></a></sup> If a tumor in a premenopausal woman is determined to be a low malignant potential tumor during surgery, and it is clearly stage I cancer, only the affected ovary is removed. For postmenopausal women with low malignant potential tumors, hysterectomy with bilateral salpingo-oophorectomy is still the preferred option. During staging, the appendix should be examined or removed. This is particularly important with mucinous tumors.<sup id="cite_ref-Hoffman35_16-37" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> In children or adolescents with ovarian cancer, surgeons typically attempt to preserve one ovary to allow for the completion of <a href="/wiki/Puberty" title="Puberty">puberty</a>, but if the cancer has spread, this is not always possible. Dysgerminomas in particular tend to affect both ovaries: 8-15% of dysgerminomas are present in both ovaries.<sup id="cite_ref-Current_17-3" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup> People with low-grade (well-differentiated) tumors are typically treated only with surgery,<sup id="cite_ref-Harrisons_12-35" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> which is often curative.<sup id="cite_ref-:1_33-8" class="reference"><a href="#cite_note-:1-33"><span>[</span>33<span>]</span></a></sup></p>
<p>In advanced cancers, where complete removal is not an option, as much tumor as possible is removed in a procedure called <a href="/wiki/Debulking" title="Debulking">debulking</a> surgery. This surgery is not always successful, and is less likely to be successful in women with extensive metastases in the peritoneum, stage- IV disease, cancer in the <a href="/wiki/Porta_hepatis" title="Porta hepatis">transverse fissure of the liver</a>, <a href="/wiki/Mesentery" title="Mesentery">mesentery</a>, or diaphragm, and large areas of ascites. Debulking surgery is usually only done once.<sup id="cite_ref-Jayson_11-25" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> More complete debulking is associated with better outcomes: women with no macroscopic evidence of disease after debulking have a median survival of 39 months, as opposed to 17 months with less complete surgery.<sup id="cite_ref-Harrisons_12-36" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Interval debulking surgery is another protocol used, where neoadjuvant chemotherapy is given, debulking surgery is performed, and chemotherapy is finished after debulking.<sup id="cite_ref-:2_41-2" class="reference"><a href="#cite_note-:2-41"><span>[</span>41<span>]</span></a></sup></p>
<p>To fully stage ovarian cancer, <a href="/wiki/Lymphadenectomy" title="Lymphadenectomy">lymphadenectomy</a> should be included in the surgery, but a significant survival benefit to this practice may not happen.<sup id="cite_ref-Jayson_11-26" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> This is particularly important in germ cell tumors because they frequently metastasize to nearby lymph nodes.<sup id="cite_ref-Harrisons_12-37" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>If ovarian cancer recurs, secondary surgery is sometimes a treatment option. This depends on how easily the tumor can be removed, how much fluid has accumulated in the abdomen, and overall health.<sup id="cite_ref-Jayson_11-27" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<p>The major side effect of an oophorectomy in younger women is early <a href="/wiki/Menopause" title="Menopause">menopause</a>, which can cause <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a>. After surgery, hormone replacement therapy can be considered, especially in younger women. This therapy can consist of a combination of estrogen and progesterone, or estrogen alone. Estrogen alone is safe after hysterectomy; when the uterus is still present, unopposed estrogen dramatically raises the risk of <a href="/wiki/Endometrial_cancer" title="Endometrial cancer">endometrial cancer</a>.<sup id="cite_ref-Jayson_11-28" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> People having ovarian cancer surgery are typically hospitalized afterwards for 3–4 days and spend around a month recovering at home.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span>[</span>42<span>]</span></a></sup> Surgery outcomes are best at hospitals that do a large number of ovarian cancer surgeries.<sup id="cite_ref-Hoffman35_16-38" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Chemotherapy">Chemotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=38" title="Edit section: Chemotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Chemotherapy" title="Chemotherapy">Chemotherapy</a> has been a general <a href="/wiki/Standard_of_care" title="Standard of care">standard of care</a> for ovarian cancer for decades, although with highly variable protocols. Chemotherapy is used after surgery to treat any residual disease, if appropriate. In some cases, there may be reason to perform chemotherapy first, followed by surgery. This is called "neoadjuvant chemotherapy", and is common when a tumor cannot be completely removed or optimally debulked via surgery. If a unilateral salpingo-oophorectomy or other surgery is performed, additional chemotherapy, called "adjuvant chemotherapy", can be given.<sup id="cite_ref-Jayson_11-29" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Chemotherapies used in ovarian cancer include <a href="/wiki/Paclitaxel" title="Paclitaxel">paclitaxel</a>, <a href="/wiki/Cisplatin" title="Cisplatin">cisplatin</a>, <a href="/wiki/Topotecan" title="Topotecan">topotecan</a>, and <a href="/wiki/Gemcitabine" title="Gemcitabine">gemcitabine</a>. Germ-cell malignancies are treated differently - a regimen of <a href="/wiki/Bleomycin" title="Bleomycin">bleomycin</a>, <a href="/wiki/Etoposide" title="Etoposide">etoposide</a>, and cisplatin (<a href="/w/index.php?title=BEP_chemotherapy&amp;action=edit&amp;redlink=1" class="new" title="BEP chemotherapy (page does not exist)">BEP chemotherapy</a>) is used.<sup id="cite_ref-Harrisons_12-38" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Adjuvant chemotherapy is used in stage 1 cancer typically if the tumor is of a high histologic grade (grade 3) or the highest substage (stage 1c).<sup id="cite_ref-:2_41-3" class="reference"><a href="#cite_note-:2-41"><span>[</span>41<span>]</span></a></sup></p>
<p>Chemotherapy in ovarian cancer typically consists of <a href="/wiki/Platins" title="Platins" class="mw-redirect">platins</a>, a group of <a href="/wiki/Platinum" title="Platinum">platinum</a>-based drugs. <a href="/wiki/Carboplatin" title="Carboplatin">Carboplatin</a> is given in combination with either <a href="/wiki/Paclitaxel" title="Paclitaxel">paclitaxel</a> or <a href="/wiki/Docetaxel" title="Docetaxel">docetaxel</a>; the typical combination is carboplatin with paclitaxel. Three-drug regimens have not been found to be more effective.<sup id="cite_ref-Jayson_11-30" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Chemotherapy can be given <a href="/wiki/Chemotherapy#Delivery" title="Chemotherapy">intravenously</a> or <a href="/w/index.php?title=Intraperitoneal_chemotherapy&amp;action=edit&amp;redlink=1" class="new" title="Intraperitoneal chemotherapy (page does not exist)">in the peritoneal cavity</a>.<sup id="cite_ref-Harrisons_12-39" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Typical cycles of treatment involve one treatment every 3 weeks, repeated for 6 weeks or more.<sup id="cite_ref-:3_43-0" class="reference"><a href="#cite_note-:3-43"><span>[</span>43<span>]</span></a></sup></p>
<p>If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months. Second-line chemotherapy should be given only after the cancer becomes symptomatic, because no difference in survival is seen between treating asymptomatic (elevated CA-125) and symptomatic recurrences. For platinum-sensitive tumors, platins are the drugs of choice for second-line chemotherapy, in combination with other cytotoxic agents. Regimens include carboplatin combined with <a href="/wiki/Doxorubicin#Liposomal_formulations" title="Doxorubicin">pegylated liposomal doxorubicin</a>, <a href="/wiki/Gemcitabine" title="Gemcitabine">gemcitabine</a>, or <a href="/wiki/Paclitaxel" title="Paclitaxel">paclitaxel</a>. For platinum-resistant tumors, there are no high-efficacy chemotherapy options. Single-drug regimens (doxorubicin or <a href="/wiki/Topotecan" title="Topotecan">topotecan</a>) do not have high response rates,<sup id="cite_ref-Jayson_11-31" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> but topotecan is used in some cases.<sup id="cite_ref-Harrisons_12-40" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Topotecan cannot be used in people with an intestinal blockage. Paclitaxel used alone is another possible regimen, or it may be combined with liposomal doxorubicin, gemcitabine, cisplatin, topotecan, <a href="/wiki/Etoposide" title="Etoposide">etoposide</a>, or <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a>.<sup id="cite_ref-:3_43-1" class="reference"><a href="#cite_note-:3-43"><span>[</span>43<span>]</span></a></sup> <a href="/wiki/Trabectedin" title="Trabectedin">Trabectedin</a> is another treatment option for recurrent ovarian cancer.<sup id="cite_ref-:6_44-0" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p>In people with <i>BRCA</i> mutations, platinum chemotherapy is more effective.<sup id="cite_ref-Jayson_11-32" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> <a href="/wiki/Olaparib" title="Olaparib">Olaparib</a>, a <a href="/wiki/PARP_inhibitor" title="PARP inhibitor">PARP inhibitor</a>, was approved by the <a href="/wiki/U.S._Food_and_Drug_Administration" title="U.S. Food and Drug Administration" class="mw-redirect">U.S. Food and Drug Administration</a> for use in BRCA-associated ovarian cancer that had previously been treated with chemotherapy.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45"><span>[</span>45<span>]</span></a></sup> Germ-cell tumors and malignant sex-cord/stromal tumors are treated with chemotherapy, though dysgerminomas and sex-cord tumors are not typically very responsive.<sup id="cite_ref-Harrisons_12-41" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-Current_17-4" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Radiation_therapy">Radiation therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=39" title="Edit section: Radiation therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Dysgerminomas are most effectively treated with radiation,<sup id="cite_ref-Current_17-5" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup> though this can cause infertility and is being phased out in favor of chemotherapy.<sup id="cite_ref-Harrisons_12-42" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p><a href="/wiki/Radiation_therapy" title="Radiation therapy">Radiation therapy</a> is not effective for advanced stages because when vital organs are in the radiation field, a high dose cannot be safely delivered. Radiation therapy is then commonly avoided in such stages as the vital organs may not be able to withstand the problems associated with these ovarian cancer treatments.<sup id="cite_ref-E_46-0" class="reference"><a href="#cite_note-E-46"><span>[</span>46<span>]</span></a></sup> Radiation therapy does not improve survival in people with well-differentiated tumors.<sup id="cite_ref-Harrisons_12-43" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>In stage 1c and 2 cancers, radiation therapy is used after surgery if there is the possibility of residual disease in the pelvis but the abdomen is cancer-free. Radiotherapy can also be used in palliative care of advanced cancers. A typical course of radiotherapy for ovarian cancer is 5 days a week for 3–4 weeks. Common side effects of radiotherapy include diarrhea, constipation, and frequent urination.<sup id="cite_ref-:4_47-0" class="reference"><a href="#cite_note-:4-47"><span>[</span>47<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Hormonal_therapy">Hormonal therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=40" title="Edit section: Hormonal therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Despite the fact that 60% of ovarian tumors have <a href="/wiki/Estrogen_receptor" title="Estrogen receptor">estrogen receptors</a>, ovarian cancer is only rarely responsive to hormonal treatments. Estrogen alone does not have an effect on the cancer, and <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a> and <a href="/wiki/Letrozole" title="Letrozole">letrozole</a> are rarely effective.<sup id="cite_ref-Jayson_11-33" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Immunotherapy">Immunotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=41" title="Edit section: Immunotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Immunotherapy is a topic of current research in ovarian cancer. In some cases, the antibody drug <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a>, though still a topic of active research, is used to treat advanced cancer along with chemotherapy.<sup id="cite_ref-:2_41-4" class="reference"><a href="#cite_note-:2-41"><span>[</span>41<span>]</span></a></sup> It has been approved for this use in the European Union.<sup id="cite_ref-:6_44-1" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Follow-up">Follow-up</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=42" title="Edit section: Follow-up">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Specific follow-up depends on, for example, the type and stage of ovarian cancer, the treatment, and the presence of any symptoms. Usually, a check-up appointment is made about every 2 to 3 months initially, followed by twice per year for up to 5 years.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48"><span>[</span>48<span>]</span></a></sup> For epithelial ovarian cancers, the most common test upon follow-up is CA-125 level. However, treatment based only on elevated CA-125 levels and not any symptoms can increase side effects without any prolongation of life, so the implication of the outcome of a CA-125 test should be discussed before taking it.<sup id="cite_ref-ACSfollowup_49-0" class="reference"><a href="#cite_note-ACSfollowup-49"><span>[</span>49<span>]</span></a></sup> The recommendation as of 2014 is recurrent cancer may be present if the CA-125 level is twice normal.<sup id="cite_ref-Jayson_11-34" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<p>For women with <a href="/w/index.php?title=Germ-cell_tumor&amp;action=edit&amp;redlink=1" class="new" title="Germ-cell tumor (page does not exist)">germ-cell tumors</a>, follow-up tests generally include <a href="/wiki/Alpha-fetoprotein" title="Alpha-fetoprotein">alpha-fetoprotein</a> (AFP) and/or <a href="/wiki/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin">human chorionic gonadotropin</a>. For women with <a href="/wiki/Stromal_cancer" title="Stromal cancer" class="mw-redirect">stromal cancers</a>, tests for hormones like estrogen, testosterone, and <a href="/wiki/Inhibin" title="Inhibin" class="mw-redirect">inhibin</a> are sometimes helpful.<sup id="cite_ref-ACSfollowup_49-1" class="reference"><a href="#cite_note-ACSfollowup-49"><span>[</span>49<span>]</span></a></sup> Inhibin can also be useful for monitoring the progress of sex-cord tumors, along with <a href="/wiki/Mullerian_inhibiting_substance" title="Mullerian inhibiting substance" class="mw-redirect">mullerian inhibiting substance</a>. AFP can also be used to monitor Sertoli-Leydig tumors.<sup id="cite_ref-Harrisons_12-44" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Women with ovarian cancer should not have routine surveillance imaging to monitor the cancer unless new symptoms appear or <a href="/wiki/Tumor_markers" title="Tumor markers" class="mw-redirect">tumor markers</a> begin rising.<sup id="cite_ref-SGOfive_50-0" class="reference"><a href="#cite_note-SGOfive-50"><span>[</span>50<span>]</span></a></sup> Imaging without these indications is discouraged because it is unlikely to detect a recurrence, improve survival, and because it has its own costs and side effects.<sup id="cite_ref-SGOfive_50-1" class="reference"><a href="#cite_note-SGOfive-50"><span>[</span>50<span>]</span></a></sup> However, CT imaging can be used if desired, though this is not common.<sup id="cite_ref-Jayson_11-35" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> If a tumor is easily imaged, imaging may be used to monitor the progress of treatment.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51"><span>[</span>51<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Palliative_care">Palliative care</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=43" title="Edit section: Palliative care">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Palliative_care" title="Palliative care">Palliative care</a> focuses on relieving symptoms and increasing or maintaining quality of life. It has been recommended as part of the treatment plan for any person with advanced ovarian cancer or patients with significant symptoms.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>52<span>]</span></a></sup></p>
<p>Palliative care can entail treatment of symptoms and complications of the cancer, including pain, nausea, constipation, ascites, <a href="/wiki/Bowel_obstruction" title="Bowel obstruction">bowel obstruction</a>, <a href="/wiki/Edema" title="Edema">edema</a>, and <a href="/wiki/Mucositis" title="Mucositis">mucositis</a>. Especially if the cancer advances and becomes incurable, treatment of symptoms becomes one of the main goals of therapy. Palliative care can also entail helping with decision-making such as if or when <a href="/wiki/Hospice_care" title="Hospice care" class="mw-redirect">hospice care</a> is appropriate, and the preferred place for the patient at end of life care.<sup id="cite_ref-Radwany_53-0" class="reference"><a href="#cite_note-Radwany-53"><span>[</span>53<span>]</span></a></sup> Bowel obstruction can be treated with <a href="/wiki/Palliative_surgery" title="Palliative surgery" class="mw-redirect">palliative surgery</a>. Other treatments of complications can include <a href="/wiki/Total_parenteral_nutrition" title="Total parenteral nutrition" class="mw-redirect">total parenteral nutrition</a>, a <a href="/w/index.php?title=Low-residue_diet&amp;action=edit&amp;redlink=1" class="new" title="Low-residue diet (page does not exist)">low-residue diet</a>, and adequate pain control.<sup id="cite_ref-Jayson_11-36" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Bowel obstruction can also be treated with <a href="/wiki/Octreotide" title="Octreotide">octreotide</a> when palliative surgery is not an option. Cancer can also block the <a href="/wiki/Ureters" title="Ureters" class="mw-redirect">ureters</a>, which can be relieved by a <a href="/wiki/Nephrostomy" title="Nephrostomy">nephrostomy</a> or a <a href="/wiki/Ureteric_stent" title="Ureteric stent">ureteric stent</a>. Ascites can be relieved by paracentesis or placement of a drain to increase comfort.<sup id="cite_ref-:5_4-1" class="reference"><a href="#cite_note-:5-4"><span>[</span>4<span>]</span></a></sup></p>
<p>Radiation therapy can be used as part of the palliative care of advanced ovarian cancer, since it can help to shrink tumors that are causing symptoms. Palliative radiotherapy typically lasts for only a few treatments, a much shorter course of therapy than non-palliative radiotherapy.<sup id="cite_ref-:4_47-1" class="reference"><a href="#cite_note-:4-47"><span>[</span>47<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=44" title="Edit section: Prognosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:302px;"><a href="/wiki/File:Relative_survival_of_ovarian_cancer_by_stage.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Relative_survival_of_ovarian_cancer_by_stage.png/300px-Relative_survival_of_ovarian_cancer_by_stage.png" width="300" height="215" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Relative_survival_of_ovarian_cancer_by_stage.png/450px-Relative_survival_of_ovarian_cancer_by_stage.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Relative_survival_of_ovarian_cancer_by_stage.png/600px-Relative_survival_of_ovarian_cancer_by_stage.png 2x" data-file-width="657" data-file-height="471" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Relative_survival_of_ovarian_cancer_by_stage.png" class="internal" title="Enlarge"></a></div>
Relative <a href="/wiki/Five-year_survival" title="Five-year survival" class="mw-redirect">five-year survival</a> of invasive epithelial ovarian cancer by stage<sup id="cite_ref-54" class="reference"><a href="#cite_note-54"><span>[</span>54<span>]</span></a></sup></div>
</div>
</div>
<p>Ovarian cancer usually has a relatively poor <a href="/wiki/Prognosis" title="Prognosis">prognosis</a>. It is disproportionately deadly because it lacks any clear early detection or screening test, meaning most cases are not diagnosed until they have reached advanced stages.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55"><span>[</span>55<span>]</span></a></sup> However, in some cases, ovarian cancer recurrences are chronically treatable.<sup id="cite_ref-Jayson_11-37" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<p>Ovarian cancer metastasizes early in its development, often before it has been diagnosed. High-grade tumors metastasize more readily than low-grade tumors. Typically, tumor cells begin to metastasize by growing in the peritoneal cavity.<sup id="cite_ref-Harrisons_12-45" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> More than 60% of women presenting with ovarian cancer have stage-III or stage-IV cancer, when it has already spread beyond the ovaries. Ovarian cancers shed cells into the naturally occurring fluid within the abdominal cavity. These cells can then implant on other abdominal (peritoneal) structures, included the uterus, <a href="/wiki/Urinary_bladder" title="Urinary bladder">urinary bladder</a>, <a href="/wiki/Bowel" title="Bowel" class="mw-redirect">bowel</a>, <a href="/wiki/Mesentery" title="Mesentery">lining of the bowel wall</a>, and <a href="/wiki/Greater_omentum" title="Greater omentum">omentum</a>, forming new tumor growths before cancer is even suspected.</p>
<p>The five-year survival rate for all stages of ovarian cancer is 46%; the one-year survival rate is 72% and the ten-year survival rate is 35%.<sup id="cite_ref-56" class="reference"><a href="#cite_note-56"><span>[</span>56<span>]</span></a></sup> For cases where a diagnosis is made early in the disease, when the cancer is still confined to the primary site, the five-year survival rate is 92.7%.<sup id="cite_ref-SEER_57-0" class="reference"><a href="#cite_note-SEER-57"><span>[</span>57<span>]</span></a></sup> About 70% of women with advanced disease respond to initial treatment, most of whom attain complete remission, but half of these women experience a recurrence 1–4 years after treatment.<sup id="cite_ref-Harrisons_12-46" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Ovarian cancer survival varies significantly with subtype. Dysgerminomas have a very favorable prognosis. In early stages, they have a five-year survival rate of 96.9%.<sup id="cite_ref-Current_17-6" class="reference"><a href="#cite_note-Current-17"><span>[</span>17<span>]</span></a></sup> Stage-III dysgerminomas have a five-year survival of 61%; when treated with BEP chemotherapy after incomplete surgical removal, dysgerminomas have a 95% two-year survival rate. Sex-cord/stromal malignancies also have a favorable prognosis; because they are slow-growing, even those with metastatic disease can survive a decade or more.<sup id="cite_ref-Harrisons_12-47" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Low malignant potential tumors usually only have a bad prognosis when there are invasive tumor implants found in the peritoneal cavity.<sup id="cite_ref-Hoffman35_16-39" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<p>Complications of ovarian cancer can include spread of the cancer to other organs, progressive function loss of various organs, ascites, and intestinal obstructions, which can be fatal. Intestinal obstructions in multiple sites are the most common proximate cause of death.<sup id="cite_ref-Jayson_11-38" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Intestinal obstruction in ovarian cancer can either be a true obstruction, where tumor blocks the <a href="/wiki/Intestinal_lumen" title="Intestinal lumen" class="mw-redirect">intestinal lumen</a>, or a pseudo-obstruction, when tumor prevents normal <a href="/wiki/Peristalsis" title="Peristalsis">peristalsis</a>.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58"><span>[</span>58<span>]</span></a></sup> Continuous accumulation of ascites can be treated by placing a drain that can be self-drained.<sup id="cite_ref-Jayson_11-39" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Survival_rates">Survival rates</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=45" title="Edit section: Survival rates">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Overall five-year survival rates for all types of ovarian cancer are presented below by stage and histologic grade:<sup id="cite_ref-Harrisons_12-48" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup></p>
<table class="wikitable" align="left" style="text-align: center; margin-right: 10px;">
<tr>
<th>Stage</th>
<th>Survival</th>
</tr>
<tr>
<td>I</td>
<td>90-95%</td>
</tr>
<tr>
<td>II</td>
<td>70-80%</td>
</tr>
<tr>
<td>III</td>
<td>20-50%</td>
</tr>
<tr>
<td>IV</td>
<td>1-5%</td>
</tr>
</table>
<table class="wikitable" align="left" style="text-align: center;">
<tr>
<th>Histologic grade</th>
<th>Survival</th>
</tr>
<tr>
<td>Low grade</td>
<td>88%</td>
</tr>
<tr>
<td>Intermediate grade</td>
<td>58%</td>
</tr>
<tr>
<td>High grade</td>
<td>27%</td>
</tr>
</table>
<div style="clear:both;"></div>
<p>The survival rates given below are for the different types of ovarian cancer, according to <a href="/wiki/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a>.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>59<span>]</span></a></sup> They come from the <a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a>, SEER, and are based on patients diagnosed from 2004 to 2010.</p>
<table class="wikitable" align="left" style="text-align: center; margin-right: 10px;">
<tr>
<th colspan="2">Invasive epithelial ovarian cancer</th>
</tr>
<tr>
<th>Stage</th>
<th>Relative five-year<br />
survival rate</th>
</tr>
<tr>
<td>I</td>
<td>90%</td>
</tr>
<tr>
<td>IA</td>
<td>94%</td>
</tr>
<tr>
<td>IB</td>
<td>92%</td>
</tr>
<tr>
<td>IC</td>
<td>85%</td>
</tr>
<tr>
<td>II</td>
<td>70%</td>
</tr>
<tr>
<td>IIA</td>
<td>78%</td>
</tr>
<tr>
<td>IIB</td>
<td>73%</td>
</tr>
<tr>
<td>III</td>
<td>39%</td>
</tr>
<tr>
<td>IIIA</td>
<td>59%</td>
</tr>
<tr>
<td>IIIB</td>
<td>52%</td>
</tr>
<tr>
<td>IIIC</td>
<td>39%</td>
</tr>
<tr>
<td>IV</td>
<td>17%</td>
</tr>
</table>
<table class="wikitable" align="left" style="text-align: center; margin-right: 10px;">
<tr>
<th colspan="2">Ovarian stromal tumors</th>
</tr>
<tr>
<th>Stage</th>
<th>Relative five-year<br />
survival rate</th>
</tr>
<tr>
<td>I</td>
<td>95%</td>
</tr>
<tr>
<td>II</td>
<td>78%</td>
</tr>
<tr>
<td>III</td>
<td>65%</td>
</tr>
<tr>
<td>IV</td>
<td>35%</td>
</tr>
</table>
<table class="wikitable" align="left" style="text-align: center; margin-right: 10px;">
<tr>
<th colspan="2">Germ cell tumors of the ovary</th>
</tr>
<tr>
<th>Stage</th>
<th>Relative 5-yr<br />
Survival Rate</th>
</tr>
<tr>
<td>I</td>
<td>98%</td>
</tr>
<tr>
<td>II</td>
<td>94%</td>
</tr>
<tr>
<td>III</td>
<td>87%</td>
</tr>
<tr>
<td>IV</td>
<td>69%</td>
</tr>
</table>
<table class="wikitable" align="left" style="text-align: center; margin-right: 10px;">
<tr>
<th colspan="2">Fallopian tube carcinoma</th>
</tr>
<tr>
<th>Stage</th>
<th>Relative five-year<br />
survival rate</th>
</tr>
<tr>
<td>I</td>
<td>87%</td>
</tr>
<tr>
<td>II</td>
<td>86%</td>
</tr>
<tr>
<td>III</td>
<td>52%</td>
</tr>
<tr>
<td>IV</td>
<td>40%</td>
</tr>
</table>
<table class="wikitable" align="left" style="text-align: center; margin-right: 10px;">
<tr>
<th colspan="2">Low malignant potential tumors<sup id="cite_ref-Hoffman35_16-40" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></th>
</tr>
<tr>
<th>Stage</th>
<th>Relative five-year<br />
survival rate</th>
</tr>
<tr>
<td>I</td>
<td>99%</td>
</tr>
<tr>
<td>II</td>
<td>98%</td>
</tr>
<tr>
<td>III</td>
<td>96%</td>
</tr>
<tr>
<td>IV</td>
<td>77%</td>
</tr>
</table>
<div style="clear:both;"></div>
<h3><span class="mw-headline" id="Recurrence_rates">Recurrence rates</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=46" title="Edit section: Recurrence rates">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Ovarian cancer frequently recurs after treatment. If a recurrence occurs in advanced disease, it typically occurs within 18 months of initial treatment (18 months <a href="/wiki/Progression-free_survival" title="Progression-free survival">progression-free survival</a>). Recurrences can be treated, but the disease-free interval tends to shorten and chemoresistance increases with each recurrence.<sup id="cite_ref-Jayson_11-40" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Low malignant potential tumors rarely relapse, even when fertility-sparing surgery is the treatment of choice. 15% of LMP tumors relapse after unilateral surgery in the previously unaffected ovary, and they are typically easily treated with surgery. More advanced tumors may take up to 20 years to relapse, if they relapse at all, and are only treated with surgery unless the tumor has changed its histological characteristics or grown very quickly. In these cases, and when there is significant ascites, chemotherapy may also be used.<sup id="cite_ref-Hoffman35_16-41" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=47" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Ovary_cancer_world_map_-_Death_-_WHO2004.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/220px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png" width="220" height="97" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/330px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/440px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png 2x" data-file-width="940" data-file-height="415" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Ovary_cancer_world_map_-_Death_-_WHO2004.svg" class="internal" title="Enlarge"></a></div>
<a href="/wiki/Age_adjustment" title="Age adjustment">Age-standardized</a> death from ovarian cancer per 100,000&#160;inhabitants in 2004<sup id="cite_ref-60" class="reference"><a href="#cite_note-60"><span>[</span>60<span>]</span></a></sup>
<div class="refbegin columns references-column-count references-column-count-2" style="-moz-column-count: 2; -webkit-column-count: 2; column-count: 2;">
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #b3b3b3; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;no data</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffff65; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;less than 0.6</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #fff200; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;0.6-1.2</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffdc00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;1.2-1.8</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffc600; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;1.8-2.4</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffb000; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;2.4-3</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff9a00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;3-3.6</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff8400; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;3.6-4.2</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff6e00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;4.2-4.8</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff5800; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;4.8-5.4</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff4200; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;5.4-6</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff2c00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;6-7</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #cb0000; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;more than 7</div>
</div>
</div>
</div>
</div>
<div class="thumb tleft">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Ovarian_cancer_by_age_group.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e0/Ovarian_cancer_by_age_group.png/220px-Ovarian_cancer_by_age_group.png" width="220" height="147" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e0/Ovarian_cancer_by_age_group.png/330px-Ovarian_cancer_by_age_group.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e0/Ovarian_cancer_by_age_group.png/440px-Ovarian_cancer_by_age_group.png 2x" data-file-width="581" data-file-height="389" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Ovarian_cancer_by_age_group.png" class="internal" title="Enlarge"></a></div>
Ovarian cancer cases diagnosed by age group<sup id="cite_ref-SEER_57-1" class="reference"><a href="#cite_note-SEER-57"><span>[</span>57<span>]</span></a></sup></div>
</div>
</div>
<p>Globally, as of 2010, about 160,000 people died from ovarian cancer, up from 113,000 in 1990.<sup id="cite_ref-Loz_2012_61-0" class="reference"><a href="#cite_note-Loz_2012-61"><span>[</span>61<span>]</span></a></sup> As of 2014, more than 220,000 diagnoses of epithelial ovarian cancer were made yearly.<sup id="cite_ref-Jayson_11-41" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> In 2010, in the United States, an estimated 21,880 new cases were diagnosed and 13,850 women died of ovarian cancer. Around 1800 of the new diagnoses were sex-cord or stromal tumors.<sup id="cite_ref-Harrisons_12-49" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> In the United Kingdom as of 2014, approximately 7,000-7,100 yearly diagnoses were made and 4,200 deaths occurred.<sup id="cite_ref-Jayson_11-42" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-CRUKRisks_18-14" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> It is the 5th most common cancer in UK women. Ovarian cancer is most commonly diagnosed after menopause,<sup id="cite_ref-CRUKRisks_18-15" class="reference"><a href="#cite_note-CRUKRisks-18"><span>[</span>18<span>]</span></a></sup> between the ages of 60 and 64. 90% of ovarian cancer occurs in women over the age of 45 and 80% in women over 50.<sup id="cite_ref-:7_14-30" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>The overall lifetime risk is around 1.6%<sup id="cite_ref-Harrisons_12-50" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> (one woman in 48-70).<sup id="cite_ref-:7_14-31" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> The risk in the UK is similar, at 1.7% (one woman in 60). <a href="/wiki/Ashkenazi_Jew" title="Ashkenazi Jew" class="mw-redirect">Ashkenazi Jewish</a> women carry mutated <i>BRCA</i> alleles at a rate five times that of the rest of the population, putting them at higher risk for ovarian cancer.<sup id="cite_ref-Jayson_11-43" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<p>In the US, ovarian cancer affects 1.3-1.4% and is the cause of death of about 1% of women.<sup id="cite_ref-Hoffman35_16-42" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-merck_62-0" class="reference"><a href="#cite_note-merck-62"><span>[</span>62<span>]</span></a></sup> This made it the fifth-leading cause of cancer-related deaths with an estimated 15,000 deaths in 2008.<sup id="cite_ref-Harrisons_12-51" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-merck_62-1" class="reference"><a href="#cite_note-merck-62"><span>[</span>62<span>]</span></a></sup> Ovarian cancer represents approximately 4% of cancers diagnosed in women.<sup id="cite_ref-:7_14-32" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup> It occurs more commonly in developed countries.<sup id="cite_ref-merck_62-2" class="reference"><a href="#cite_note-merck-62"><span>[</span>62<span>]</span></a></sup> Ovarian cancer is the fifth-most common cancer in women in the UK (around 7,100 women were diagnosed with the disease in 2011), and it is the fifth-most common cause of cancer death in women (around 4,300 women died in 2012).<sup id="cite_ref-63" class="reference"><a href="#cite_note-63"><span>[</span>63<span>]</span></a></sup> It is the most deadly gynecologic cancer.<sup id="cite_ref-Hoffman35_16-43" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> In 2014, the incidence rate for women in developed countries was about 9.4 per 100,000, compared to 5.0 per 100,000 in developing countries.<sup id="cite_ref-Jayson_11-44" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> In the US, the incidence rate in women over 50 is approximately 33 per 100,000.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64"><span>[</span>64<span>]</span></a></sup> In Europe, <a href="/wiki/Lithuania" title="Lithuania">Lithuania</a>, <a href="/wiki/Latvia" title="Latvia">Latvia</a>, <a href="/wiki/Ireland" title="Ireland">Ireland</a>, <a href="/wiki/Slovakia" title="Slovakia">Slovakia</a>, and the <a href="/wiki/Czech_Republic" title="Czech Republic">Czech Republic</a> have the highest incidences of ovarian cancer, whereas <a href="/wiki/Portugal" title="Portugal">Portugal</a> and <a href="/wiki/Cyprus" title="Cyprus">Cyprus</a> have the lowest incidences.<sup id="cite_ref-:7_14-33" class="reference"><a href="#cite_note-:7-14"><span>[</span>14<span>]</span></a></sup></p>
<p>The rate of ovarian cancer between 1993 and 2008 decreased in women of the 40-49 age cohort and in the 50-64 age cohort, possibly due to this group's widespread adoption of oral contraceptives.<sup id="cite_ref-Jayson_11-45" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> This decrease made it the ninth-most common cancer in women.<sup id="cite_ref-Hoffman35_16-44" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Society_and_culture">Society and culture</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=48" title="Edit section: Society and culture">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/List_of_women_with_ovarian_cancer" title="List of women with ovarian cancer">List of women with ovarian cancer</a></li>
</ul>
<h2><span class="mw-headline" id="Other_animals">Other animals</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=49" title="Edit section: Other animals">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Ovarian tumors have been reported in <a href="/wiki/Mare" title="Mare">mares</a>. Reported tumor types include teratoma,<sup id="cite_ref-pmid15065985_65-0" class="reference"><a href="#cite_note-pmid15065985-65"><span>[</span>65<span>]</span></a></sup><sup id="cite_ref-pmid16363331_66-0" class="reference"><a href="#cite_note-pmid16363331-66"><span>[</span>66<span>]</span></a></sup> <a href="/wiki/Cystadenocarcinoma" title="Cystadenocarcinoma">cystadenocarcinoma</a>,<sup id="cite_ref-pmid15957389_67-0" class="reference"><a href="#cite_note-pmid15957389-67"><span>[</span>67<span>]</span></a></sup> and particularly <a href="/wiki/Granulosa_cell_tumor" title="Granulosa cell tumor" class="mw-redirect">granulosa cell tumor</a>.<sup id="cite_ref-pmid17542368_68-0" class="reference"><a href="#cite_note-pmid17542368-68"><span>[</span>68<span>]</span></a></sup><sup id="cite_ref-pmid12867740_69-0" class="reference"><a href="#cite_note-pmid12867740-69"><span>[</span>69<span>]</span></a></sup><sup id="cite_ref-pmid9364230_70-0" class="reference"><a href="#cite_note-pmid9364230-70"><span>[</span>70<span>]</span></a></sup><sup id="cite_ref-pmid3507181_71-0" class="reference"><a href="#cite_note-pmid3507181-71"><span>[</span>71<span>]</span></a></sup><sup id="cite_ref-pmid2835223_72-0" class="reference"><a href="#cite_note-pmid2835223-72"><span>[</span>72<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Research">Research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=50" title="Edit section: Research">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Researchers are assessing different ways to screen for ovarian cancer. Screening tests that could potentially be used alone or in combination for routine screening include the CA-125 marker and transvaginal ultrasound. Doctors can measure the levels of the CA-125 protein in a woman’s blood; high levels could be a sign of ovarian cancer, but this is not always the case, and not all women with ovarian cancer have high CA-125 levels. Transvaginal ultrasound involves using an ultrasound probe to scan the ovaries from inside the vagina, giving a clearer image than scanning the abdomen. The UK Collaborative Trial of Ovarian Cancer Screening is testing a screening technique that combines CA-125 blood tests with transvaginal ultrasound. Several large studies are going on, but none has identified an effective technique.<sup id="cite_ref-Jayson_11-46" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-73" class="reference"><a href="#cite_note-73"><span>[</span>73<span>]</span></a></sup> In 2009, however, early results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) showed that a technique combining annual CA-125 tests with ultrasound imaging did help to detect the disease at an early stage.<sup id="cite_ref-:6_44-2" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup><sup id="cite_ref-74" class="reference"><a href="#cite_note-74"><span>[</span>74<span>]</span></a></sup> However, it's not yet clear if this approach could actually help to save lives—the full results of the trial will be published in 2015. One major problem with screening is no clear progression of the disease from stage I (noninvasive) to stage III (invasive) is seen, and it may not be possible to find cancers before they reach stage III. Another problem is that screening methods tend to find too many suspicious lesions, most of which are not cancer, but malignancy can only be assessed with surgery.<sup id="cite_ref-Jayson_11-47" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> The ROCA method combined with transvaginal ultrasonography is being researched in high-risk women to determine if it is a viable screening method. It is also being investigated in normal-risk women as it has shown promise in the wider population.<sup id="cite_ref-Hoffman35_16-45" class="reference"><a href="#cite_note-Hoffman35-16"><span>[</span>16<span>]</span></a></sup> Studies are also in progress to determine if screening helps detect cancer earlier in people with BRCA mutations.<sup id="cite_ref-:6_44-3" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p>Research into various <a href="/w/index.php?title=Prognostic_factor&amp;action=edit&amp;redlink=1" class="new" title="Prognostic factor (page does not exist)">prognostic factors</a> for ovarian cancer is also going on. Recent research shows that <a href="/wiki/Thrombocytosis" title="Thrombocytosis">thrombocytosis</a> predicts lower survival and higher stage cancer.<sup id="cite_ref-Jayson_11-48" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Ongoing research is also investigating the benefits of surgery for recurrent ovarian cancer.<sup id="cite_ref-:6_44-4" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p>While an active area of research, no <a href="/wiki/Immunotherapy" title="Immunotherapy">immunotherapy</a> has been shown to be effective as of 2013.<sup id="cite_ref-75" class="reference"><a href="#cite_note-75"><span>[</span>75<span>]</span></a></sup> However, trials of the antibody and <a href="/wiki/VEGF" title="VEGF" class="mw-redirect">VEGF</a> inhibitor <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a>, which can slow the <a href="/wiki/Angiogenesis" title="Angiogenesis">growth of new blood vessels</a> in the cancer, have shown promising results, especially in combination with <a href="/wiki/Pazopanib" title="Pazopanib">pazopanib</a>, which also slows the process of blood vessel growth. Bevacizumab has been particularly effective in preliminary studies on stage-III and -IV cancer<sup id="cite_ref-Jayson_11-49" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> and has been cited as having at least a 15% response rate.<sup id="cite_ref-Harrisons_12-52" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> It is being investigated particularly in mucinous ovarian cancers.<sup id="cite_ref-:6_44-5" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup> Bevacizumab can also be combined with platinum chemotherapy, a combination that has had positive preliminary results in PFS, but equivocal results regarding overall survival. One disadvantage to these treatments is the side effect profile, which includes <a href="/wiki/Hypertension" title="Hypertension">high blood pressure</a> and <a href="/wiki/Proteinuria" title="Proteinuria">proteinuria</a>. The drug can also exacerbate bowel disease, leading to <a href="/wiki/Fistula" title="Fistula">fistulae</a> or <a href="/wiki/Bowel_perforation" title="Bowel perforation" class="mw-redirect">bowel perforation</a>. <a href="/wiki/Vintafolide" title="Vintafolide">Vintafolide</a>, which consists of an <a href="/wiki/Antifolate" title="Antifolate">antifolate</a> conjugated with <a href="/wiki/Vinblastine" title="Vinblastine">vinblastine</a>, is also in clinical trials; it may prove beneficial because <a href="/wiki/Folate_receptor" title="Folate receptor">folate receptors</a> are overexpressed in many ovarian cancers.<sup id="cite_ref-Jayson_11-50" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Another potential immunotherapy is <a href="/wiki/Trastuzumab" title="Trastuzumab">trastuzumab</a> (Herceptin), which is active against tumors positive for Her2/neu mutations.<sup id="cite_ref-Harrisons_12-53" class="reference"><a href="#cite_note-Harrisons-12"><span>[</span>12<span>]</span></a></sup> Other angiogenesis inhibitors are also being investigated as potential ovarian cancer treatments. <a href="/wiki/Combretastatin" title="Combretastatin">Combretastatin</a> and <a href="/wiki/Pazopanib" title="Pazopanib">pazopanib</a> are being researched in combination for recurrent ovarian cancer. <a href="/w/index.php?title=Trebananib&amp;action=edit&amp;redlink=1" class="new" title="Trebananib (page does not exist)">Trebananib</a> and <a href="/wiki/Tasquinimod" title="Tasquinimod">tasquinimod</a> are other angiogenesis inhibitors being investigated. The <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> <a href="/wiki/Farletuzumab" title="Farletuzumab">farletuzumab</a> is being researched as an adjuvant to traditional chemotherapy. Another type of immunotherapy involves <a href="/wiki/Vaccines" title="Vaccines" class="mw-redirect">vaccines</a>, including <a href="/wiki/TroVax" title="TroVax">TroVax</a>.<sup id="cite_ref-:6_44-6" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p><a href="/w/index.php?title=Intraperitoneal_chemotherapy&amp;action=edit&amp;redlink=1" class="new" title="Intraperitoneal chemotherapy (page does not exist)">Intraperitoneal chemotherapy</a> has also been under investigation during the 2000s and 2010s for its potential to deliver higher doses of cytotoxic agent to tumors. Preliminary trials with cisplatin and paclitaxel have shown it is not well tolerated, but does improve survival, and more tolerable regimens are being researched.<sup id="cite_ref-Jayson_11-51" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Cisplatin and paclitaxel are both being researched as intraperitoneal chemotherapy agents. A specific chemotherapy regimen for rare clear-cell cancers is also under investigation: <a href="/wiki/Irinotecan" title="Irinotecan">irinotecan</a> combined with cisplatin.<sup id="cite_ref-:6_44-7" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p><a href="/wiki/PARP_inhibitor" title="PARP inhibitor">PARP inhibitors</a> have also shown promise in early trials, particularly in people with <i>BRCA</i> gene mutations, since the BRCA protein interacts with the PARP pathway. It is also being studied in recurrent ovarian cancer in general, where preliminary studies have shown longer PFS. Specifically, <a href="/wiki/Olaparib" title="Olaparib">olaparib</a> has shown greater survival compared to doxorubicin, though this treatment is still being investigated. It is not clear yet which <a href="/wiki/Biomarker" title="Biomarker">biomarkers</a> are predictive of responsiveness to PARP inhibitors.<sup id="cite_ref-Jayson_11-52" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> <a href="/wiki/Rucaparib" title="Rucaparib">Rucaparib</a> is another PARP inhibitor being researched in BRCA-positive and BRCA-negative recurrent advanced ovarian cancer. <a href="/w/index.php?title=Niraparib&amp;action=edit&amp;redlink=1" class="new" title="Niraparib (page does not exist)">Niraparib</a> is a PARP inhibitor being tested in BRCA-positive recurrent ovarian cancer.<sup id="cite_ref-:6_44-8" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p><a href="/wiki/MTOR_inhibitor" title="MTOR inhibitor" class="mw-redirect">mTOR inhibitors</a> were a highly investigated potential treatment in the 2000s and 2010s, but the side effects of these drugs (particularly <a href="/wiki/Hyperglycemia" title="Hyperglycemia">hyperglycemia</a> and <a href="/wiki/Hyperlipidemia" title="Hyperlipidemia">hyperlipidemia</a>) were not well tolerated and the survival benefit not confirmed. PI3 kinase inhibitors have been of interest, but they tend to be highly toxic and cause <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a>. Another investigated drug is <a href="/wiki/Selumetinib" title="Selumetinib">selumetinib</a>, a <a href="/wiki/MAPK" title="MAPK" class="mw-redirect">MAPK</a> inhibitor. It improved survival, but did not correlate with any mutations found in tumors.<sup id="cite_ref-Jayson_11-53" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup></p>
<p><a href="/wiki/Tyrosine_kinase_inhibitors" title="Tyrosine kinase inhibitors" class="mw-redirect">Tyrosine kinase inhibitors</a> are another investigational drug class that may have applications in ovarian cancer. Angiogenesis inhibitors in the <a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">receptor tyrosine kinase</a> inhibitor group, including <a href="/wiki/Pazopanib" title="Pazopanib">pazopanib</a>, <a href="/wiki/Cediranib" title="Cediranib">cediranib</a>, and <a href="/wiki/Nintedanib" title="Nintedanib">nintedanib</a>, have also been shown to increase progression free survival (PFS), but their benefit for overall survival has not been investigated as of 2015.<sup id="cite_ref-Jayson_11-54" class="reference"><a href="#cite_note-Jayson-11"><span>[</span>11<span>]</span></a></sup> Preliminary research showed that cediranib combined with platins in recurrent ovarian cancer increased the time to second recurrence by 3–4 months and increased survival by 3 months.<sup id="cite_ref-:6_44-9" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup> <a href="/w/index.php?title=MK-1775&amp;action=edit&amp;redlink=1" class="new" title="MK-1775 (page does not exist)">MK-1775</a> is a tyrosine kinase inhibitor that is being used in combination with paclitaxel and carboplatin in platinum-sensitive cancers with p53 mutations. <a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a> is being researched as a potential therapy in combination with cyclophosphamide for people with recurrences.<sup id="cite_ref-:6_44-10" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p>Hormone therapies are a topic of current research in ovarian cancer, particularly, the value of certain medications used to treat breast cancer. These include <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a>, <a href="/wiki/Letrozole" title="Letrozole">letrozole</a>, and <a href="/wiki/Anastrozole" title="Anastrozole">anastrozole</a>. Preliminary studies have showed a benefit for tamoxifen in a small number of people with advanced ovarian cancer. Letrozole may help to slow or stop growth of <a href="/wiki/Estrogen_receptor" title="Estrogen receptor">estrogen receptor</a> positive ovarian cancer. Anastrozole is being investigated in postmenopausal people with estrogen receptor-positive cancer.<sup id="cite_ref-:6_44-11" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<p>Research into mitigating side effects of ovarian cancer treatment is also ongoing. <a href="/w/index.php?title=Radiation_fibrosis&amp;action=edit&amp;redlink=1" class="new" title="Radiation fibrosis (page does not exist)">Radiation fibrosis</a>, the formation of scar tissue in an area treated with radiation, may be relieved with <a href="/wiki/Hyperbaric_medicine" title="Hyperbaric medicine">hyperbaric oxygen therapy</a>, but research has not been completed in this area. Treatment of ovarian cancer may also cause people to experience psychiatric difficulties, including <a href="/wiki/Depression_(mood)" title="Depression (mood)">depression</a>. Research is ongoing to determine how counseling and psychotherapy can help people who have ovarian cancer during treatment.<sup id="cite_ref-:6_44-12" class="reference"><a href="#cite_note-:6-44"><span>[</span>44<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=51" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 35em; -webkit-column-width: 35em; column-width: 35em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-NCI2014PrePt-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-NCI2014PrePt_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NCI2014PrePt_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NCI2014PrePt_1-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient/page1/AllPages">"Ovarian Cancer Prevention (PDQ®)"</a>. <i>NCI</i>. December 6, 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">1 July</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+Cancer+Prevention+%28PDQ%C2%AE%29&amp;rft.date=December+6%2C+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fprevention%2Fovarian%2FPatient%2Fpage1%2FAllPages&amp;rft.jtitle=NCI&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer">"Defining Cancer"</a>. <i>National Cancer Institute</i><span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Defining+Cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fcancerlibrary%2Fwhat-is-cancer&amp;rft.jtitle=National+Cancer+Institute&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NCI2014TxPt-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-NCI2014TxPt_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NCI2014TxPt_3-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NCI2014TxPt_3-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1/AllPages">"Ovarian Epithelial Cancer Treatment (PDQ®)"</a>. <i>NCI</i>. 2014-05-12<span class="reference-accessdate">. Retrieved <span class="nowrap">1 July</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+Epithelial+Cancer+Treatment+%28PDQ%C2%AE%29&amp;rft.date=2014-05-12&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Ftreatment%2Fovarianepithelial%2FPatient%2Fpage1%2FAllPages&amp;rft.jtitle=NCI&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:5-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-:5_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:5_4-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/treating-advanced-ovarian-cancer">"Treating advanced ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Treating+advanced+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Ftreating-advanced-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><span class="citation book">Ruddon, Raymond W. (2007). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=PymZ1ORk0TcC&amp;pg=PA223"><i>Cancer biology</i></a> (4th ed. ed.). Oxford: Oxford University Press. p.&#160;223. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780195175431" title="Special:BookSources/9780195175431">9780195175431</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.aufirst=Raymond+W.&amp;rft.aulast=Ruddon&amp;rft.au=Ruddon%2C+Raymond+W.&amp;rft.btitle=Cancer+biology&amp;rft.date=2007&amp;rft.edition=4th+ed.&amp;rft.genre=book&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DPymZ1ORk0TcC%26pg%3DPA223&amp;rft.isbn=9780195175431&amp;rft.pages=223&amp;rft.place=Oxford&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-WCR2014-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-WCR2014_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-WCR2014_6-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-WCR2014_6-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-WCR2014_6-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-WCR2014_6-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-WCR2014_6-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation book"><i>World Cancer Report 2014</i>. World Health Organization. 2014. pp.&#160;Chapter 5.12. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9283204298" title="Special:BookSources/9283204298">9283204298</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=World+Cancer+Report+2014&amp;rft.date=2014&amp;rft.genre=book&amp;rft.isbn=9283204298&amp;rft.pages=Chapter+5.12&amp;rft.pub=World+Health+Organization&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NCI2014PrePro-7"><span class="mw-cite-backlink">^ <a href="#cite_ref-NCI2014PrePro_7-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NCI2014PrePro_7-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional/page1/AllPages">"Ovarian Cancer Prevention (PDQ®)"</a>. <i>NCI</i>. 2014-06-20<span class="reference-accessdate">. Retrieved <span class="nowrap">1 July</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+Cancer+Prevention+%28PDQ%C2%AE%29&amp;rft.date=2014-06-20&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fprevention%2Fovarian%2FHealthProfessional%2Fpage1%2FAllPages&amp;rft.jtitle=NCI&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><span class="citation journal">Piek JM, van Diest PJ, Verheijen RH (2008). "Ovarian carcinogenesis: an alternative hypothesis". <i>Adv. Exp. Med. Biol</i>. Advances in Experimental Medicine and Biology <b>622</b>: 79–87. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2F978-0-387-68969-2_7">10.1007/978-0-387-68969-2_7</a>. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-387-68966-1" title="Special:BookSources/978-0-387-68966-1">978-0-387-68966-1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18546620">18546620</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+carcinogenesis%3A+an+alternative+hypothesis&amp;rft.aufirst=JM&amp;rft.aulast=Piek&amp;rft.au=Piek%2C+JM&amp;rft.au=van+Diest%2C+PJ&amp;rft.au=Verheijen%2C+RH&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2F978-0-387-68969-2_7&amp;rft_id=info%3Apmid%2F18546620&amp;rft.isbn=978-0-387-68966-1&amp;rft.jtitle=Adv.+Exp.+Med.+Biol.&amp;rft.pages=79-87&amp;rft.series=Advances+in+Experimental+Medicine+and+Biology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=622" class="Z3988"><span style="display:none;">&#160;</span></span><a href="/wiki/Paywall" title="Closed access"><img alt="Closed access" src="//upload.wikimedia.org/wikipedia/commons/thumb/c/c1/Closed_Access_logo_alternative.svg/8px-Closed_Access_logo_alternative.svg.png" width="8" height="13" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/c/c1/Closed_Access_logo_alternative.svg/12px-Closed_Access_logo_alternative.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c1/Closed_Access_logo_alternative.svg/16px-Closed_Access_logo_alternative.svg.png 2x" data-file-width="640" data-file-height="1000" /></a></span></li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><span class="citation journal">Moyer VA (Dec 18, 2012). "Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.". <i>Annals of internal medicine</i> <b>157</b> (12): 900–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.7326%2F0003-4819-157-11-201212040-00539">10.7326/0003-4819-157-11-201212040-00539</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22964825">22964825</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Screening+for+ovarian+cancer%3A+U.S.+Preventive+Services+Task+Force+reaffirmation+recommendation+statement.&amp;rft.aufirst=VA&amp;rft.aulast=Moyer&amp;rft.au=Moyer%2C+VA&amp;rft.date=Dec+18%2C+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.7326%2F0003-4819-157-11-201212040-00539&amp;rft_id=info%3Apmid%2F22964825&amp;rft.issue=12&amp;rft.jtitle=Annals+of+internal+medicine&amp;rft.pages=900-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=157" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://seer.cancer.gov/statfacts/html/ovary.html">"SEER Stat Fact Sheets: Ovary Cancer"</a>. <i>NCI</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 June</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=SEER+Stat+Fact+Sheets%3A+Ovary+Cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fseer.cancer.gov%2Fstatfacts%2Fhtml%2Fovary.html&amp;rft.jtitle=NCI&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Jayson-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-Jayson_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Jayson_11-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Jayson_11-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Jayson_11-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Jayson_11-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Jayson_11-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Jayson_11-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Jayson_11-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Jayson_11-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Jayson_11-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Jayson_11-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Jayson_11-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Jayson_11-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Jayson_11-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Jayson_11-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Jayson_11-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Jayson_11-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Jayson_11-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Jayson_11-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Jayson_11-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Jayson_11-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Jayson_11-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Jayson_11-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Jayson_11-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Jayson_11-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Jayson_11-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-Jayson_11-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-Jayson_11-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-Jayson_11-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-Jayson_11-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-Jayson_11-30"><sup><i><b>ae</b></i></sup></a> <a href="#cite_ref-Jayson_11-31"><sup><i><b>af</b></i></sup></a> <a href="#cite_ref-Jayson_11-32"><sup><i><b>ag</b></i></sup></a> <a href="#cite_ref-Jayson_11-33"><sup><i><b>ah</b></i></sup></a> <a href="#cite_ref-Jayson_11-34"><sup><i><b>ai</b></i></sup></a> <a href="#cite_ref-Jayson_11-35"><sup><i><b>aj</b></i></sup></a> <a href="#cite_ref-Jayson_11-36"><sup><i><b>ak</b></i></sup></a> <a href="#cite_ref-Jayson_11-37"><sup><i><b>al</b></i></sup></a> <a href="#cite_ref-Jayson_11-38"><sup><i><b>am</b></i></sup></a> <a href="#cite_ref-Jayson_11-39"><sup><i><b>an</b></i></sup></a> <a href="#cite_ref-Jayson_11-40"><sup><i><b>ao</b></i></sup></a> <a href="#cite_ref-Jayson_11-41"><sup><i><b>ap</b></i></sup></a> <a href="#cite_ref-Jayson_11-42"><sup><i><b>aq</b></i></sup></a> <a href="#cite_ref-Jayson_11-43"><sup><i><b>ar</b></i></sup></a> <a href="#cite_ref-Jayson_11-44"><sup><i><b>as</b></i></sup></a> <a href="#cite_ref-Jayson_11-45"><sup><i><b>at</b></i></sup></a> <a href="#cite_ref-Jayson_11-46"><sup><i><b>au</b></i></sup></a> <a href="#cite_ref-Jayson_11-47"><sup><i><b>av</b></i></sup></a> <a href="#cite_ref-Jayson_11-48"><sup><i><b>aw</b></i></sup></a> <a href="#cite_ref-Jayson_11-49"><sup><i><b>ax</b></i></sup></a> <a href="#cite_ref-Jayson_11-50"><sup><i><b>ay</b></i></sup></a> <a href="#cite_ref-Jayson_11-51"><sup><i><b>az</b></i></sup></a> <a href="#cite_ref-Jayson_11-52"><sup><i><b>ba</b></i></sup></a> <a href="#cite_ref-Jayson_11-53"><sup><i><b>bb</b></i></sup></a> <a href="#cite_ref-Jayson_11-54"><sup><i><b>bc</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (October 2014). "Ovarian cancer". <i>Lancet</i> <b>384</b> (9951): 1376–88. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2813%2962146-7">10.1016/S0140-6736(13)62146-7</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24767708">24767708</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+cancer&amp;rft.aufirst=GC&amp;rft.au=Jayson%2C+GC&amp;rft.au=Kitchener%2C+HC&amp;rft.au=Kohn%2C+EC&amp;rft.aulast=Jayson&amp;rft.au=Ledermann%2C+JA&amp;rft.date=October+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2813%2962146-7&amp;rft_id=info%3Apmid%2F24767708&amp;rft.issue=9951&amp;rft.jtitle=Lancet&amp;rft.pages=1376-88&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=384" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Harrisons-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Harrisons_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Harrisons_12-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Harrisons_12-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Harrisons_12-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Harrisons_12-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Harrisons_12-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Harrisons_12-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Harrisons_12-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Harrisons_12-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Harrisons_12-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Harrisons_12-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Harrisons_12-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Harrisons_12-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Harrisons_12-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Harrisons_12-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Harrisons_12-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Harrisons_12-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Harrisons_12-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Harrisons_12-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Harrisons_12-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Harrisons_12-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Harrisons_12-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Harrisons_12-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Harrisons_12-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Harrisons_12-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Harrisons_12-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-Harrisons_12-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-Harrisons_12-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-Harrisons_12-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-Harrisons_12-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-Harrisons_12-30"><sup><i><b>ae</b></i></sup></a> <a href="#cite_ref-Harrisons_12-31"><sup><i><b>af</b></i></sup></a> <a href="#cite_ref-Harrisons_12-32"><sup><i><b>ag</b></i></sup></a> <a href="#cite_ref-Harrisons_12-33"><sup><i><b>ah</b></i></sup></a> <a href="#cite_ref-Harrisons_12-34"><sup><i><b>ai</b></i></sup></a> <a href="#cite_ref-Harrisons_12-35"><sup><i><b>aj</b></i></sup></a> <a href="#cite_ref-Harrisons_12-36"><sup><i><b>ak</b></i></sup></a> <a href="#cite_ref-Harrisons_12-37"><sup><i><b>al</b></i></sup></a> <a href="#cite_ref-Harrisons_12-38"><sup><i><b>am</b></i></sup></a> <a href="#cite_ref-Harrisons_12-39"><sup><i><b>an</b></i></sup></a> <a href="#cite_ref-Harrisons_12-40"><sup><i><b>ao</b></i></sup></a> <a href="#cite_ref-Harrisons_12-41"><sup><i><b>ap</b></i></sup></a> <a href="#cite_ref-Harrisons_12-42"><sup><i><b>aq</b></i></sup></a> <a href="#cite_ref-Harrisons_12-43"><sup><i><b>ar</b></i></sup></a> <a href="#cite_ref-Harrisons_12-44"><sup><i><b>as</b></i></sup></a> <a href="#cite_ref-Harrisons_12-45"><sup><i><b>at</b></i></sup></a> <a href="#cite_ref-Harrisons_12-46"><sup><i><b>au</b></i></sup></a> <a href="#cite_ref-Harrisons_12-47"><sup><i><b>av</b></i></sup></a> <a href="#cite_ref-Harrisons_12-48"><sup><i><b>aw</b></i></sup></a> <a href="#cite_ref-Harrisons_12-49"><sup><i><b>ax</b></i></sup></a> <a href="#cite_ref-Harrisons_12-50"><sup><i><b>ay</b></i></sup></a> <a href="#cite_ref-Harrisons_12-51"><sup><i><b>az</b></i></sup></a> <a href="#cite_ref-Harrisons_12-52"><sup><i><b>ba</b></i></sup></a> <a href="#cite_ref-Harrisons_12-53"><sup><i><b>bb</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Seiden, Michael V. (2012). "Gynecologic Malignancies". In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href="/wiki/Harrison%27s_Principles_of_Internal_Medicine" title="Harrison's Principles of Internal Medicine">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-174889-6" title="Special:BookSources/978-0-07-174889-6">978-0-07-174889-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Gynecologic+Malignancies&amp;rft.aufirst=Michael+V.&amp;rft.aulast=Seiden&amp;rft.au=Seiden%2C+Michael+V.&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.date=2012&amp;rft.edition=18th&amp;rft.genre=bookitem&amp;rft.isbn=978-0-07-174889-6&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:0-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_13-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-symptoms">"Ovarian cancer symptoms"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+cancer+symptoms&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fabout%2Fovarian-cancer-symptoms&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:7-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-:7_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:7_14-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:7_14-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:7_14-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:7_14-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-:7_14-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-:7_14-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-:7_14-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-:7_14-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-:7_14-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-:7_14-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-:7_14-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-:7_14-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-:7_14-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-:7_14-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-:7_14-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-:7_14-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-:7_14-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-:7_14-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-:7_14-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-:7_14-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-:7_14-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-:7_14-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-:7_14-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-:7_14-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-:7_14-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-:7_14-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-:7_14-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-:7_14-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-:7_14-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-:7_14-30"><sup><i><b>ae</b></i></sup></a> <a href="#cite_ref-:7_14-31"><sup><i><b>af</b></i></sup></a> <a href="#cite_ref-:7_14-32"><sup><i><b>ag</b></i></sup></a> <a href="#cite_ref-:7_14-33"><sup><i><b>ah</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.dynamed.com/topics/dmp~AN~T900705/Ovarian-cancer">"Ovarian cancer"</a>. DynaMed. June 18, 2015.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Ovarian+cancer&amp;rft.date=June+18%2C+2015&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.dynamed.com%2Ftopics%2Fdmp~AN~T900705%2FOvarian-cancer&amp;rft.pub=DynaMed&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Goff2012-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-Goff2012_15-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Goff BA (June 2012). "Ovarian cancer: screening and early detection". <i>Obstetrics and gynecology clinics of North America</i> <b>39</b> (2): 183–94. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.ogc.2012.02.007">10.1016/j.ogc.2012.02.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22640710">22640710</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+cancer%3A+screening+and+early+detection&amp;rft.aufirst=BA&amp;rft.au=Goff%2C+BA&amp;rft.aulast=Goff&amp;rft.date=June+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ogc.2012.02.007&amp;rft_id=info%3Apmid%2F22640710&amp;rft.issue=2&amp;rft.jtitle=Obstetrics+and+gynecology+clinics+of+North+America&amp;rft.pages=183-94&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=39" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Hoffman35-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-Hoffman35_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-27"><sup><i><b>ab</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-28"><sup><i><b>ac</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-29"><sup><i><b>ad</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-30"><sup><i><b>ae</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-31"><sup><i><b>af</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-32"><sup><i><b>ag</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-33"><sup><i><b>ah</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-34"><sup><i><b>ai</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-35"><sup><i><b>aj</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-36"><sup><i><b>ak</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-37"><sup><i><b>al</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-38"><sup><i><b>am</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-39"><sup><i><b>an</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-40"><sup><i><b>ao</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-41"><sup><i><b>ap</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-42"><sup><i><b>aq</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-43"><sup><i><b>ar</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-44"><sup><i><b>as</b></i></sup></a> <a href="#cite_ref-Hoffman35_16-45"><sup><i><b>at</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Hoffman, Barbara L.; Schorge, John O.; Schaffer, Joseph I.; Halvorson, Lisa M.; Bradshaw, Karen D.; Cunningham, F. Gary (2012). "Epithelial Ovarian Cancer". <i>Williams Gynecology</i> (2nd ed.). McGraw Hill Medical. pp.&#160;853–878. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-171672-7" title="Special:BookSources/978-0-07-171672-7">978-0-07-171672-7</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Epithelial+Ovarian+Cancer&amp;rft.au=Bradshaw%2C+Karen+D.&amp;rft.au=Cunningham%2C+F.+Gary&amp;rft.aufirst=Barbara+L.&amp;rft.au=Halvorson%2C+Lisa+M.&amp;rft.au=Hoffman%2C+Barbara+L.&amp;rft.aulast=Hoffman&amp;rft.au=Schaffer%2C+Joseph+I.&amp;rft.au=Schorge%2C+John+O.&amp;rft.btitle=Williams+Gynecology&amp;rft.date=2012&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=978-0-07-171672-7&amp;rft.pages=853-878&amp;rft.pub=McGraw+Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Current-17"><span class="mw-cite-backlink">^ <a href="#cite_ref-Current_17-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Current_17-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Current_17-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Current_17-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Current_17-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Current_17-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Current_17-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation book">DeCherney, Alan; Nathan, Lauren; Goodwin, T. Murphy; Laufer, Neri; Roman, Ashley (2012). "Pediatric and Adolescent Gynecology". <i>Current Diagnosis &amp; Treatment Obstetrics &amp; Gynecology</i> (11th ed.). <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0071638562" title="Special:BookSources/978-0071638562">978-0071638562</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Pediatric+and+Adolescent+Gynecology&amp;rft.au=DeCherney%2C+Alan&amp;rft.aufirst=Alan&amp;rft.au=Goodwin%2C+T.+Murphy&amp;rft.aulast=DeCherney&amp;rft.au=Laufer%2C+Neri&amp;rft.au=Nathan%2C+Lauren&amp;rft.au=Roman%2C+Ashley&amp;rft.btitle=Current+Diagnosis+%26+Treatment+Obstetrics+%26+Gynecology&amp;rft.date=2012&amp;rft.edition=11th&amp;rft.genre=bookitem&amp;rft.isbn=978-0071638562&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-CRUKRisks-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-CRUKRisks_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-CRUKRisks_18-15"><sup><i><b>p</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes">"Ovarian cancer risks and causes"</a>. Cancer Research UK. 15 January 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">29 January</span> 2015</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Ovarian+cancer+risks+and+causes&amp;rft.date=15+January+2014&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fabout%2Fovarian-cancer-risks-and-causes&amp;rft.pub=Cancer+Research+UK&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><span class="citation book">Manson, JoAnn E.; Bassuk, Shari S. (2012). "The Menopause Transition and Postmenopausal Hormone Therapy". In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href="/wiki/Harrison%27s_Principles_of_Internal_Medicine" title="Harrison's Principles of Internal Medicine">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-174889-6" title="Special:BookSources/978-0-07-174889-6">978-0-07-174889-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=The+Menopause+Transition+and+Postmenopausal+Hormone+Therapy&amp;rft.au=Bassuk%2C+Shari+S.&amp;rft.aufirst=JoAnn+E.&amp;rft.aulast=Manson&amp;rft.au=Manson%2C+JoAnn+E.&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.date=2012&amp;rft.edition=18th&amp;rft.genre=bookitem&amp;rft.isbn=978-0-07-174889-6&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NCIPrevention-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-NCIPrevention_20-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/healthprofessional">"Ovarian Cancer Prevention (PDQ®)"</a>. <a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a>. 2013. <a rel="nofollow" class="external text" href="http://archive.is/Ltiyp">Archived</a> from the original on 2013-12-30<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-12-30</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Ovarian+Cancer+Prevention+%28PDQ%C2%AE%29&amp;rft.date=2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fprevention%2Fovarian%2Fhealthprofessional&amp;rft.pub=National+Cancer+Institute&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><span class="citation journal">Hjartåker A, Meo MS, Weiderpass E (January 2010). "Alcohol and gynecological cancers: an overview". <i>European Journal of Cancer Prevention</i> <b>19</b> (1): 1–10. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FCEJ.0b013e328333fb3a">10.1097/CEJ.0b013e328333fb3a</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19926999">19926999</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Alcohol+and+gynecological+cancers%3A+an+overview&amp;rft.aufirst=A&amp;rft.au=Hjart%C3%A5ker%2C+A&amp;rft.aulast=Hjart%C3%A5ker&amp;rft.au=Meo%2C+MS&amp;rft.au=Weiderpass%2C+E&amp;rft.date=January+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2FCEJ.0b013e328333fb3a&amp;rft_id=info%3Apmid%2F19926999&amp;rft.issue=1&amp;rft.jtitle=European+Journal+of+Cancer+Prevention&amp;rft.pages=1-10&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Biswas-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-Biswas_22-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS et al. (2015). "Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis". <i>Annals of Internal Medicine</i> <b>162</b> (2): 123–32. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.7326%2FM14-1651">10.7326/M14-1651</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25599350">25599350</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Sedentary+Time+and+Its+Association+With+Risk+for+Disease+Incidence%2C+Mortality%2C+and+Hospitalization+in+Adults%3A+A+Systematic+Review+and+Meta-analysis&amp;rft.au=Alter%2C+DA&amp;rft.au=Bajaj%2C+RR&amp;rft.au=Biswas%2C+A&amp;rft.au=Faulkner%2C+GE&amp;rft.aufirst=A&amp;rft.aulast=Biswas&amp;rft.au=Mitchell%2C+MS&amp;rft.au=Oh%2C+PI&amp;rft.au=Silver%2C+MA&amp;rft.date=2015&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.7326%2FM14-1651&amp;rft_id=info%3Apmid%2F25599350&amp;rft.issue=2&amp;rft.jtitle=Annals+of+Internal+Medicine&amp;rft.pages=123-32&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=162" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><span class="citation web">Margolies, Liz (7 October 2013). <a rel="nofollow" class="external text" href="http://www.cancer-network.org/cancer_information/transgender_gender-nonconforming_people_and_cancer/transgender_men_and_ovarian_cancer.php">"Ovarian Cancer in Transgender Men"</a>. National LGBT Cancer Network<span class="reference-accessdate">. Retrieved <span class="nowrap">5 May</span> 2015</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.aufirst=Liz&amp;rft.aulast=Margolies&amp;rft.au=Margolies%2C+Liz&amp;rft.btitle=Ovarian+Cancer+in+Transgender+Men&amp;rft.date=7+October+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer-network.org%2Fcancer_information%2Ftransgender_gender-nonconforming_people_and_cancer%2Ftransgender_men_and_ovarian_cancer.php&amp;rft.pub=National+LGBT+Cancer+Network&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DeVita100-24"><span class="mw-cite-backlink">^ <a href="#cite_ref-DeVita100_24-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DeVita100_24-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Odunsi, Kunle; Pejovic, Tanja; Anderson, Matthew L. (2011). <i>Molecular Biology of Gynecologic Cancers</i>. <i>DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology</i> (Wolters Kluwer/Lippincott Williams &amp; Wilkins). pp.&#160;1302–1310. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1-4511-0545-2" title="Special:BookSources/978-1-4511-0545-2">978-1-4511-0545-2</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Molecular+Biology+of+Gynecologic+Cancers&amp;rft.au=Anderson%2C+Matthew+L.&amp;rft.aufirst=Kunle&amp;rft.aulast=Odunsi&amp;rft.au=Odunsi%2C+Kunle&amp;rft.au=Pejovic%2C+Tanja&amp;rft.date=2011&amp;rft.genre=article&amp;rft.isbn=978-1-4511-0545-2&amp;rft.jtitle=DeVita%2C+Hellman%2C+and+Rosenberg%27s+Cancer%3A+Principles+and+Practice+of+Oncology&amp;rft.pages=1302-1310&amp;rft.pub=Wolters+Kluwer%2FLippincott+Williams+%26+Wilkins&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NCIGenetics-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-NCIGenetics_25-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional">"Genetics of Breast and Ovarian Cancer (PDQ®)"</a>. NCI. 2 October 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">27 October</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Genetics+of+Breast+and+Ovarian+Cancer+%28PDQ%C2%AE%29&amp;rft.date=2+October+2014&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fgenetics%2Fbreast-and-ovarian%2FHealthProfessional&amp;rft.pub=NCI&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><span class="citation journal">Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS (2010-01-28). <a rel="nofollow" class="external text" href="http://jnci.oxfordjournals.org/cgi/content/full/djp500v1">"Predictive Value of Symptoms for Early Detection of Ovarian Cancer"</a>. <i>J Natl Cancer Inst.</i> <b>102</b> (4): 222–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Fjnci%2Fdjp500">10.1093/jnci/djp500</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2826180">2826180</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20110551">20110551</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Predictive+Value+of+Symptoms+for+Early+Detection+of+Ovarian+Cancer&amp;rft.au=Cushing-Haugen%2C+KL&amp;rft.aufirst=MA&amp;rft.aulast=Rossing&amp;rft.au=Rossing%2C+MA&amp;rft.au=Weiss%2C+NS&amp;rft.au=Wicklund%2C+KG&amp;rft.date=2010-01-28&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fdjp500v1&amp;rft_id=info%3Adoi%2F10.1093%2Fjnci%2Fdjp500&amp;rft_id=info%3Apmc%2F2826180&amp;rft_id=info%3Apmid%2F20110551&amp;rft.issue=4&amp;rft.jtitle=J+Natl+Cancer+Inst.&amp;rft.pages=222-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=102" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Miller-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-Miller_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Miller_27-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Miller_27-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Miller RW, Ueland FR (March 2012). "Risk of malignancy in sonographically confirmed ovarian tumors.". <i>Clinical obstetrics and gynecology</i> <b>55</b> (1): 52–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FGRF.0b013e31824970cf">10.1097/GRF.0b013e31824970cf</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22343229">22343229</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Risk+of+malignancy+in+sonographically+confirmed+ovarian+tumors.&amp;rft.aufirst=RW&amp;rft.aulast=Miller&amp;rft.au=Miller%2C+RW&amp;rft.au=Ueland%2C+FR&amp;rft.date=March+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2FGRF.0b013e31824970cf&amp;rft_id=info%3Apmid%2F22343229&amp;rft.issue=1&amp;rft.jtitle=Clinical+obstetrics+and+gynecology&amp;rft.pages=52-64&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=55" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/diagnosis/ovarian-cancer-tests">"Ovarian cancer tests"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+cancer+tests&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fdiagnosis%2Fovarian-cancer-tests&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><span class="citation book">Dunn, J. D. (Ed.). <i>Associated Title(s): PROTEOMICS&#160;– Clinical Applications</i> <b>11</b> (15). Online ISSN: 1615-9861.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.au=Dunn%2C+J.+D.+%28Ed.%29&amp;rft.aulast=Dunn%2C+J.+D.+%28Ed.%29&amp;rft.btitle=Associated+Title%28s%29%3A+PROTEOMICS%26nbsp%3B%E2%80%93+Clinical+Applications&amp;rft.genre=book&amp;rft.issue=15&amp;rft.pub=Online+ISSN%3A+1615-9861&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NICE2011-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-NICE2011_30-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://publications.nice.org.uk/ovarian-cancer-cg122/appendix-d-risk-of-malignancy-index-rmi-i">"Guideline CG122. Ovarian cancer: The recognition and initial management of ovarian cancer, Appendix D: Risk of malignancy index (RMI I)."</a>. <i>NICE clinical guidelines</i>. April 2011.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Guideline+CG122.+Ovarian+cancer%3A+The+recognition+and+initial+management+of+ovarian+cancer%2C+Appendix+D%3A+Risk+of+malignancy+index+%28RMI+I%29.&amp;rft.date=April+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpublications.nice.org.uk%2Fovarian-cancer-cg122%2Fappendix-d-risk-of-malignancy-index-rmi-i&amp;rft.jtitle=NICE+clinical+guidelines&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><span class="citation journal">Geomini, Peggy; Kruitwagen, Roy; Bremer, Gérard L.; Cnossen, Jeltsje; Mol, Ben W. J. (Feb 2009). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pubmed/19155910">"The accuracy of risk scores in predicting ovarian malignancy: a systematic review"</a>. <i>Obstetrics and Gynecology</i> <b>113</b> (2 Pt 1): 384–394. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FAOG.0b013e318195ad17">10.1097/AOG.0b013e318195ad17</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0029-7844">0029-7844</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19155910">19155910</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=The+accuracy+of+risk+scores+in+predicting+ovarian+malignancy%3A+a+systematic+review&amp;rft.au=Bremer%2C+G%C3%A9rard+L.&amp;rft.au=Cnossen%2C+Jeltsje&amp;rft.aufirst=Peggy&amp;rft.au=Geomini%2C+Peggy&amp;rft.au=Kruitwagen%2C+Roy&amp;rft.aulast=Geomini&amp;rft.au=Mol%2C+Ben+W.+J.&amp;rft.date=Feb+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F19155910&amp;rft_id=info%3Adoi%2F10.1097%2FAOG.0b013e318195ad17&amp;rft_id=info%3Apmid%2F19155910&amp;rft.issn=0029-7844&amp;rft.issue=2+Pt+1&amp;rft.jtitle=Obstetrics+and+Gynecology&amp;rft.pages=384-394&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=113" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-SEER6215ch16-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-SEER6215ch16_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SEER6215ch16_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Kosary, Carol L. (2007). <a rel="nofollow" class="external text" href="http://seer.cancer.gov/publications/survival/surv_ovary.pdf">"Chapter 16: Cancers of the Ovary"</a> <span style="font-size:85%;">(PDF)</span>. In Baguio, RNL; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J. <a rel="nofollow" class="external text" href="http://seer.cancer.gov/publications/survival/"><i>SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics</i></a>. SEER Program. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp.&#160;133–144.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Chapter+16%3A+Cancers+of+the+Ovary&amp;rft.aufirst=Carol+L.&amp;rft.au=Kosary%2C+Carol+L.&amp;rft.aulast=Kosary&amp;rft.btitle=SEER+Survival+Monograph%3A+Cancer+Survival+Among+Adults%3A+US+SEER+Program%2C+1988-2001%2C+Patient+and+Tumor+Characteristics&amp;rft.date=2007&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fseer.cancer.gov%2Fpublications%2Fsurvival%2F&amp;rft.pages=133-144&amp;rft.place=Bethesda%2C+MD&amp;rft.pub=National+Cancer+Institute&amp;rft.series=SEER+Program&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.volume=NIH+Pub.+No.+07-6215" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:1-33"><span class="mw-cite-backlink">^ <a href="#cite_ref-:1_33-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:1_33-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:1_33-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:1_33-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:1_33-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-:1_33-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-:1_33-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-:1_33-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-:1_33-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/types-of-ovarian-cancer">"Types of ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Types+of+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fabout%2Ftypes-of-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Levy-34"><span class="mw-cite-backlink">^ <a href="#cite_ref-Levy_34-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Levy_34-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Levy_34-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Levy, Gary; Purcell; Karen (2013). DeCherney, AH; Nathan, L; Laufer, N et al., eds. <i>Premalignant &amp; Malignant Disorders of the Ovaries &amp; Oviducts</i>. <i>CURRENT Diagnosis &amp; Treatment: Obstetrics &amp; Gynecology, 11e</i> (McGraw-Hill).</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Premalignant+%26+Malignant+Disorders+of+the+Ovaries+%26+Oviducts&amp;rft.aufirst=Gary&amp;rft.au=Karen&amp;rft.aulast=Levy&amp;rft.au=Levy%2C+Gary&amp;rft.au=Purcell&amp;rft.date=2013&amp;rft.genre=article&amp;rft.jtitle=CURRENT+Diagnosis+%26+Treatment%3A+Obstetrics+%26+Gynecology%2C+11e&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="display:none;font-size:100%" class="error citation-comment"><code style="color:inherit; border:inherit; padding:inherit;">|displayeditors=</code> suggested (<a href="/wiki/Help:CS1_errors#displayeditors" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/primary-peritoneal-carcinoma">"Primary peritoneal carcinoma"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Primary+peritoneal+carcinoma&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Frare-cancers%2Frare-cancers-name%2Fprimary-peritoneal-carcinoma&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-SGO-36"><span class="mw-cite-backlink">^ <a href="#cite_ref-SGO_36-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SGO_36-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf">"Ovarian Cancer Staging"</a> <span style="font-size:85%;">(PDF)</span>. Society for Gynecologic Oncology. 1 January 2014.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Ovarian+Cancer+Staging&amp;rft.date=1+January+2014&amp;rft.genre=book&amp;rft_id=https%3A%2F%2Fwww.sgo.org%2Fwp-content%2Fuploads%2F2012%2F09%2FFIGO-Ovarian-Cancer-Staging_1.10.14.pdf&amp;rft.pub=Society+for+Gynecologic+Oncology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-A-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-A_37-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-staging">"How is ovarian cancer staged?"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">July 27,</span> 2010</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=How+is+ovarian+cancer+staged%3F&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Fdetailedguide%2Fovarian-cancer-staging&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-B-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-B_38-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerfacts.com/GeneralContent/Ovarian/gen_diagnosis.asp?CB=9">"Diagnosis and Staging"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">July 27,</span> 2010</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Diagnosis+and+Staging&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancerfacts.com%2FGeneralContent%2FOvarian%2Fgen_diagnosis.asp%3FCB%3D9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/stages-of-ovarian-cancer">"Stages of ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Stages+of+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fstages-of-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Harrisons82-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-Harrisons82_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Harrisons82_40-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Harrisons82_40-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Croswell, Jennifer M.; Brawley, Otis W.; Kramer, Barnett S. (2012). "Prevention and Early Detection of Cancer". In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href="/wiki/Harrison%27s_Principles_of_Internal_Medicine" title="Harrison's Principles of Internal Medicine">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-174889-6" title="Special:BookSources/978-0-07-174889-6">978-0-07-174889-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Prevention+and+Early+Detection+of+Cancer&amp;rft.au=Brawley%2C+Otis+W.&amp;rft.au=Croswell%2C+Jennifer+M.&amp;rft.aufirst=Jennifer+M.&amp;rft.au=Kramer%2C+Barnett+S.&amp;rft.aulast=Croswell&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.date=2012&amp;rft.edition=18th&amp;rft.genre=bookitem&amp;rft.isbn=978-0-07-174889-6&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:2-41"><span class="mw-cite-backlink">^ <a href="#cite_ref-:2_41-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:2_41-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:2_41-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:2_41-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:2_41-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/which-treatment-for-ovarian-cancer">"Types of treatment for ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Types+of+treatment+for+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fwhich-treatment-for-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/surgery-for-ovarian-cancer">"Surgery for ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Surgery+for+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fsurgery-for-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:3-43"><span class="mw-cite-backlink">^ <a href="#cite_ref-:3_43-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:3_43-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/drugs-used-for-ovarian-cancer">"Drugs used for ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Drugs+used+for+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fdrugs-used-for-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:6-44"><span class="mw-cite-backlink">^ <a href="#cite_ref-:6_44-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:6_44-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:6_44-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:6_44-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:6_44-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-:6_44-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-:6_44-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-:6_44-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-:6_44-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-:6_44-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-:6_44-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-:6_44-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-:6_44-12"><sup><i><b>m</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/whats-new-in-ovarian-cancer-research">"Ovarian cancer research"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+cancer+research&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fwhats-new-in-ovarian-cancer-research&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><span class="citation web">Yao, Stephanie (19 December 2014). <a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm?sf34855004=1">"FDA approves Lynparza to treat advanced ovarian cancer: First LDT companion diagnostic test also approved to identify appropriate patients"</a>. U.S. Food and Drug Administration.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.aufirst=Stephanie&amp;rft.aulast=Yao&amp;rft.au=Yao%2C+Stephanie&amp;rft.btitle=FDA+approves+Lynparza+to+treat+advanced+ovarian+cancer%3A+First+LDT+companion+diagnostic+test+also+approved+to+identify+appropriate+patients&amp;rft.date=19+December+2014&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm427554.htm%3Fsf34855004%3D1&amp;rft.pub=U.S.+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-E-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-E_46-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20100827190431/http://www.ovariancancersymptoms.us/treatment.php">"Ovarian Cancer Treatments Available"</a>. Archived from <a rel="nofollow" class="external text" href="http://www.ovariancancersymptoms.us/treatment.php">the original</a> on 2010-08-27<span class="reference-accessdate">. Retrieved <span class="nowrap">July 27,</span> 2010</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Ovarian+Cancer+Treatments+Available&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.ovariancancersymptoms.us%2Ftreatment.php&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-:4-47"><span class="mw-cite-backlink">^ <a href="#cite_ref-:4_47-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:4_47-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/radiotherapy-for-ovarian-cancer">"Radiotherapy for ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Radiotherapy+for+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fradiotherapy-for-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/treatment/follow-up-for-ovarian-cancer">"Follow up for ovarian cancer"</a>. Cancer Research UK.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Follow+up+for+ovarian+cancer&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fcancer-help%2Ftype%2Fovarian-cancer%2Ftreatment%2Ffollow-up-for-ovarian-cancer&amp;rft.pub=Cancer+Research+UK&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ACSfollowup-49"><span class="mw-cite-backlink">^ <a href="#cite_ref-ACSfollowup_49-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ACSfollowup_49-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-after-follow-up">Follow-up care</a> from <a href="/wiki/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a>. Last Medical Review: 03/21/2013. Last Revised: 02/06/2014</span></li>
<li id="cite_note-SGOfive-50"><span class="mw-cite-backlink">^ <a href="#cite_ref-SGOfive_50-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SGOfive_50-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span id="CITEREFSociety_of_Gynecologic_Oncology2014" class="citation"><a href="/wiki/Society_of_Gynecologic_Oncology" title="Society of Gynecologic Oncology">Society of Gynecologic Oncology</a> (February 2014), <a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/society-of-gynecologic-oncology/">"Five Things Physicians and Patients Should Question"</a>, <i><a href="/wiki/Choosing_Wisely" title="Choosing Wisely">Choosing Wisely</a>: an initiative of the <a href="/wiki/ABIM_Foundation" title="ABIM Foundation">ABIM Foundation</a></i> (Society of Gynecologic Oncology)<span class="reference-accessdate">, retrieved <span class="nowrap">19 February</span> 2013</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Five+Things+Physicians+and+Patients+Should+Question&amp;rft.aulast=Society+of+Gynecologic+Oncology&amp;rft.au=Society+of+Gynecologic+Oncology&amp;rft.date=February+2014&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Fsociety-of-gynecologic-oncology%2F&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.pub=Society+of+Gynecologic+Oncology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span>, which cites</span>
<ul>
<li><span class="citation journal">Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E et al. (August 2010). "Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels". <i>International Journal of Gynecological Cancer</i> <b>20</b> (6): 936–944. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2FIGC.0b013e3181e82a7f">10.1111/IGC.0b013e3181e82a7f</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20683399">20683399</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Clinical+Utility+of+Positron+Emission+Tomography%2FComputed+Tomography+in+the+Evaluation+of+Suspected+Recurrent+Ovarian+Cancer+in+the+Setting+of+Normal+CA-125+Levels&amp;rft.au=Bhosale%2C+P&amp;rft.aufirst=P&amp;rft.au=Iyer%2C+RB&amp;rft.aulast=Bhosale&amp;rft.au=Levenback%2C+CF&amp;rft.au=Macapinlac%2C+HA&amp;rft.au=Peungjesada%2C+S&amp;rft.au=Rohren%2C+E&amp;rft.au=Schmeler%2C+K&amp;rft.au=Wei%2C+W&amp;rft.date=August+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2FIGC.0b013e3181e82a7f&amp;rft_id=info%3Apmid%2F20683399&amp;rft.issue=6&amp;rft.jtitle=International+Journal+of+Gynecological+Cancer&amp;rft.pages=936-944&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
</li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/chemotherapy-for-ovarian-cancer">"Chemotherapy for ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Chemotherapy+for+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fchemotherapy-for-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.asco.org/quality-guidelines/asco-provisional-clinical-opinion-integration-palliative-care-standard-oncology">"ASCO Provisional Clinical Opinion: The Integration of Palliative Care into Standard Oncology Care"</a>. ASCO<span class="reference-accessdate">. Retrieved <span class="nowrap">20 August</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=ASCO+Provisional+Clinical+Opinion%3A+The+Integration+of+Palliative+Care+into+Standard+Oncology+Care&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.asco.org%2Fquality-guidelines%2Fasco-provisional-clinical-opinion-integration-palliative-care-standard-oncology&amp;rft.pub=ASCO&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Radwany-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-Radwany_53-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Radwany SM, von Gruenigen VE (Mar 2012). "Palliative and end-of-life care for patients with ovarian cancer.". <i>Clinical obstetrics and gynecology</i> <b>55</b> (1): 173–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2Fgrf.0b013e31824b1af1">10.1097/grf.0b013e31824b1af1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22343236">22343236</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Palliative+and+end-of-life+care+for+patients+with+ovarian+cancer.&amp;rft.aufirst=SM&amp;rft.aulast=Radwany&amp;rft.au=Radwany%2C+SM&amp;rft.au=von+Gruenigen%2C+VE&amp;rft.date=Mar+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2Fgrf.0b013e31824b1af1&amp;rft_id=info%3Apmid%2F22343236&amp;rft.issue=1&amp;rft.jtitle=Clinical+obstetrics+and+gynecology&amp;rft.pages=173-84&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=55" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.org/cancer/ovariancancer/overviewguide/ovarian-cancer-overview-survival">"Survival rates for ovarian cancer"</a>. American Cancer Society. April 22, 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-12-30</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.btitle=Survival+rates+for+ovarian+cancer&amp;rft.date=April+22%2C+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Foverviewguide%2Fovarian-cancer-overview-survival&amp;rft.pub=American+Cancer+Society&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><span id="CITEREFSociety_of_Gynecologic_Oncology2014" class="citation"><a href="/wiki/Society_of_Gynecologic_Oncology" title="Society of Gynecologic Oncology">Society of Gynecologic Oncology</a> (February 2014), <a rel="nofollow" class="external text" href="http://www.choosingwisely.org/doctor-patient-lists/society-of-gynecologic-oncology/">"Five Things Physicians and Patients Should Question"</a>, <i><a href="/wiki/Choosing_Wisely" title="Choosing Wisely">Choosing Wisely</a>: an initiative of the <a href="/wiki/ABIM_Foundation" title="ABIM Foundation">ABIM Foundation</a></i> (Society of Gynecologic Oncology)<span class="reference-accessdate">, retrieved <span class="nowrap">19 February</span> 2013</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Five+Things+Physicians+and+Patients+Should+Question&amp;rft.aulast=Society+of+Gynecologic+Oncology&amp;rft.au=Society+of+Gynecologic+Oncology&amp;rft.date=February+2014&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Fsociety-of-gynecologic-oncology%2F&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.pub=Society+of+Gynecologic+Oncology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span>, which cites</span>
<ul>
<li><span class="citation journal">Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM et al. (6 February 2012). "American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care". <i>Journal of Clinical Oncology</i> <b>30</b> (8): 880–887. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1200%2FJCO.2011.38.5161">10.1200/JCO.2011.38.5161</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22312101">22312101</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=American+Society+of+Clinical+Oncology+Provisional+Clinical+Opinion%3A+The+Integration+of+Palliative+Care+Into+Standard+Oncology+Care&amp;rft.au=Abernethy%2C+AP&amp;rft.au=Alesi%2C+ER&amp;rft.au=Balboni%2C+TA&amp;rft.au=Basch%2C+EM&amp;rft.au=Ferrell%2C+BR&amp;rft.aufirst=TJ&amp;rft.aulast=Smith&amp;rft.au=Loscalzo%2C+M&amp;rft.au=Meier%2C+DE&amp;rft.au=Paice%2C+JA&amp;rft.au=Peppercorn%2C+JM&amp;rft.au=Smith%2C+TJ&amp;rft.au=Somerfield%2C+M&amp;rft.au=Stovall%2C+E&amp;rft.au=Temin%2C+S&amp;rft.au=Von+Roenn%2C+JH&amp;rft.date=6+February+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2011.38.5161&amp;rft_id=info%3Apmid%2F22312101&amp;rft.issue=8&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.pages=880-887&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></li>
<li><span class="citation journal">Rezk Y, Timmins PF, Smith HS (26 December 2010). "Review Article: Palliative Care in Gynecologic Oncology". <i>American Journal of Hospice and Palliative Medicine</i> <b>28</b> (5): 356–374. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1177%2F1049909110392204">10.1177/1049909110392204</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21187291">21187291</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Review+Article%3A+Palliative+Care+in+Gynecologic+Oncology&amp;rft.aufirst=Y&amp;rft.aulast=Rezk&amp;rft.au=Rezk%2C+Y&amp;rft.au=Smith%2C+HS&amp;rft.au=Timmins%2C+PF&amp;rft.date=26+December+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F1049909110392204&amp;rft_id=info%3Apmid%2F21187291&amp;rft.issue=5&amp;rft.jtitle=American+Journal+of+Hospice+and+Palliative+Medicine&amp;rft.pages=356-374&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></li>
<li><span class="citation journal">Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG et al. (November 2005). "Resource utilization for ovarian cancer patients at the end of life: How much is too much?". <i>Gynecologic Oncology</i> <b>99</b> (2): 261–266. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.ygyno.2005.07.102">10.1016/j.ygyno.2005.07.102</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16140364">16140364</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Resource+utilization+for+ovarian+cancer+patients+at+the+end+of+life%3A+How+much+is+too+much%3F&amp;rft.au=Buttin%2C+BM&amp;rft.aufirst=SN&amp;rft.au=Gibb%2C+RK&amp;rft.au=Herzog%2C+TJ&amp;rft.aulast=Lewin&amp;rft.au=Lewin%2C+SN&amp;rft.au=Mutch%2C+DG&amp;rft.au=Powell%2C+MA&amp;rft.au=Rader%2C+JS&amp;rft.date=November+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ygyno.2005.07.102&amp;rft_id=info%3Apmid%2F16140364&amp;rft.issue=2&amp;rft.jtitle=Gynecologic+Oncology&amp;rft.pages=261-266&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=99" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
</li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/statistics-and-outlook-for-ovarian-cancer">"Statistics and outlook for ovarian cancer"</a>. <i>www.cancerresearchuk.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-16</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Statistics+and+outlook+for+ovarian+cancer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fstatistics-and-outlook-for-ovarian-cancer&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-SEER-57"><span class="mw-cite-backlink">^ <a href="#cite_ref-SEER_57-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SEER_57-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Survival rates based on SEER incidence and NCHS mortality statistics, as cited by the National Cancer Institute in <a rel="nofollow" class="external text" href="http://seer.cancer.gov/statfacts/html/ovary.html">SEER Stat Fact Sheets&#160;— Cancer of the Ovary</a></span></li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><span class="citation book">Gucalp, Rasim; Dutcher, Janice (2012). "Oncologic Emergencies". In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href="/wiki/Harrison%27s_Principles_of_Internal_Medicine" title="Harrison's Principles of Internal Medicine">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-174889-6" title="Special:BookSources/978-0-07-174889-6">978-0-07-174889-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Oncologic+Emergencies&amp;rft.au=Dutcher%2C+Janice&amp;rft.aufirst=Rasim&amp;rft.au=Gucalp%2C+Rasim&amp;rft.aulast=Gucalp&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.date=2012&amp;rft.edition=18th&amp;rft.genre=bookitem&amp;rft.isbn=978-0-07-174889-6&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates">"Survival rates for ovarian cancer, by stage"</a>. <i>American Cancer Society</i><span class="reference-accessdate">. Retrieved <span class="nowrap">29 October</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Survival+rates+for+ovarian+cancer%2C+by+stage&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Fdetailedguide%2Fovarian-cancer-survival-rates&amp;rft.jtitle=American+Cancer+Society&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html">"WHO Disease and injury country estimates"</a>. <i>World Health Organization</i>. 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">November 11,</span> 2009</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=WHO+Disease+and+injury+country+estimates&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fhealthinfo%2Fglobal_burden_disease%2Festimates_country%2Fen%2Findex.html&amp;rft.jtitle=World+Health+Organization&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Loz_2012-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-Loz_2012_61-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". <i>Lancet</i> <b>380</b> (9859): 2095–128. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2812%2961728-0">10.1016/S0140-6736(12)61728-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23245604">23245604</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Global+and+regional+mortality+from+235+causes+of+death+for+20+age+groups+in+1990+and+2010%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2010&amp;rft.au=Aboyans%2C+V&amp;rft.au=Abraham%2C+J&amp;rft.au=Adair%2C+T&amp;rft.au=Aggarwal%2C+R&amp;rft.au=Ahn%2C+SY&amp;rft.au=AlMazroa%2C+MA&amp;rft.au=Alvarado%2C+M&amp;rft.au=Anderson%2C+HR&amp;rft.au=Anderson%2C+LM&amp;rft.au=Andrews%2C+KG&amp;rft.au=Atkinson%2C+C&amp;rft.au=Baddour%2C+LM&amp;rft.au=Barker-Collo%2C+S&amp;rft.au=Bartels%2C+DH&amp;rft.au=Bell%2C+ML&amp;rft.au=Benjamin%2C+EJ&amp;rft.au=Bennett%2C+D&amp;rft.au=Bhalla%2C+K&amp;rft.au=Bikbov%2C+B&amp;rft.au=Bin+Abdulhak%2C+A&amp;rft.au=Birbeck%2C+G&amp;rft.au=Blyth%2C+F&amp;rft.au=Bolliger%2C+I&amp;rft.au=Boufous%2C+S&amp;rft.au=Bucello%2C+C&amp;rft.au=Burch%2C+M&amp;rft.au=Burney%2C+P&amp;rft.au=Carapetis%2C+J&amp;rft.au=Chen%2C+H&amp;rft.au=Chou%2C+D&amp;rft.au=Chugh%2C+SS&amp;rft.au=Coffeng%2C+LE&amp;rft.au=Colan%2C+SD&amp;rft.au=Colquhoun%2C+S&amp;rft.au=Colson%2C+KE&amp;rft.au=Condon%2C+J&amp;rft.au=Connor%2C+MD&amp;rft.au=Cooper%2C+LT&amp;rft.au=Corriere%2C+M&amp;rft.au=Cortinovis%2C+M&amp;rft.au=Couser%2C+W&amp;rft.au=Cowie%2C+BC&amp;rft.au=Criqui%2C+MH&amp;rft.au=Cross%2C+M&amp;rft.au=Dabhadkar%2C+KC&amp;rft.au=Dahodwala%2C+N&amp;rft.au=Degenhardt%2C+L&amp;rft.au=De+Le%C3%B3n%2C+FR&amp;rft.au=De+Leo%2C+D&amp;rft.au=Delossantos%2C+A&amp;rft.au=Denenberg%2C+J&amp;rft.au=Des+Jarlais%2C+DC&amp;rft.au=de+Vaccaro%2C+KC&amp;rft.au=Dharmaratne%2C+SD&amp;rft.au=Dorsey%2C+ER&amp;rft.au=Driscoll%2C+T&amp;rft.au=Duber%2C+H&amp;rft.au=Ebel%2C+B&amp;rft.au=Erwin%2C+PJ&amp;rft.au=Espindola%2C+P&amp;rft.au=Ezzati%2C+M&amp;rft.au=Feigin%2C+V&amp;rft.aufirst=R&amp;rft.au=Flaxman%2C+AD&amp;rft.au=Foreman%2C+K&amp;rft.au=Forouzanfar%2C+MH&amp;rft.au=Fowkes%2C+FG&amp;rft.au=Franklin%2C+R&amp;rft.au=Fransen%2C+M&amp;rft.au=Freeman%2C+MK&amp;rft.au=Gabriel%2C+SE&amp;rft.au=Gakidou%2C+E&amp;rft.au=Gaspari%2C+F&amp;rft.au=Gillum%2C+RF&amp;rft.au=Gonzalez-Medina%2C+D&amp;rft.au=Halasa%2C+YA&amp;rft.au=Haring%2C+D&amp;rft.au=Harrison%2C+JE&amp;rft.au=Havmoeller%2C+R&amp;rft.au=Hay%2C+RJ&amp;rft.au=Hoen%2C+B&amp;rft.au=Hotez%2C+PJ&amp;rft.au=Hoy%2C+D&amp;rft.au=Jacobsen%2C+KH&amp;rft.au=James%2C+SL&amp;rft.au=Jasrasaria%2C+R&amp;rft.au=Jayaraman%2C+S&amp;rft.au=Johns%2C+N&amp;rft.au=Karthikeyan%2C+G&amp;rft.au=Kassebaum%2C+N&amp;rft.au=Keren%2C+A&amp;rft.au=Khoo%2C+JP&amp;rft.au=Knowlton%2C+LM&amp;rft.au=Kobusingye%2C+O&amp;rft.au=Koranteng%2C+A&amp;rft.au=Krishnamurthi%2C+R&amp;rft.aulast=Lozano&amp;rft.au=Lim%2C+S&amp;rft.au=Lipnick%2C+M&amp;rft.au=Lipshultz%2C+SE&amp;rft.au=Lopez%2C+AD&amp;rft.au=Lozano%2C+R&amp;rft.au=Mabweijano%2C+J&amp;rft.au=MacIntyre%2C+MF&amp;rft.au=Mallinger%2C+L&amp;rft.au=March%2C+L&amp;rft.au=Marks%2C+GB&amp;rft.au=Marks%2C+R&amp;rft.au=Matsumori%2C+A&amp;rft.au=Matzopoulos%2C+R&amp;rft.au=Mayosi%2C+BM&amp;rft.au=McAnulty%2C+JH&amp;rft.au=McDermott%2C+MM&amp;rft.au=McGrath%2C+J&amp;rft.au=Memish%2C+ZA&amp;rft.au=Mensah%2C+GA&amp;rft.au=Merriman%2C+TR&amp;rft.au=Michaud%2C+C&amp;rft.au=Miller%2C+M&amp;rft.au=Miller%2C+TR&amp;rft.au=Mock%2C+C&amp;rft.au=Mocumbi%2C+AO&amp;rft.au=Mokdad%2C+AA&amp;rft.au=Moran%2C+A&amp;rft.au=Mulholland%2C+K&amp;rft.au=Murray%2C+CJ&amp;rft.au=Naghavi%2C+M&amp;rft.au=Nair%2C+MN&amp;rft.au=Naldi%2C+L&amp;rft.au=Narayan%2C+KM&amp;rft.au=Nasseri%2C+K&amp;rft.au=Norman%2C+P&amp;rft.au=O%27Donnell%2C+M&amp;rft.au=Ohno%2C+SL&amp;rft.au=Omer%2C+SB&amp;rft.au=Ortblad%2C+K&amp;rft.au=Osborne%2C+R&amp;rft.au=Ozgediz%2C+D&amp;rft.au=Padilla%2C+RP&amp;rft.au=Pahari%2C+B&amp;rft.au=Pandian%2C+JD&amp;rft.au=Perez-Ruiz%2C+F&amp;rft.au=Perico%2C+N&amp;rft.au=Phillips%2C+D&amp;rft.au=Pierce%2C+K&amp;rft.au=Pope%2C+CA&amp;rft.au=Porrini%2C+E&amp;rft.au=Pourmalek%2C+F&amp;rft.au=Raju%2C+M&amp;rft.au=Ranganathan%2C+D&amp;rft.au=Rehm%2C+JT&amp;rft.au=Rein%2C+DB&amp;rft.au=Remuzzi%2C+G&amp;rft.au=Rivara%2C+FP&amp;rft.au=Rivero%2C+AP&amp;rft.au=Roberts%2C+T&amp;rft.au=Rosenfeld%2C+LC&amp;rft.au=Rushton%2C+L&amp;rft.au=Sacco%2C+RL&amp;rft.au=Salomon%2C+JA&amp;rft.au=Sampson%2C+U&amp;rft.au=Sanman%2C+E&amp;rft.au=Schwebel%2C+DC&amp;rft.au=Segui-Gomez%2C+M&amp;rft.au=Shepard%2C+DS&amp;rft.au=Shibuya%2C+K&amp;rft.au=Singh%2C+D&amp;rft.au=Singleton%2C+J&amp;rft.au=Sliwa%2C+K&amp;rft.au=Smith%2C+E&amp;rft.au=Steer%2C+A&amp;rft.au=Taylor%2C+JA&amp;rft.au=Thomas%2C+B&amp;rft.au=Tleyjeh%2C+IM&amp;rft.au=Towbin%2C+JA&amp;rft.au=Truelsen%2C+T&amp;rft.au=Undurraga%2C+EA&amp;rft.au=Venketasubramanian%2C+N&amp;rft.au=Vijayakumar%2C+L&amp;rft.au=Vos%2C+T&amp;rft.au=Wagner%2C+GR&amp;rft.au=Wang%2C+M&amp;rft.au=Wang%2C+W&amp;rft.au=Watt%2C+K&amp;rft.au=Weinstock%2C+MA&amp;rft.au=Weintraub%2C+R&amp;rft.au=Wilkinson%2C+JD&amp;rft.au=Woolf%2C+AD&amp;rft.au=Wulf%2C+S&amp;rft.au=Yeh%2C+PH&amp;rft.au=Yip%2C+P&amp;rft.au=Zabetian%2C+A&amp;rft.au=Zheng%2C+ZJ&amp;rft.date=Dec+15%2C+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2812%2961728-0&amp;rft_id=info%3Apmid%2F23245604&amp;rft.issue=9859&amp;rft.jtitle=Lancet&amp;rft.pages=2095-128&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=380" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-merck-62"><span class="mw-cite-backlink">^ <a href="#cite_ref-merck_62-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-merck_62-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-merck_62-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web">Ramirez, Pedro T.; Gershenson, David M. (September 2013). <a rel="nofollow" class="external text" href="http://www.merckmanuals.com/professional/gynecology_and_obstetrics/gynecologic_tumors/ovarian_cancer.htm">"Ovarian Cancer"</a>. <i>The Merck Manual for Health Care Professionals</i>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+Cancer&amp;rft.aufirst=Pedro+T.&amp;rft.au=Gershenson%2C+David+M.&amp;rft.aulast=Ramirez&amp;rft.au=Ramirez%2C+Pedro+T.&amp;rft.date=September+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.merckmanuals.com%2Fprofessional%2Fgynecology_and_obstetrics%2Fgynecologic_tumors%2Fovarian_cancer.htm&amp;rft.jtitle=The+Merck+Manual+for+Health+Care+Professionals&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span><a href="/wiki/Open_access" title="open access publication - free to read"><img alt="open access publication - free to read" src="//upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/8px-Open_Access_logo_PLoS_transparent.svg.png" width="8" height="13" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/12px-Open_Access_logo_PLoS_transparent.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/16px-Open_Access_logo_PLoS_transparent.svg.png 2x" data-file-width="640" data-file-height="1000" /></a></span></li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/">"Ovarian cancer statistics"</a>. <i>Cancer Research UK</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 October</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+cancer+statistics&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fcancer-info%2Fcancerstats%2Ftypes%2Fovary%2F&amp;rft.jtitle=Cancer+Research+UK&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><span class="citation book">Hennessy, Bryan T.; Suh, Grace K.; Markman, Maurie (2011). Kantarjian, HM; Wolff, RA; Koller, CA, eds. <i>Ovarian Cancer</i>. <i>The MD Anderson Manual of Medical Oncology</i> (McGraw-Hill).</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+Cancer&amp;rft.aufirst=Bryan+T.&amp;rft.au=Hennessy%2C+Bryan+T.&amp;rft.aulast=Hennessy&amp;rft.au=Markman%2C+Maurie&amp;rft.au=Suh%2C+Grace+K.&amp;rft.date=2011&amp;rft.genre=article&amp;rft.jtitle=The+MD+Anderson+Manual+of+Medical+Oncology&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15065985-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15065985_65-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Catone G, Marino G, Mancuso R, Zanghì A (April 2004). "Clinicopathological features of an equine ovarian teratoma". <i>Reprod. Domest. Anim.</i> <b>39</b> (2): 65–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1439-0531.2003.00476.x">10.1111/j.1439-0531.2003.00476.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15065985">15065985</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Clinicopathological+features+of+an+equine+ovarian+teratoma&amp;rft.au=Catone%2C+G&amp;rft.aufirst=G&amp;rft.aulast=Catone&amp;rft.au=Mancuso%2C+R&amp;rft.au=Marino%2C+G&amp;rft.au=Zangh%C3%AC%2C+A&amp;rft.date=April+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1439-0531.2003.00476.x&amp;rft_id=info%3Apmid%2F15065985&amp;rft.issue=2&amp;rft.jtitle=Reprod.+Domest.+Anim.&amp;rft.pages=65-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=39" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16363331-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16363331_66-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lefebvre R, Theoret C, Doré M, Girard C, Laverty S, Vaillancourt D (November 2005). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1259148">"Ovarian teratoma and endometritis in a mare"</a>. <i>Can. Vet. J.</i> <b>46</b> (11): 1029–33. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1259148">1259148</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16363331">16363331</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+teratoma+and+endometritis+in+a+mare&amp;rft.au=Dor%C3%A9%2C+M&amp;rft.aufirst=R&amp;rft.au=Girard%2C+C&amp;rft.aulast=Lefebvre&amp;rft.au=Laverty%2C+S&amp;rft.au=Lefebvre%2C+R&amp;rft.au=Theoret%2C+C&amp;rft.au=Vaillancourt%2C+D&amp;rft.date=November+2005&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1259148&amp;rft_id=info%3Apmc%2F1259148&amp;rft_id=info%3Apmid%2F16363331&amp;rft.issue=11&amp;rft.jtitle=Can.+Vet.+J.&amp;rft.pages=1029-33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=46" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15957389-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15957389_67-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Son YS, Lee CS, Jeong WI, Hong IH, Park SJ, Kim TH et al. (May 2005). "Cystadenocarcinoma in the ovary of a Thoroughbred mare". <i>Aust. Vet. J.</i> <b>83</b> (5): 283–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1751-0813.2005.tb12740.x">10.1111/j.1751-0813.2005.tb12740.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15957389">15957389</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Cystadenocarcinoma+in+the+ovary+of+a+Thoroughbred+mare&amp;rft.au=Cho%2C+EM&amp;rft.aufirst=YS&amp;rft.au=Hong%2C+IH&amp;rft.au=Jeong%2C+KS&amp;rft.au=Jeong%2C+WI&amp;rft.au=Kim%2C+TH&amp;rft.aulast=Son&amp;rft.au=Lee%2C+CS&amp;rft.au=Park%2C+SJ&amp;rft.au=Park%2C+TI&amp;rft.au=Son%2C+YS&amp;rft.date=May+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1751-0813.2005.tb12740.x&amp;rft_id=info%3Apmid%2F15957389&amp;rft.issue=5&amp;rft.jtitle=Aust.+Vet.+J.&amp;rft.pages=283-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=83" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17542368-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17542368_68-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Frederico LM, Gerard MP, Pinto CR, Gradil CM (May 2007). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1852596">"Bilateral occurrence of granulosa-theca cell tumors in an Arabian mare"</a>. <i>Can. Vet. J.</i> <b>48</b> (5): 502–5. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1852596">1852596</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17542368">17542368</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Bilateral+occurrence+of+granulosa-theca+cell+tumors+in+an+Arabian+mare&amp;rft.aufirst=LM&amp;rft.au=Frederico%2C+LM&amp;rft.au=Gerard%2C+MP&amp;rft.au=Gradil%2C+CM&amp;rft.aulast=Frederico&amp;rft.au=Pinto%2C+CR&amp;rft.date=May+2007&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1852596&amp;rft_id=info%3Apmc%2F1852596&amp;rft_id=info%3Apmid%2F17542368&amp;rft.issue=5&amp;rft.jtitle=Can.+Vet.+J.&amp;rft.pages=502-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=48" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12867740-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid12867740_69-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Hoque S, Derar RI, Osawa T, Taya K, Watanabe G, Miyake Y (June 2003). <a rel="nofollow" class="external text" href="http://joi.jlc.jst.go.jp/JST.JSTAGE/jvms/65.749?from=PubMed">"Spontaneous repair of the atrophic contralateral ovary without ovariectomy in the case of a granulosa theca cell tumor (GTCT) affected mare"</a> <span style="font-size:85%;">(&amp;NBSP;– <sup><a rel="nofollow" class="external text" href="HTTP://SCHOLAR.GOOGLE.CO.UK/SCHOLAR?HL=EN&amp;LR=&amp;Q=INTITLE%3ASPONTANEOUS+REPAIR+OF+THE+ATROPHIC+CONTRALATERAL+OVARY+WITHOUT+OVARIECTOMY+IN+THE+CASE+OF+A+GRANULOSA+THECA+CELL+TUMOR+%28GTCT%29+AFFECTED+MARE&amp;AS_PUBLICATION=J.+VET.+MED.+SCI.&amp;AS_YLO=2003&amp;AS_YHI=2003&amp;BTNG=SEARCH">SCHOLAR SEARCH</a></sup>)</span>. <i>J. Vet. Med. Sci.</i> <b>65</b> (6): 749–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1292%2Fjvms.65.749">10.1292/jvms.65.749</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12867740">12867740</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Spontaneous+repair+of+the+atrophic+contralateral+ovary+without+ovariectomy+in+the+case+of+a+granulosa+theca+cell+tumor+%28GTCT%29+affected+mare&amp;rft.au=Derar%2C+RI&amp;rft.aufirst=S&amp;rft.au=Hoque%2C+S&amp;rft.aulast=Hoque&amp;rft.au=Miyake%2C+Y&amp;rft.au=Osawa%2C+T&amp;rft.au=Taya%2C+K&amp;rft.au=Watanabe%2C+G&amp;rft.date=June+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjoi.jlc.jst.go.jp%2FJST.JSTAGE%2Fjvms%2F65.749%3Ffrom%3DPubMed&amp;rft_id=info%3Adoi%2F10.1292%2Fjvms.65.749&amp;rft_id=info%3Apmid%2F12867740&amp;rft.issue=6&amp;rft.jtitle=J.+Vet.+Med.+Sci.&amp;rft.pages=749-51&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=65" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since March 2009">dead link</span></a></i>]</span></sup></span></li>
<li id="cite_note-pmid9364230-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid9364230_70-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Sedrish SA, McClure JR, Pinto C, Oliver J, Burba DJ (November 1997). "Ovarian torsion associated with granulosa-theca cell tumor in a mare". <i>J. Am. Vet. Med. Assoc.</i> <b>211</b> (9): 1152–4. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9364230">9364230</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Ovarian+torsion+associated+with+granulosa-theca+cell+tumor+in+a+mare&amp;rft.au=Burba%2C+DJ&amp;rft.aufirst=SA&amp;rft.aulast=Sedrish&amp;rft.au=McClure%2C+JR&amp;rft.au=Oliver%2C+J&amp;rft.au=Pinto%2C+C&amp;rft.au=Sedrish%2C+SA&amp;rft.date=November+1997&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F9364230&amp;rft.issue=9&amp;rft.jtitle=J.+Am.+Vet.+Med.+Assoc.&amp;rft.pages=1152-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=211" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid3507181-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid3507181_71-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Moll HD, Slone DE, Juzwiak JS, Garrett PD (1987). <a rel="nofollow" class="external text" href="http://www3.interscience.wiley.com/journal/119849124/abstract">"Diagonal paramedian approach for removal of ovarian tumors in the mare"</a>. <i>Vet Surg</i> <b>16</b> (6): 456–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1532-950X.1987.tb00987.x">10.1111/j.1532-950X.1987.tb00987.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3507181">3507181</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Diagonal+paramedian+approach+for+removal+of+ovarian+tumors+in+the+mare&amp;rft.aufirst=HD&amp;rft.au=Garrett%2C+PD&amp;rft.au=Juzwiak%2C+JS&amp;rft.aulast=Moll&amp;rft.au=Moll%2C+HD&amp;rft.au=Slone%2C+DE&amp;rft.date=1987&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww3.interscience.wiley.com%2Fjournal%2F119849124%2Fabstract&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1532-950X.1987.tb00987.x&amp;rft_id=info%3Apmid%2F3507181&amp;rft.issue=6&amp;rft.jtitle=Vet+Surg&amp;rft.pages=456-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid2835223-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid2835223_72-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Doran R, Allen D, Gordon B (January 1988). "Use of stapling instruments to aid in the removal of ovarian tumours in mares". <i>Equine Vet. J.</i> <b>20</b> (1): 37–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.2042-3306.1988.tb01450.x">10.1111/j.2042-3306.1988.tb01450.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2835223">2835223</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Use+of+stapling+instruments+to+aid+in+the+removal+of+ovarian+tumours+in+mares&amp;rft.au=Allen%2C+D&amp;rft.au=Doran%2C+R&amp;rft.aufirst=R&amp;rft.au=Gordon%2C+B&amp;rft.aulast=Doran&amp;rft.date=January+1988&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.2042-3306.1988.tb01450.x&amp;rft_id=info%3Apmid%2F2835223&amp;rft.issue=1&amp;rft.jtitle=Equine+Vet.+J.&amp;rft.pages=37-40&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><span class="citation journal">Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR et al. (April 2009). <a rel="nofollow" class="external text" href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0029-7844&amp;volume=113&amp;issue=4&amp;spage=775">"Results from four rounds of ovarian cancer screening in a randomized trial"</a>. <i>Obstet Gynecol</i> <b>113</b> (4): 775–82. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1097%2FAOG.0b013e31819cda77">10.1097/AOG.0b013e31819cda77</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2728067">2728067</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19305319">19305319</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Results+from+four+rounds+of+ovarian+cancer+screening+in+a+randomized+trial&amp;rft.au=Andriole%2C+GL&amp;rft.au=Buys%2C+SS&amp;rft.au=Church%2C+TR&amp;rft.aufirst=E&amp;rft.au=Greenlee%2C+RT&amp;rft.au=Isaacs%2C+C&amp;rft.au=Johnson%2C+CC&amp;rft.au=Kessel%2C+B&amp;rft.au=Kreimer%2C+AR&amp;rft.aulast=Partridge&amp;rft.au=Ogden%2C+S&amp;rft.au=Partridge%2C+E&amp;rft.au=Ragard%2C+LR&amp;rft.au=Weissfeld%2C+JL&amp;rft.au=Williams%2C+C&amp;rft.au=Xu%2C+JL&amp;rft.date=April+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fmeta.wkhealth.com%2Fpt%2Fpt-core%2Ftemplate-journal%2Flwwgateway%2Fmedia%2Flandingpage.htm%3Fissn%3D0029-7844%26volume%3D113%26issue%3D4%26spage%3D775&amp;rft_id=info%3Adoi%2F10.1097%2FAOG.0b013e31819cda77&amp;rft_id=info%3Apmc%2F2728067&amp;rft_id=info%3Apmid%2F19305319&amp;rft.issue=4&amp;rft.jtitle=Obstet+Gynecol&amp;rft.pages=775-82&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=113" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><span class="citation journal">Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A et al. (April 2009). <a rel="nofollow" class="external text" href="http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(09)70026-9">"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)"</a>. <i>Lancet Oncol.</i> <b>10</b> (4): 327–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1470-2045%2809%2970026-9">10.1016/S1470-2045(09)70026-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19282241">19282241</a>. [<a rel="nofollow" class="external text" href="http://scienceblog.cancerresearchuk.org/2009/03/12/early-results-from-ovarian-cancer-screening-trial-look-promising/Early">results from ovarian cancer screening trial look promising</a> Lay summary] – <i>Cancer Research UK, Science Update blog</i> (March 2009).</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Sensitivity+and+specificity+of+multimodal+and+ultrasound+screening+for+ovarian+cancer%2C+and+stage+distribution+of+detected+cancers%3A+results+of+the+prevalence+screen+of+the+UK+Collaborative+Trial+of+Ovarian+Cancer+Screening+%28UKCTOCS%29&amp;rft.au=Amso%2C+NN&amp;rft.au=Burnell%2C+M&amp;rft.au=Campbell%2C+S&amp;rft.au=Cruickshank%2C+D&amp;rft.au=Davies%2C+S&amp;rft.au=Dawnay%2C+A&amp;rft.au=Dobbs%2C+S&amp;rft.au=Fallowfield%2C+L&amp;rft.aufirst=U&amp;rft.au=Gentry-Maharaj%2C+A&amp;rft.au=Godfrey%2C+K&amp;rft.au=Hallett%2C+R&amp;rft.au=Herod%2C+J&amp;rft.au=Jacobs%2C+I&amp;rft.aulast=Menon&amp;rft.au=Leeson%2C+S&amp;rft.au=Lewis%2C+S&amp;rft.au=Lopes%2C+A&amp;rft.au=McGuire%2C+A&amp;rft.au=Menon%2C+U&amp;rft.au=Mould%2C+T&amp;rft.au=Murdoch%2C+J&amp;rft.au=Oram%2C+D&amp;rft.au=Parmar%2C+M&amp;rft.au=Philpott%2C+S&amp;rft.au=Ryan%2C+A&amp;rft.au=Scott%2C+I&amp;rft.au=Seif%2C+MW&amp;rft.au=Sharma%2C+A&amp;rft.au=Singh%2C+N&amp;rft.au=Skates%2C+SJ&amp;rft.au=Williamson%2C+K&amp;rft.au=Woolas%2C+R&amp;rft.date=April+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1470-2045%2809%2970026-9&amp;rft_id=info%3Adoi%2F10.1016%2FS1470-2045%2809%2970026-9&amp;rft_id=info%3Apmid%2F19282241&amp;rft.issue=4&amp;rft.jtitle=Lancet+Oncol.&amp;rft.pages=327-40&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><span class="citation journal">Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ et al. (Sep 17, 2014). "Antigen-specific active immunotherapy for ovarian cancer". <i>The Cochrane database of systematic reviews</i> <b>9</b>: CD007287. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD007287.pub3">10.1002/14651858.CD007287.pub3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25229990">25229990</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Antigen-specific+active+immunotherapy+for+ovarian+cancer&amp;rft.au=Boezen%2C+HM&amp;rft.au=Cohlen%2C+BJ&amp;rft.au=Daemen%2C+T&amp;rft.aufirst=N&amp;rft.au=Helfrich%2C+W&amp;rft.aulast=Leffers&amp;rft.au=Leffers%2C+N&amp;rft.au=Melief%2C+CJ&amp;rft.au=Nijman%2C+HW&amp;rft.date=Sep+17%2C+2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007287.pub3&amp;rft_id=info%3Apmid%2F25229990&amp;rft.jtitle=The+Cochrane+database+of+systematic+reviews&amp;rft.pages=CD007287&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=52" title="Edit section: Further reading">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="refbegin" style="">
<ul>
<li><span class="citation journal">Cannistra SA (December 2004). <a rel="nofollow" class="external text" href="http://content.nejm.org/cgi/content/full/351/24/2519">"Cancer of the ovary"</a>. <i>N. Engl. J. Med.</i> <b>351</b> (24): 2519–29. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMra041842">10.1056/NEJMra041842</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15590954">15590954</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer&amp;rft.atitle=Cancer+of+the+ovary&amp;rft.au=Cannistra%2C+SA&amp;rft.aufirst=SA&amp;rft.aulast=Cannistra&amp;rft.date=December+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2F351%2F24%2F2519&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMra041842&amp;rft_id=info%3Apmid%2F15590954&amp;rft.issue=24&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=2519-29&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=351" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=53" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=33">Ovarian Cancer</a> at <a href="/wiki/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a></li>
<li><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=brca1">GeneReviews/NCBI/NIH/UW entry on BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer</a></li>
<li><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/tutorials/ovariancancer/htm/index.htm">Interactive Health Tutorials Medline Plus: Ovarian cancer</a> Using animated graphics and you can also listen to the tutorial</li>
<li><a rel="nofollow" class="external text" href="http://info.cancerresearchuk.org/cancerstats/types/ovary/">UK statistics for ovarian cancer</a></li>
<li><a rel="nofollow" class="external text" href="http://cancerhelp.cancerresearchuk.org/type/ovarian-cancer/">Patient information about ovarian cancer from Cancer Research UK</a></li>
<li><a rel="nofollow" class="external text" href="http://www.mountsinai.org/patient-care/service-areas/obgyn-and-reproductive-services/areas-of-care/gynecologic-oncology/ovarian-cancer/infographic/ovariancancerinfo">What is Ovarian Cancer Infographic, information on ovarian cancer</a> - <a href="/wiki/Mount_Sinai_Hospital,_New_York" title="Mount Sinai Hospital, New York" class="mw-redirect">Mount Sinai Hospital, New York</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Female_genital_neoplasia" title="Template:Female genital neoplasia"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Female_genital_neoplasia" title="Template talk:Female genital neoplasia"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Female_genital_neoplasia&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Tumor" title="Tumor" class="mw-redirect">Tumors</a>: female <a href="/wiki/Urogenital_neoplasm" title="Urogenital neoplasm">urogenital neoplasia</a> (<a href="/wiki/ICD-10_Chapter_II:_Neoplasms#.28C50.E2.80.93C58.29_Malignant_neoplasms.2C_breast_and_female_genital_organs" title="ICD-10 Chapter II: Neoplasms">C51–C58/D25–D28</a>, <a href="/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms#Malignant_neoplasm_of_genitourinary_organs_.28179.E2.80.93189.29" title="List of ICD-9 codes 140–239: neoplasms">179–184/218–221</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Adnexa_of_uterus" title="Adnexa of uterus">Adnexa</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><strong class="selflink">Ovaries</strong></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Glandular_and_epithelial_neoplasm" title="Glandular and epithelial neoplasm">Glandular and epithelial</a>/<br />
<a href="/wiki/Surface_epithelial-stromal_tumor" title="Surface epithelial-stromal tumor">surface epithelial-<br />
stromal tumor</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cystic,_mucinous,_and_serous_neoplasms" title="Cystic, mucinous, and serous neoplasms">CMS</a>:</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Ovarian_serous_cystadenoma" title="Ovarian serous cystadenoma">Ovarian serous cystadenoma</a></li>
<li><a href="/wiki/Mucinous_cystadenoma" title="Mucinous cystadenoma">Mucinous cystadenoma</a></li>
<li><a href="/wiki/Cystadenocarcinoma" title="Cystadenocarcinoma">Cystadenocarcinoma</a>
<ul>
<li><a href="/wiki/Papillary_serous_cystadenocarcinoma" title="Papillary serous cystadenocarcinoma">Papillary serous cystadenocarcinoma</a></li>
</ul>
</li>
<li><a href="/wiki/Krukenberg_tumor" title="Krukenberg tumor">Krukenberg tumor</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Endometrioid_tumor" title="Endometrioid tumor">Endometrioid tumor</a></li>
<li><a href="/wiki/Clear-cell_ovarian_carcinoma" title="Clear-cell ovarian carcinoma">Clear-cell ovarian carcinoma</a></li>
<li><a href="/wiki/Brenner_tumour" title="Brenner tumour">Brenner tumour</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Sex_cord-gonadal_stromal_tumour" title="Sex cord-gonadal stromal tumour" class="mw-redirect">Sex cord-gonadal stromal</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Leydig_cell_tumour" title="Leydig cell tumour">Leydig cell tumour</a></li>
<li><a href="/wiki/Sertoli_cell_tumour" title="Sertoli cell tumour">Sertoli cell tumour</a></li>
<li><a href="/wiki/Sertoli-Leydig_cell_tumour" title="Sertoli-Leydig cell tumour" class="mw-redirect">Sertoli-Leydig cell tumour</a></li>
<li><a href="/wiki/Thecoma" title="Thecoma">Thecoma</a></li>
<li><a href="/wiki/Granulosa_cell_tumour" title="Granulosa cell tumour">Granulosa cell tumour</a></li>
<li><a href="/wiki/Luteoma" title="Luteoma">Luteoma</a></li>
<li><a href="/wiki/Sex_cord_tumour_with_annular_tubules" title="Sex cord tumour with annular tubules">Sex cord tumour with annular tubules</a></li>
<li><a href="/w/index.php?title=Steroid_cell_tumor_(NOS)&amp;action=edit&amp;redlink=1" class="new" title="Steroid cell tumor (NOS) (page does not exist)">Steroid cell tumor (NOS)</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Germ_cell_tumor" title="Germ cell tumor">Germ cell</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Dysgerminoma" title="Dysgerminoma">Dysgerminoma</a></li>
<li><a href="/wiki/Germ_cell_tumor#Nongerminomatous" title="Germ cell tumor">Nongerminomatous</a>
<ul>
<li><a href="/wiki/Embryonal_carcinoma" title="Embryonal carcinoma">Embryonal carcinoma</a></li>
<li><a href="/wiki/Endodermal_sinus_tumor" title="Endodermal sinus tumor">Endodermal sinus tumor</a></li>
<li><a href="/wiki/Gonadoblastoma" title="Gonadoblastoma">Gonadoblastoma</a></li>
<li><a href="/wiki/Teratoma" title="Teratoma">Teratoma</a>/<a href="/wiki/Struma_ovarii" title="Struma ovarii">Struma ovarii</a></li>
<li><a href="/wiki/Choriocarcinoma" title="Choriocarcinoma">Choriocarcinoma</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Fibroma#Ovarian_fibroma" title="Fibroma">Fibroma</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Meigs_syndrome" title="Meigs syndrome" class="mw-redirect">Meigs syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Fallopian_tube_cancer" title="Fallopian tube cancer">Fallopian tube</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Adenomatoid_tumor" title="Adenomatoid tumor">Adenomatoid tumor</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Uterine_cancer" title="Uterine cancer">Uterus</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Myometrium" title="Myometrium">Myometrium</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Uterine_fibroid" title="Uterine fibroid">Uterine fibroids/leiomyoma</a></li>
<li><a href="/wiki/Leiomyosarcoma" title="Leiomyosarcoma">Leiomyosarcoma</a></li>
<li><a href="/wiki/Adenomyoma" title="Adenomyoma">Adenomyoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Endometrial_cancer" title="Endometrial cancer">Endometrium</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Endometrioid_tumor" title="Endometrioid tumor">Endometrioid tumor</a></li>
<li><a href="/wiki/Uterine_serous_carcinoma" title="Uterine serous carcinoma">Uterine papillary serous carcinoma</a></li>
<li><a href="/wiki/Clear_cell_adenocarcinoma_of_the_vagina" title="Clear cell adenocarcinoma of the vagina" class="mw-redirect">Clear cell carcinoma</a></li>
<li><a href="/wiki/Endometrial_intraepithelial_neoplasia" title="Endometrial intraepithelial neoplasia">Endometrial intraepithelial neoplasia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cervical_cancer" title="Cervical cancer">Cervix</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Cervical_intraepithelial_neoplasia" title="Cervical intraepithelial neoplasia">Cervical intraepithelial neoplasia</a></li>
<li><a href="/wiki/Squamous-cell_carcinoma#Vagina_and_cervix" title="Squamous-cell carcinoma">SCC</a></li>
<li><a href="/wiki/Glassy_cell_carcinoma_of_the_cervix" title="Glassy cell carcinoma of the cervix">Glassy cell carcinoma</a></li>
<li><a href="/wiki/Villoglandular_adenocarcinoma_of_the_cervix" title="Villoglandular adenocarcinoma of the cervix">Villoglandular adenocarcinoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Placenta" title="Placenta">Placenta</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Choriocarcinoma" title="Choriocarcinoma">Choriocarcinoma</a></li>
<li><a href="/wiki/Gestational_trophoblastic_disease" title="Gestational trophoblastic disease">Gestational trophoblastic disease</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">General</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Uterine_sarcoma" title="Uterine sarcoma">Uterine sarcoma</a></li>
<li><a href="/wiki/Mixed_M%C3%BCllerian_tumor" title="Mixed Müllerian tumor">Mixed Müllerian tumor</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Vaginal_cancer" title="Vaginal cancer">Vagina</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Squamous-cell_carcinoma#Vagina_and_cervix" title="Squamous-cell carcinoma">SCC</a></li>
<li><a href="/wiki/Sarcoma_botryoides" title="Sarcoma botryoides">Botryoid rhabdomyosarcoma</a></li>
<li><a href="/wiki/Clear_cell_adenocarcinoma_of_the_vagina" title="Clear cell adenocarcinoma of the vagina" class="mw-redirect">Clear cell adenocarcinoma of the vagina</a></li>
<li><a href="/wiki/Vaginal_intraepithelial_neoplasia" title="Vaginal intraepithelial neoplasia">Vaginal intraepithelial neoplasia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Vulvar_cancer" title="Vulvar cancer">Vulva</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Squamous-cell_carcinoma" title="Squamous-cell carcinoma">SCC</a></li>
<li><a href="/wiki/Melanoma" title="Melanoma">Melanoma</a></li>
<li><a href="/wiki/Papillary_hidradenoma" title="Papillary hidradenoma">Papillary hidradenoma</a></li>
<li><a href="/wiki/Extramammary_Paget%27s_disease" title="Extramammary Paget's disease">Extramammary Paget's disease</a></li>
<li><a href="/wiki/Vulvar_intraepithelial_neoplasia" title="Vulvar intraepithelial neoplasia">Vulvar intraepithelial neoplasia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Reproductive_medicine_navs" title="Template:Reproductive medicine navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Reproductive_medicine_navs" title="Template talk:Reproductive medicine navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Reproductive_medicine_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of <a href="/wiki/Reproductive_medicine" title="Reproductive medicine">reproductive medicine</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>Anatomy
<ul>
<li><a href="/wiki/Template:Male_reproductive_system" title="Template:Male reproductive system">male</a></li>
<li><a href="/wiki/Template:Female_reproductive_system" title="Template:Female reproductive system">female</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Human_reproductive_physiology" title="Template:Human reproductive physiology">Physiology</a>
<ul>
<li><a href="/wiki/Template:Menstrual_cycle" title="Template:Menstrual cycle">menstrual cycle</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Development_of_urinary_and_reproductive_systems" title="Template:Development of urinary and reproductive systems">Development</a>
<ul>
<li><a href="/wiki/Template:Sex_determination_and_differentiation" title="Template:Sex determination and differentiation">sex determination and differentiation</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>Infections
<ul>
<li><a href="/wiki/Template:STD_and_STI" title="Template:STD and STI">STD and STI</a></li>
</ul>
</li>
<li>Congenital
<ul>
<li><a href="/wiki/Template:Male_congenital_anomalies_of_genital_organs" title="Template:Male congenital anomalies of genital organs">male</a></li>
<li><a href="/wiki/Template:Female_congenital_anomalies_of_genital_organs" title="Template:Female congenital anomalies of genital organs">female</a></li>
</ul>
</li>
<li>Neoplasms and cancer
<ul>
<li><a href="/wiki/Template:Male_genital_neoplasia" title="Template:Male genital neoplasia">male</a></li>
<li><a href="/wiki/Template:Female_genital_neoplasia" title="Template:Female genital neoplasia">female</a></li>
<li><a href="/wiki/Template:Gonadal_tumors,_paraganglioma,_and_glomus" title="Template:Gonadal tumors, paraganglioma, and glomus">gonadal</a></li>
<li><a href="/wiki/Template:Germ_cell_tumors" title="Template:Germ cell tumors">germ cell</a></li>
</ul>
</li>
<li>Other
<ul>
<li><a href="/wiki/Template:Male_diseases_of_the_pelvis_and_genitals" title="Template:Male diseases of the pelvis and genitals">male</a></li>
<li><a href="/wiki/Template:Female_diseases_of_the_pelvis_and_genitals" title="Template:Female diseases of the pelvis and genitals">female</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Reproductive_system_symptoms_and_signs" title="Template:Reproductive system symptoms and signs">Symptoms and signs</a>
<ul>
<li><a href="/wiki/Template:Eponymous_medical_signs_for_reproductive_system" title="Template:Eponymous medical signs for reproductive system">eponymous</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li>Procedures
<ul>
<li><a href="/wiki/Template:Male_genital_procedures" title="Template:Male genital procedures">male</a></li>
<li><a href="/wiki/Template:Female_genital_procedures" title="Template:Female genital procedures">female</a></li>
</ul>
</li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Drugs_used_in_benign_prostatic_hypertrophy" title="Template:Drugs used in benign prostatic hypertrophy">benign prostatic hypertrophy</a></li>
<li><a href="/wiki/Template:Drugs_for_erectile_dysfunction_and_PE" title="Template:Drugs for erectile dysfunction and PE">erectile dysfunction and premature ejaculation</a></li>
<li><a href="/wiki/Template:Sexual_dysfunction_pharmacotherapies" title="Template:Sexual dysfunction pharmacotherapies">sexual dysfunction</a></li>
<li><a href="/wiki/Template:Gynecological_anti-infectives_and_antiseptics" title="Template:Gynecological anti-infectives and antiseptics">infection</a>
<ul>
<li><i><a href="/wiki/Template:Microbicides_for_sexually_transmitted_diseases" title="Template:Microbicides for sexually transmitted diseases">STDs</a></i></li>
</ul>
</li>
<li>hormones
<ul>
<li><i><a href="/wiki/Template:Androgens_and_antiandrogens" title="Template:Androgens and antiandrogens">androgens</a></i></li>
<li><i><a href="/wiki/Template:Estrogens_and_antiestrogens" title="Template:Estrogens and antiestrogens">estrogens</a></i></li>
<li><i><a href="/wiki/Template:Progestogens_and_antiprogestogens" title="Template:Progestogens and antiprogestogens">progestogens</a></i></li>
<li><i><a href="/wiki/Template:Gonadotropins_and_GnRH" title="Template:Gonadotropins and GnRH">GnRH</a></i></li>
<li><i><a href="/wiki/Template:Prolactin_inhibitors_and_anti-inflammatory_products_for_vaginal_administration" title="Template:Prolactin inhibitors and anti-inflammatory products for vaginal administration">prolactin</a></i></li>
</ul>
</li>
</ul>
</li>
<li><a href="/wiki/Template:Assisted_reproductive_technology" title="Template:Assisted reproductive technology">Assisted reproduction</a></li>
<li><a href="/wiki/Template:Birth_control_methods" title="Template:Birth control methods">Birth control</a>
<ul>
<li><a href="/wiki/Template:Hormonal_contraceptives" title="Template:Hormonal contraceptives">hormonal</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks hlist navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Help:Authority_control" title="Help:Authority control">Authority control</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/National_Diet_Library" title="National Diet Library">NDL</a>: <span class="uid"><a rel="nofollow" class="external text" href="http://id.ndl.go.jp/auth/ndlna/00569292">00569292</a></span></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1183
CPU time usage: 1.309 seconds
Real time usage: 1.487 seconds
Preprocessor visited node count: 11160/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 271961/2097152 bytes
Template argument size: 3291/2097152 bytes
Highest expansion depth: 12/40
Expensive parser function count: 3/500
Lua time usage: 0.472/10.000 seconds
Lua memory usage: 4.41 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00% 1200.260      1 - -total
 51.01%  612.205      1 - Template:Reflist
 19.74%  236.954     26 - Template:Vcite2_journal
 11.16%  133.904     36 - Template:Cite_web
  7.36%   88.349      1 - Template:Infobox_disease
  6.92%   83.086      6 - Template:Navbox
  6.54%   78.546      1 - Template:Infobox
  4.68%   56.215      3 - Template:Citation_needed
  4.59%   55.149      4 - Template:Fix
  4.45%   53.390      1 - Template:Genital_neoplasia
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:414192-0!*!0!!en!4!* and timestamp 20150711144218 and revision id 668902162
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Ovarian_cancer&amp;oldid=668902162">https://en.wikipedia.org/w/index.php?title=Ovarian_cancer&amp;oldid=668902162</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Ovarian_cancer" title="Category:Ovarian cancer">Ovarian cancer</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Pages_using_citations_with_old-style_implicit_et_al._in_editors" title="Category:Pages using citations with old-style implicit et al. in editors">Pages using citations with old-style implicit et al. in editors</a></li><li><a href="/wiki/Category:All_articles_with_dead_external_links" title="Category:All articles with dead external links">All articles with dead external links</a></li><li><a href="/wiki/Category:Articles_with_dead_external_links_from_March_2009" title="Category:Articles with dead external links from March 2009">Articles with dead external links from March 2009</a></li><li><a href="/wiki/Category:Articles_with_contributors_link" title="Category:Articles with contributors link">Articles with contributors link</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_December_2014" title="Category:Articles with unsourced statements from December 2014">Articles with unsourced statements from December 2014</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_November_2014" title="Category:Articles with unsourced statements from November 2014">Articles with unsourced statements from November 2014</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Ovarian+cancer&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Ovarian+cancer" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Ovarian_cancer"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Ovarian_cancer"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Ovarian_cancer" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Ovarian_cancer&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Ovarian_cancer&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Ovarian_cancer" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Ovarian_cancer" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Ovarian_cancer&amp;oldid=668902162" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Ovarian_cancer&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q172341" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Ovarian_cancer&amp;id=668902162" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Ovarian+cancer">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Ovarian+cancer&amp;oldid=668902162&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Ovarian_cancer&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D8%B3%D8%B1%D8%B7%D8%A7%D9%86_%D8%A7%D9%84%D9%85%D8%A8%D9%8A%D8%B6" title="سرطان المبيض – Arabic" lang="ar" hreflang="ar">العربية</a></li><li class="interlanguage-link interwiki-bs"><a href="//bs.wikipedia.org/wiki/Rak_jajnika" title="Rak jajnika – Bosnian" lang="bs" hreflang="bs">Bosanski</a></li><li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/C%C3%A0ncer_d%27ovari" title="Càncer d'ovari – Catalan" lang="ca" hreflang="ca">Català</a></li><li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Rakovina_vaje%C4%8Dn%C3%ADk%C5%AF" title="Rakovina vaječníků – Czech" lang="cs" hreflang="cs">Čeština</a></li><li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Ovarialkarzinom" title="Ovarialkarzinom – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-dv"><a href="//dv.wikipedia.org/wiki/%DE%84%DE%A8%DE%90%DE%B0%DE%83%DE%A6%DE%88%DE%A6%DE%87%DE%A8%DE%8E%DE%AC_%DE%86%DE%AC%DE%82%DE%B0%DE%90%DE%A6%DE%83%DE%AA" title="ބިސްރަވައިގެ ކެންސަރު – Divehi" lang="dv" hreflang="dv">ދިވެހިބަސް</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/C%C3%A1ncer_de_ovario" title="Cáncer de ovario – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D8%B3%D8%B1%D8%B7%D8%A7%D9%86_%D8%AA%D8%AE%D9%85%D8%AF%D8%A7%D9%86" title="سرطان تخمدان – Persian" lang="fa" hreflang="fa">فارسی</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Cancer_de_l%27ovaire" title="Cancer de l'ovaire – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-fy"><a href="//fy.wikipedia.org/wiki/Aaistokkanker" title="Aaistokkanker – Western Frisian" lang="fy" hreflang="fy">Frysk</a></li><li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%EB%82%9C%EC%86%8C%EC%95%94" title="난소암 – Korean" lang="ko" hreflang="ko">한국어</a></li><li class="interlanguage-link interwiki-id"><a href="//id.wikipedia.org/wiki/Kanker_ovarium" title="Kanker ovarium – Indonesian" lang="id" hreflang="id">Bahasa Indonesia</a></li><li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Carcinoma_dell%27ovaio" title="Carcinoma dell'ovaio – Italian" lang="it" hreflang="it">Italiano</a></li><li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%A1%D7%A8%D7%98%D7%9F_%D7%94%D7%A9%D7%97%D7%9C%D7%94" title="סרטן השחלה – Hebrew" lang="he" hreflang="he">עברית</a></li><li class="interlanguage-link interwiki-kk"><a href="//kk.wikipedia.org/wiki/%D0%90%D0%BD%D0%B0%D0%BB%D1%8B%D2%9B_%D0%B1%D0%B5%D0%B7_%D0%BE%D0%B1%D1%8B%D1%80%D1%8B" title="Аналық без обыры – Kazakh" lang="kk" hreflang="kk">Қазақша</a></li><li class="interlanguage-link interwiki-hu badge-Q17437796 badge-featuredarticle" title="featured article"><a href="//hu.wikipedia.org/wiki/Petef%C3%A9szekr%C3%A1k" title="Petefészekrák – Hungarian" lang="hu" hreflang="hu">Magyar</a></li><li class="interlanguage-link interwiki-ml"><a href="//ml.wikipedia.org/wiki/%E0%B4%85%E0%B4%A3%E0%B5%8D%E0%B4%A1%E0%B4%BE%E0%B4%B6%E0%B4%AF_%E0%B4%85%E0%B5%BC%E0%B4%AC%E0%B5%81%E0%B4%A6%E0%B4%82" title="അണ്ഡാശയ അർബുദം – Malayalam" lang="ml" hreflang="ml">മലയാളം</a></li><li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Ovariumcarcinoom" title="Ovariumcarcinoom – Dutch" lang="nl" hreflang="nl">Nederlands</a></li><li class="interlanguage-link interwiki-new"><a href="//new.wikipedia.org/wiki/%E0%A4%93%E0%A4%AD%E0%A4%B0%E0%A4%BF%E0%A4%AF%E0%A4%A8_%E0%A4%95%E0%A5%8D%E0%A4%AF%E0%A4%BE%E0%A4%A8%E0%A5%8D%E0%A4%B8%E0%A4%B0" title="ओभरियन क्यान्सर – Newari" lang="new" hreflang="new">नेपाल भाषा</a></li><li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E5%8D%B5%E5%B7%A3%E8%85%AB%E7%98%8D" title="卵巣腫瘍 – Japanese" lang="ja" hreflang="ja">日本語</a></li><li class="interlanguage-link interwiki-no"><a href="//no.wikipedia.org/wiki/Eggstokkreft" title="Eggstokkreft – Norwegian" lang="no" hreflang="no">Norsk bokmål</a></li><li class="interlanguage-link interwiki-or"><a href="//or.wikipedia.org/wiki/%E0%AC%93%E0%AC%AD%E0%AC%BE%E0%AC%B0%E0%AC%BF_%E0%AC%95%E0%AC%B0%E0%AD%8D%E0%AC%95%E0%AC%9F" title="ଓଭାରି କର୍କଟ – Oriya" lang="or" hreflang="or">ଓଡ଼ିଆ</a></li><li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Rak_jajnika" title="Rak jajnika – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/C%C3%A2ncer_ovariano" title="Câncer ovariano – Portuguese" lang="pt" hreflang="pt">Português</a></li><li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%A0%D0%B0%D0%BA_%D1%8F%D0%B8%D1%87%D0%BD%D0%B8%D0%BA%D0%B0" title="Рак яичника – Russian" lang="ru" hreflang="ru">Русский</a></li><li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Ovarian_cancer" title="Ovarian cancer – Simple English" lang="simple" hreflang="simple">Simple English</a></li><li class="interlanguage-link interwiki-sk"><a href="//sk.wikipedia.org/wiki/Rakovina_vaje%C4%8Dn%C3%ADkov" title="Rakovina vaječníkov – Slovak" lang="sk" hreflang="sk">Slovenčina</a></li><li class="interlanguage-link interwiki-sl"><a href="//sl.wikipedia.org/wiki/Rak_jaj%C4%8Dnika" title="Rak jajčnika – Slovenian" lang="sl" hreflang="sl">Slovenščina</a></li><li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Munasarjasy%C3%B6p%C3%A4" title="Munasarjasyöpä – Finnish" lang="fi" hreflang="fi">Suomi</a></li><li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/%C3%84ggstockscancer" title="Äggstockscancer – Swedish" lang="sv" hreflang="sv">Svenska</a></li><li class="interlanguage-link interwiki-ta"><a href="//ta.wikipedia.org/wiki/%E0%AE%9A%E0%AF%82%E0%AE%B2%E0%AF%8D%E0%AE%AA%E0%AF%88%E0%AE%AA%E0%AF%8D_%E0%AE%AA%E0%AF%81%E0%AE%B1%E0%AF%8D%E0%AE%B1%E0%AF%81%E0%AE%A8%E0%AF%8B%E0%AE%AF%E0%AF%8D" title="சூல்பைப் புற்றுநோய் – Tamil" lang="ta" hreflang="ta">தமிழ்</a></li><li class="interlanguage-link interwiki-th"><a href="//th.wikipedia.org/wiki/%E0%B8%A1%E0%B8%B0%E0%B9%80%E0%B8%A3%E0%B9%87%E0%B8%87%E0%B8%A3%E0%B8%B1%E0%B8%87%E0%B9%84%E0%B8%82%E0%B9%88" title="มะเร็งรังไข่ – Thai" lang="th" hreflang="th">ไทย</a></li><li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Yumurtal%C4%B1k_kanseri" title="Yumurtalık kanseri – Turkish" lang="tr" hreflang="tr">Türkçe</a></li><li class="interlanguage-link interwiki-ur"><a href="//ur.wikipedia.org/wiki/%D9%85%D8%A8%DB%8C%D8%B6%DB%8C_%D8%B3%D8%B1%D8%B7%D8%A7%D9%86" title="مبیضی سرطان – Urdu" lang="ur" hreflang="ur">اردو</a></li><li class="interlanguage-link interwiki-vi"><a href="//vi.wikipedia.org/wiki/Ung_th%C6%B0_bu%E1%BB%93ng_tr%E1%BB%A9ng" title="Ung thư buồng trứng – Vietnamese" lang="vi" hreflang="vi">Tiếng Việt</a></li><li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E5%8D%B5%E5%B7%A2%E7%99%8C" title="卵巢癌 – Chinese" lang="zh" hreflang="zh">中文</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q172341#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 27 June 2015, at 13:23.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Ovarian_cancer&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":1661,"wgHostname":"mw1183"});
}</script>
	</body>
</html>
